PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
19592611-7	2009	Stimulation of NE release with tyramine and infusion of the beta-agonist dobutamine revealed blunted adrenergic transmission that correlated with decreased beta-receptor expression in gp130(DBH-Cre/lox) hearts.	Dobutamine	73-83	interleukin 6 signal transducer	Mus musculus	184-189
19592611-7	2009	Stimulation of NE release with tyramine and infusion of the beta-agonist dobutamine revealed blunted adrenergic transmission that correlated with decreased beta-receptor expression in gp130(DBH-Cre/lox) hearts.	Dobutamine	73-83	dopamine beta hydroxylase	Mus musculus	190-193
19592611-7	2009	Stimulation of NE release with tyramine and infusion of the beta-agonist dobutamine revealed blunted adrenergic transmission that correlated with decreased beta-receptor expression in gp130(DBH-Cre/lox) hearts.	Dobutamine	73-83	lysyl oxidase	Mus musculus	198-201
19401301-9	2009	A correlation was found between increase in IVA under Dobutamine and BNP levels (r = 0.57, P < 0.02).	Dobutamine	54-64	natriuretic peptide B	Homo sapiens	69-72
19542315-0	2009	Effect of 393T>C polymorphism of GNAS1 gene on dobutamine response in Chinese healthy subjects.	Dobutamine	50-60	GNAS complex locus	Homo sapiens	36-41
19548031-7	2009	Lipopolysaccharide administration results in significant lung injury with impaired AFC, while dobutamine improves alveolar fluid reabsorption with elevation of aquaporin-1 and aquaporin-5.	Dobutamine	94-104	aquaporin 1	Rattus norvegicus	160-171
19548031-7	2009	Lipopolysaccharide administration results in significant lung injury with impaired AFC, while dobutamine improves alveolar fluid reabsorption with elevation of aquaporin-1 and aquaporin-5.	Dobutamine	94-104	aquaporin 5	Rattus norvegicus	176-187
19548031-8	2009	Our study indicates that dobutamine may enhance alveolar fluid reabsorption by increasing the expression of aquaporin-1 and aquaporin-5.	Dobutamine	25-35	aquaporin 1	Rattus norvegicus	108-119
19548031-8	2009	Our study indicates that dobutamine may enhance alveolar fluid reabsorption by increasing the expression of aquaporin-1 and aquaporin-5.	Dobutamine	25-35	aquaporin 5	Rattus norvegicus	124-135
19401301-10	2009	CONCLUSION: Elevated BNP levels correlate with response of systolic right ventricular function assessed by IVA to Dobutamine stress.	Dobutamine	114-124	natriuretic peptide B	Homo sapiens	21-24
19539144-0	2009	Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure.	Dobutamine	66-76	natriuretic peptide B	Homo sapiens	8-34
18253135-1	2008	Our objective was to determine if beta(1)-adrenergic receptor (beta(1)-AR) and beta(2)-AR gene polymorphisms influence heart rate (HR), systolic blood pressure (SBP) and diastolic blood pressure (DBP) response to dobutamine during dobutamine stress echocardiography (DSE).	Dobutamine	213-223	adrenoceptor beta 1	Homo sapiens	34-73
19174769-4	2009	Elevated cTnT levels (>0.01 ng/ml) were associated with left ventricular hypertrophy, reduced left ventricular ejection fraction and ischemia or resting ventricular wall motion abnormalities on dobutamine stress echocardiography, and also predicted mortality independently of age, diabetes or history of heart disease.	Dobutamine	197-207	troponin T2, cardiac type	Homo sapiens	9-13
18636040-7	2009	Furthermore, GSTA1-1 levels did not correlate with IL-6 levels but did with dobutamine infusion rate (Spearman r = 0.94; P = 0.02), suggesting that the extent of hemodynamic instability and not the degree of inflammation could be of importance for the occurrence of liver damage.	Dobutamine	76-86	glutathione S-transferase alpha 1	Homo sapiens	13-20
19691565-9	2009	CONCLUSION: Vasopressin (0.01-0.04 U/min, IV) should be considered in small animal veterinary patients with vasodilatory shock that is unresponsive to fluid resuscitation and catecholamine (dobutamine, dopamine, and norepinephrine) administration.	Dobutamine	190-200	arginine vasopressin	Homo sapiens	12-23
19027145-3	2009	In the control and levosimendan groups, cecal ligation and puncture resulted in moderate IL-1beta immunolabelling in lung tissue; marked IL-1beta immunolabelling was demonstrated in the dobutamine group.	Dobutamine	186-196	interleukin 1 beta	Rattus norvegicus	137-145
19027145-8	2009	In addition, iNOS immunoreactivity was strongly detected in the control group; this immunoreactivity was less in the levosimendan group than the dobutamine group.	Dobutamine	145-155	nitric oxide synthase 2	Rattus norvegicus	13-17
18253135-5	2008	beta(2)-AR Glu27 homozygotes had a greater HR response at the highest dobutamine dose than Gln27 carriers (P=0.002).	Dobutamine	70-80	adrenoceptor beta 2	Homo sapiens	0-10
18253135-6	2008	Beta(2)-AR Gly16 homozygotes had a lower HR response during 5-30 microg kg(-1) min(-1) of the dobutamine infusion protocol compared to Arg16 carriers (P=0.03).	Dobutamine	94-104	adrenoceptor beta 2	Homo sapiens	0-10
18785956-6	2008	High cTnT also related to cardiac anomalies, including left ventricular hypertrophy (LVH), wall motion abnormalities and stress-inducible ischemia by dobutamine echo (DSE).	Dobutamine	150-160	troponin T2, cardiac type	Homo sapiens	5-9
19356507-10	2008	CONCLUSIONS: Dobutamine stress testing is a useful diagnostic tool for identifying reduced adrenergic myocardial contractile reserve related to altered myocardial expression of beta(1)-adrenergic receptor, sarcoplasmic reticulum Ca(2+)-adenosine triphosphatase, and phospholamban genes even in asymptomatic or mildly symptomatic patients with DCM.	Dobutamine	13-23	adrenoceptor beta 1	Homo sapiens	177-204
18375318-12	2008	ACE-Is were well tolerated in all patients in group R. CONCLUSIONS: ACE-Is can be used as a dobutamine substitute as early as the first postoperative day after cardiac surgery without renal consequences.	Dobutamine	92-102	angiotensin I converting enzyme	Homo sapiens	0-3
18657656-0	2008	Additive prognostic value of interleukin-6 at peak phase of dobutamine stress echocardiography in patients with coronary artery disease.	Dobutamine	60-70	interleukin 6	Homo sapiens	29-42
18657656-2	2008	BACKGROUND: Interleukin-6 (IL-6) and tissue factor (TF) are elevated after myocardial ischemia during dobutamine stress echo (DSE).	Dobutamine	102-112	interleukin 6	Homo sapiens	12-25
18657656-2	2008	BACKGROUND: Interleukin-6 (IL-6) and tissue factor (TF) are elevated after myocardial ischemia during dobutamine stress echo (DSE).	Dobutamine	102-112	interleukin 6	Homo sapiens	27-31
18657656-2	2008	BACKGROUND: Interleukin-6 (IL-6) and tissue factor (TF) are elevated after myocardial ischemia during dobutamine stress echo (DSE).	Dobutamine	102-112	coagulation factor III, tissue factor	Homo sapiens	37-50
18657656-2	2008	BACKGROUND: Interleukin-6 (IL-6) and tissue factor (TF) are elevated after myocardial ischemia during dobutamine stress echo (DSE).	Dobutamine	102-112	coagulation factor III, tissue factor	Homo sapiens	52-54
18434255-0	2008	Dobutamine inhibits vasopressin-mediated water transport across toad bladder epithelium.	Dobutamine	0-10	arginine vasopressin	Homo sapiens	20-31
18434255-3	2008	Dobutamine had no effect on basal water transport, but partially inhibited transport stimulated by vasopressin.	Dobutamine	0-10	arginine vasopressin	Homo sapiens	99-110
18855529-10	2008	Transgenic mice with cardiac-specific overexpression of PPARalpha showed significantly reduced myocardial contractile and chronotropic responses to the beta-sympathomimetic dobutamine (p < 0.05) compared with wild-type littermates, supporting the hypothesis that increased PPARalpha levels result in a blunted beta-adrenergic response.	Dobutamine	173-183	peroxisome proliferator activated receptor alpha	Mus musculus	56-65
18445058-1	2008	High-dose dobutamine used in dobutamine stress echocardiography (DSE) has hemodynamically based side effects due to a variable combination of beta1 (inotropic) and beta2 (vasodilator) effects.	Dobutamine	10-20	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	142-169
18445058-1	2008	High-dose dobutamine used in dobutamine stress echocardiography (DSE) has hemodynamically based side effects due to a variable combination of beta1 (inotropic) and beta2 (vasodilator) effects.	Dobutamine	29-39	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	142-169
18434255-9	2008	Taken together, the results of this study demonstrate that dobutamine inhibits vasopressin-stimulated water transport in toad bladders through a mechanism mediated by the stimulation of alpha(2)-adrenoceptors, thus suggesting that such a drug may exert a direct cellular effect on membrane permeability to water in transporting epithelia.	Dobutamine	59-69	arginine vasopressin	Homo sapiens	79-90
18275933-2	2008	The selective beta(1)-receptor subtype agonist, dobutamine, induced mucin secretion while the selective beta(2)-, alpha(1)- and alpha(2)-agonists, soterenol, phenylephrine and clonidine, respectively, did not.	Dobutamine	48-58	solute carrier family 13 member 2	Rattus norvegicus	68-73
18375318-12	2008	ACE-Is were well tolerated in all patients in group R. CONCLUSIONS: ACE-Is can be used as a dobutamine substitute as early as the first postoperative day after cardiac surgery without renal consequences.	Dobutamine	92-102	angiotensin I converting enzyme	Homo sapiens	68-71
17689141-3	2007	In this study, we found that lipolysis induced by the beta1-AR agonist dobutamine is decreased and is no longer inhibited by PMA in adipocytes that have been treated with 20 nM insulin for 30 min followed by washing out insulin.	Dobutamine	71-81	adrenoceptor beta 1	Rattus norvegicus	54-62
18222358-1	2008	OBJECTIVES: The purpose of this study was to investigate whether a direct relation can be demonstrated between myocardial perfusion defects detected during dobutamine stress test (DST) by cardiovascular magnetic resonance (CMR) and impairment of coronary microvascular dilatory function in patients with cardiac syndrome X (CSX).	Dobutamine	156-166	NK2 homeobox 5	Homo sapiens	324-327
17681645-6	2008	BDNF levels in astrocytes were increased by the specific beta1-adrenergic agonist dobutamine and the beta2-adrenergic agonist salbutamol, as well as by adenylate cyclase activation (by forskolin) and PKA activation (by dBcAMP).	Dobutamine	82-92	brain-derived neurotrophic factor	Rattus norvegicus	0-4
17901358-4	2007	Tg-GSK-3beta-DN exhibited concentric hypertrophy at baseline, accompanied by upregulation of the alpha-myosin heavy chain gene and increases in cardiac function, as evidenced by a significantly greater Emax after dobutamine infusion and percentage of contraction in isolated cardiac myocytes, indicating that inhibition of GSK-3beta induces well-compensated hypertrophy.	Dobutamine	213-223	glycogen synthase kinase 3 beta	Mus musculus	3-12
17976576-8	2008	Selective inhibition of iNOS by 1400 W (N-3-aminomethyl-benzyl-acetamidine) did not alter responses to dobutamine in the control rats, but augmented the effects of dobutamine on left ventricular developed pressure and rate pressure product in the diabetic rats.	Dobutamine	164-174	nitric oxide synthase 2	Rattus norvegicus	24-28
18031577-7	2007	Dobutamine administration produced a rapid increase in heart rate (9.4 +/- 5.9 beats/min2).	Dobutamine	0-10	CD59 molecule (CD59 blood group)	Homo sapiens	85-89
17541557-2	2007	In vivo, dobutamine infusion evoked smaller heart rate and/or contractility increases in subjects carrying Gly389Gly-beta(1)AR vs subjects carrying Arg389Arg-beta(1)AR.	Dobutamine	9-19	adrenoceptor beta 1	Homo sapiens	117-126
17382451-11	2007	CONCLUSIONS: While the upregulation of Mac-1 expression is inhibited in a dose-dependent manner, the expression of L-selectin is enhanced at low concentrations of dobutamine and dopexamine and partly counter-regulated at high concentrations.	Dobutamine	163-173	selectin L	Homo sapiens	115-125
17537427-8	2007	On the other hand, isoproterenol, a general beta-adrenoceptor agonist and dobutamine, a beta(1)-adrenoceptor agonist, both elicited similar behaviours as those induced by neuropeptide-EI.	Dobutamine	74-84	adrenoceptor beta 1	Rattus norvegicus	88-108
16849043-1	2007	AIMS: Aim of the study was to determine the effect of dobutamine stress echocardiography (DSE)-induced ischemia on circulating levels of N-terminal fragment of B-type natriuretic peptide (NT-pro-BNP).	Dobutamine	54-64	natriuretic peptide B	Homo sapiens	195-198
17541557-2	2007	In vivo, dobutamine infusion evoked smaller heart rate and/or contractility increases in subjects carrying Gly389Gly-beta(1)AR vs subjects carrying Arg389Arg-beta(1)AR.	Dobutamine	9-19	adrenoceptor beta 1	Homo sapiens	158-167
16815566-10	2006	During dobutamine plasma ET-1 and AM showed a great individual variability resulting in no significant difference among groups.	Dobutamine	7-17	endothelin 1	Homo sapiens	25-36
17362986-5	2007	At 14 weeks, there was no decreased heart function reviled by echocardiography at rest, but when dobutamine stress echocardiography was used, a lower cardiac reserve was shown in the mice with antibodies against the second extracellular loop of the beta(1)-adrenergic receptor.	Dobutamine	97-107	adrenergic receptor, beta 1	Mus musculus	249-276
17242014-1	2007	AIMS: The aim of this study was to investigate whether erythropoietin (EPO) has cardioprotective effects in a chronic myocardial ischaemia model regarding strain-rate imaging parameters during dobutamine stress echocardiography (DSE).	Dobutamine	193-203	erythropoietin	Sus scrofa	55-69
17218198-2	2007	Data regarding BNP as a marker of ischemia during dobutamine stress echocardiography (DSE) are not conclusive.	Dobutamine	50-60	natriuretic peptide B	Homo sapiens	15-18
17456988-7	2007	During dobutamine infusion, the LV Endo-torsion increased (9.5+/-2.8 to 19.3+/-4.8 degrees, p<0.01) and these values were greater than those for Epi.	Dobutamine	7-17	tissue factor pathway inhibitor	Homo sapiens	148-151
17325594-4	2007	In group A patients, dobutamine was administered at a starting dose of 5 microg x kg(-1) x min(-1) increased to 10, 20 and 30 microg x kg(-1) x min(-1) to a maximum dose of 40 microg x kg(-1) x min(-1) at 3 min intervals until the target heart rate (THR, 85% of age predicted maximum heart rate) or other standard end point criteria were achieved.	Dobutamine	21-31	CD59 molecule (CD59 blood group)	Homo sapiens	91-97
17325594-7	2007	The mean dose of dobutamine infused in group A was significantly higher than in group B (36.2 vs. 23.5 microg x kg(-1) x min(-1), P<0.01).	Dobutamine	17-27	CD59 molecule (CD59 blood group)	Homo sapiens	121-127
25310654-1	2007	BACKGROUND AND OBJECTIVES: Dobutamine is an inotropic agent with predominant beta1- adrenergic properties frequently used to increase blood flow in critically ill patients.	Dobutamine	27-37	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	77-82
17184500-7	2006	In addition, IGF-I significantly increased pulse pressure increases induced by low doses of dobutamine (from an increase in pulse pressure of 9.9 +/- 1.2 to 13.4 +/- 1.9 mmHg; n = 39; P < 0.05).	Dobutamine	92-102	insulin-like growth factor 1	Rattus norvegicus	13-18
17184500-12	2006	These data indicate that the maximal effects of exogenously administered IGF-I include modest direct vasodilation and inhibition of constrictor responses to NA and an increase in the effect of dobutamine on pulse pressure.	Dobutamine	193-203	insulin-like growth factor 1	Rattus norvegicus	73-78
16815566-12	2006	During dobutamine ET-1 was significantly correlated to Pap/CO characteristics (Slope and ET-1ven, r=-0.59, p<0.05; Slope and ET-1art-ven, r=-0.60, p<0.05; Intercept and ET-1art-ven, r=0.63, p<0.004), and ET-1art-ven was the only independent variable related to Slope and Intercept.	Dobutamine	7-17	endothelin 1	Homo sapiens	18-22
16627864-8	2006	MAIN RESULTS: Pretreatment with dobutamine induced HO-1 in pericentral hepatocytes and improved PDR(ICG) (Vehicle/Shock: 11.7 +/- 8.12%/min vs. Dob/Shock: 19.7 +/- 2.46%/min, p = 0.006).	Dobutamine	32-42	PDR	Homo sapiens	96-104
16627864-9	2006	Blockade of the HO pathway after preconditioning and the combined pretreatment with dobutamine and esmolol decreased PDR(ICG) (Dob/SnMP/Shock: 12.6 +/- 4.24%/min, p = 0.011; Dob/Esmolol/Shock: 10.2 +/- 4.34%/min, p = 0.008).	Dobutamine	84-94	PDR	Homo sapiens	117-125
16627864-11	2006	CONCLUSIONS: These results suggest a beta(1)-adrenoceptor-dependent hepatic up-regulation of HO-1 and a better maintained hepatocellular function after hemorrhagic shock in animals pretreated with dobutamine.	Dobutamine	197-207	adrenoceptor beta 1	Homo sapiens	37-57
16887496-5	2006	Dobutamine stress dose-dependently increased cardiac function, which, however, was significantly smaller with a right shift of the dose-response curve in apoE-KO mice compared with WT controls.	Dobutamine	0-10	apolipoprotein E	Mus musculus	154-158
16627864-0	2006	Dobutamine improves liver function after hemorrhagic shock through induction of heme oxygenase-1.	Dobutamine	0-10	heme oxygenase 1	Homo sapiens	80-96
16627864-2	2006	Previous data suggest that the beta(1)-adrenoceptor agonist dobutamine induces HO-1 in hepatocytes.	Dobutamine	60-70	adrenoceptor beta 1	Homo sapiens	31-51
16730451-2	2006	The purpose of this study is to assess the value of intramyocardial injection of slow-released basic fibroblast growth factor microspheres on angiogenesis and cardiac function in the early period of acute infarcted myocardium with dobutamine cardiovascular magnetic resonance tagging.	Dobutamine	231-241	fibroblast growth factor 2	Canis lupus familiaris	95-125
16772527-9	2006	PLB-Thr17 phosphorylation was inversely correlated with dobutamine-induced increases in contractility in PO animals (r2 = 0.81, P < 0.05).	Dobutamine	56-66	phospholamban	Homo sapiens	0-3
16760913-7	2006	One day after I/R-injury, upregulation of transforming growth factor (TGF)-beta 1 and 2 and phosphorylation of p42/p44 mitogen-activated protein kinases was observed in kidneys of animals treated with DA or DB.	Dobutamine	207-209	transforming growth factor, beta 1	Rattus norvegicus	42-87
16760913-7	2006	One day after I/R-injury, upregulation of transforming growth factor (TGF)-beta 1 and 2 and phosphorylation of p42/p44 mitogen-activated protein kinases was observed in kidneys of animals treated with DA or DB.	Dobutamine	207-209	mitogen activated protein kinase 3	Rattus norvegicus	115-118
16887496-7	2006	Thus, despite an elevated resting aortic flow velocity and left ventricular contractility, cardiac functional reserve in response to dobutamine stress was significantly reduced in apoE-KO mice, which could be the consequence of coronary atherosclerosis and endothelial dysfunction that limits blood supply to the heart.	Dobutamine	133-143	apolipoprotein E	Mus musculus	180-184
17032443-3	2006	The purpose of the present study was to evaluate whether dobutamine may be titrated to reverse the AVP-related decrease in cardiac index (CI) and systemic oxygen delivery index (DO2I) in an established model of ovine endotoxemia.	Dobutamine	57-67	vasopressin-neurophysin 2-copeptin	Ovis aries	99-102
16550155-9	2006	Dobutamine is recommended when the cardiac index is less than 2.5 L x min(-1) x m(-2).	Dobutamine	0-10	CD59 molecule (CD59 blood group)	Homo sapiens	70-76
17032443-9	2006	Dobutamine dose-dependently reversed the decrease in CI (8.8 +/- 0.7 l min-1 m-2 versus 4.4 +/- 0.5 l min-1 m-2), DO2I (1323 +/- 102 versus 633 +/- 61 ml min-1 m-2) and SvO2 (72.2 +/- 1.7% versus 56.5 +/- 2.0%, all p < 0.001 at dobutamine 10 microg kg-1 min-1 versus AVP group) and further increased MAP.	Dobutamine	0-10	vasopressin-neurophysin 2-copeptin	Ovis aries	270-273
17032443-10	2006	CONCLUSION: This study provides evidence that dobutamine is a useful agent for reversing the AVP-associated impairment in systemic blood flow and global oxygen transport.	Dobutamine	46-56	vasopressin-neurophysin 2-copeptin	Ovis aries	93-96
16344403-5	2005	Sham-operated nNOS(-/-) mice showed enhanced basal LV contractility (P<0.03 versus WT, as evaluated by preload-recruitable stroke work) but an attenuated inotropic response to dobutamine infusion (P<0.01 versus WT).	Dobutamine	179-189	nitric oxide synthase 1, neuronal	Mus musculus	14-18
17094270-4	2006	In a pharmacogenetic study composed of 107 subjects, our bivariate model has probed two haplotypes within the beta 2AR candidate gene that exert a significant effect on both SBP and DBP respond to dobutamine.	Dobutamine	197-207	selenium binding protein 1	Homo sapiens	174-177
17094270-4	2006	In a pharmacogenetic study composed of 107 subjects, our bivariate model has probed two haplotypes within the beta 2AR candidate gene that exert a significant effect on both SBP and DBP respond to dobutamine.	Dobutamine	197-207	D-box binding PAR bZIP transcription factor	Homo sapiens	182-185
16344403-10	2005	In contrast, infarcted nNOS(-/-) mice responded to dobutamine with a dramatic fall in LV contractility (P<0.01 for preload-recruitable stroke work).	Dobutamine	51-61	nitric oxide synthase 1, neuronal	Mus musculus	23-27
16150794-9	2005	A blunted HR, SBP and LV contractility (SBP/ESCA; PRE 29 +/- 6 versus POST 20 +/- 6 mmHg cm(-2); P < 0.05) response to dobutamine was demonstrated POST, with values returning towards baseline in REC.	Dobutamine	122-132	solute carrier family 35 member G1	Homo sapiens	150-154
16286589-0	2005	Myocardial ischemia induces interleukin-6 and tissue factor production in patients with coronary artery disease: a dobutamine stress echocardiography study.	Dobutamine	115-125	interleukin 6	Homo sapiens	28-41
16286589-0	2005	Myocardial ischemia induces interleukin-6 and tissue factor production in patients with coronary artery disease: a dobutamine stress echocardiography study.	Dobutamine	115-125	coagulation factor III, tissue factor	Homo sapiens	46-59
16325050-1	2005	OBJECTIVES: The purpose of this research was to find out whether, in humans, dobutamine-induced hemodynamic effects and increase in plasma-renin activity (PRA) might be beta1-adrenoceptor (beta1AR) genotype-dependent.	Dobutamine	77-87	adrenoceptor beta 1	Homo sapiens	169-187
16325050-1	2005	OBJECTIVES: The purpose of this research was to find out whether, in humans, dobutamine-induced hemodynamic effects and increase in plasma-renin activity (PRA) might be beta1-adrenoceptor (beta1AR) genotype-dependent.	Dobutamine	77-87	adrenoceptor beta 1	Homo sapiens	189-196
16325050-5	2005	RESULTS: With regard to PRA, dobutamine increased PRA more potently in Arg389-beta1AR versus Gly389-beta1AR subjects.	Dobutamine	29-39	adrenoceptor beta 1	Homo sapiens	78-85
16325050-5	2005	RESULTS: With regard to PRA, dobutamine increased PRA more potently in Arg389-beta1AR versus Gly389-beta1AR subjects.	Dobutamine	29-39	adrenoceptor beta 1	Homo sapiens	100-107
16325050-6	2005	Bisoprolol markedly suppressed the dobutamine-induced PRA increase in Arg389- but only marginally in Gly389-beta1AR subjects.	Dobutamine	35-45	adrenoceptor beta 1	Homo sapiens	108-115
16325050-7	2005	With regard to hemodynamics, dobutamine caused larger heart rate and contractility increases and diastolic blood pressure decreases in Arg389- versus Gly389-beta1AR subjects.	Dobutamine	29-39	adrenoceptor beta 1	Homo sapiens	157-164
15821035-9	2005	Previous studies have demonstrated that AMPK can be inhibited by protein kinase B (PKB); however, PKB was activated by dobutamine and the elevated insulin that accompanied hyperglycemia, but there was no effect on AMPK activity.	Dobutamine	119-129	AKT serine/threonine kinase 1	Sus scrofa	98-101
15951344-5	2005	Dobutamine challenge resulted in a small increase in contractility in PKC epsilon mice but failed to enhance cardiac output.	Dobutamine	0-10	protein kinase C, epsilon	Mus musculus	70-81
16177543-7	2005	Intraperitoneal injection of dobutamine at 0.3 and 1 mg/kg increased HR, FS, and COI of the P30-anesthetized mice and the P40-anesthetized rats, respectively, whereas the percent responses of these parameters in KX animals were greater than those in pentobarbital-anesthetized ones due to the lower basal values for the cardiac functional parameters.	Dobutamine	29-39	high mobility group box 1	Mus musculus	92-95
16177543-7	2005	Intraperitoneal injection of dobutamine at 0.3 and 1 mg/kg increased HR, FS, and COI of the P30-anesthetized mice and the P40-anesthetized rats, respectively, whereas the percent responses of these parameters in KX animals were greater than those in pentobarbital-anesthetized ones due to the lower basal values for the cardiac functional parameters.	Dobutamine	29-39	interleukin 9	Mus musculus	122-125
16015444-5	2005	At dobutamine echocardiography, a composite of dysfunctional and ischemic myocardium was the strongest correlate of BNP (r = 0.48, p < 0.0001), with less strong correlations by global parameters.	Dobutamine	3-13	natriuretic peptide B	Homo sapiens	116-119
15689500-8	2005	Among the extrahepatic UGTs, the formation of monoglucuronides, mainly catecholic meta-O-glucuronide, by UGTs 1A7 and 1A8 was similar to that by 1A9, whereas UGT1A10 also efficiently catalyzed the formation of catecholic dobutamine para-O-glucuronide.	Dobutamine	221-231	UDP glucuronosyltransferase family 1 member A10	Homo sapiens	158-165
15849228-8	2005	The moderate proteolysis of a cytoskeleton protein, alpha-fodrin was identified (n = 7 of the 8 hearts with the decreased intercept), after clearance of blood dobutamine.	Dobutamine	159-169	spectrin, alpha, non-erythrocytic 1	Rattus norvegicus	52-64
15849228-9	2005	In agreement with our hypothesis, the detrimental effect of the post-beta-adrenergic receptor stimulation was induced by a moderate concentration of dobutamine; we found systolic dysfunction due to the impairment of Ca2+ handling in excitation-contraction coupling in the rat LV and proteolysis of a cytoskeleton protein, alpha-fodrin.	Dobutamine	149-159	spectrin, alpha, non-erythrocytic 1	Rattus norvegicus	322-334
15918589-6	2005	The relaxing response to dobutamine in coronary artery was significantly reduced by blockage of the adrenergic beta1-receptor, but not by removal of endothelium, blockage of the adrenergic beta2-receptor, inhibitors of nitric oxide synthase, guanylate cyclase and prostaglandin synthase.	Dobutamine	25-35	adrenoceptor beta 1	Sus scrofa	100-125
15723960-6	2005	In normotensive controls, midwall shortening increased from baseline during 2 microg x kg(-1) x min(-1) dobutamine by an average of 16+/-4.5% (P<0.01); a value of 2 standard deviations below this mean response was taken as the lower limit of normal.	Dobutamine	104-114	CD59 molecule (CD59 blood group)	Homo sapiens	96-102
16112956-6	2005	Patients with signs of exercise-induced ischemia by dobutamine stress echocardiography have been reported to have higher baseline BNP values.	Dobutamine	52-62	natriuretic peptide B	Homo sapiens	130-133
15813619-13	2005	Drugs with predominantly beta1-adrenergic receptor affinity were associated with a higher incidence of postoperative AF (dopamine 44%, dobutamine 41% vs. phenylepherine 20%, p = 0.001).	Dobutamine	135-145	adrenoceptor beta 1	Homo sapiens	25-50
15698484-11	2005	Dobutamine in LRS+HES resuscitation+dobutamine treatment group could also greatly decrease lactate and Pt-aCO2 gap, significantly improve pHi compared with LRS resuscitation+dobutamine treatment group (all P<0.05).	Dobutamine	36-46	glucose-6-phosphate isomerase	Oryctolagus cuniculus	138-141
15659150-6	2005	4 (-)-Dobutamine (beta1-adrenoceptor-selective agonist)-induced tachycardia was significantly suppressed by ELF-EMF exposure in MF-1 for the increase in HR (DeltaHR), the decrease in QRS interval (DeltaQRS) and the decrease in QT (DeltaQT) interval.	Dobutamine	2-16	adrenoceptor beta 1	Rattus norvegicus	18-36
15698484-10	2005	Dobutamine in LRS resuscitation+dobutamine treatment and LRS+HES resuscitation+dobutamine treatment group could greatly decrease lactate and Pt-aCO2 gap, significantly improve pHi and DO2 compared with other two resuscitation groups (all P<0.05).	Dobutamine	0-10	aconitate hydratase, mitochondrial	Oryctolagus cuniculus	144-148
15698484-10	2005	Dobutamine in LRS resuscitation+dobutamine treatment and LRS+HES resuscitation+dobutamine treatment group could greatly decrease lactate and Pt-aCO2 gap, significantly improve pHi and DO2 compared with other two resuscitation groups (all P<0.05).	Dobutamine	0-10	glucose-6-phosphate isomerase	Oryctolagus cuniculus	176-179
15698484-10	2005	Dobutamine in LRS resuscitation+dobutamine treatment and LRS+HES resuscitation+dobutamine treatment group could greatly decrease lactate and Pt-aCO2 gap, significantly improve pHi and DO2 compared with other two resuscitation groups (all P<0.05).	Dobutamine	79-89	aconitate hydratase, mitochondrial	Oryctolagus cuniculus	144-148
15698484-11	2005	Dobutamine in LRS+HES resuscitation+dobutamine treatment group could also greatly decrease lactate and Pt-aCO2 gap, significantly improve pHi compared with LRS resuscitation+dobutamine treatment group (all P<0.05).	Dobutamine	0-10	aconitate hydratase, mitochondrial	Oryctolagus cuniculus	106-110
15698484-11	2005	Dobutamine in LRS+HES resuscitation+dobutamine treatment group could also greatly decrease lactate and Pt-aCO2 gap, significantly improve pHi compared with LRS resuscitation+dobutamine treatment group (all P<0.05).	Dobutamine	0-10	glucose-6-phosphate isomerase	Oryctolagus cuniculus	138-141
15698484-11	2005	Dobutamine in LRS+HES resuscitation+dobutamine treatment group could also greatly decrease lactate and Pt-aCO2 gap, significantly improve pHi compared with LRS resuscitation+dobutamine treatment group (all P<0.05).	Dobutamine	36-46	aconitate hydratase, mitochondrial	Oryctolagus cuniculus	106-110
15505502-7	2004	pD2 and Emax values for dobutamine were significantly higher than those for rolipram.	Dobutamine	24-34	PAF1 homolog, Paf1/RNA polymerase II complex component	Homo sapiens	0-3
15502056-5	2004	Therefore, we examined the effects of various adrenergic drugs (dobutamine, xamoterol, clenbuterol, epinephrine, norepinephrine, and phenylephrine) on the activation of NF-kappaB, on the NF-kappaB-driven reporter gene activity, and on the expression of the NF-kappaB target gene interleukin (IL)-8.	Dobutamine	64-74	nuclear factor kappa B subunit 1	Homo sapiens	169-178
15502056-7	2004	Here we report that dobutamine inhibited the activation of NF-kappaB in primary human CD3(+) T lymphocytes.	Dobutamine	20-30	nuclear factor kappa B subunit 1	Homo sapiens	59-68
15502056-10	2004	Our results demonstrate that dobutamine is a potent and specific inhibitor of NF-kappaB, and they thus provide a possible molecular mechanism for the immunomodulation associated with beta-adrenergic therapy.	Dobutamine	29-39	nuclear factor kappa B subunit 1	Homo sapiens	78-87
15564877-7	2004	RESULTS: Subjects homozygous for the Arg389 beta1AR showed a significantly higher increase in fractional shortening upon cumulative doses of dobutamine as compared to subjects carrying one or two copies of the Gly389 allele.	Dobutamine	141-151	adrenoceptor beta 1	Homo sapiens	44-51
15315609-0	2004	Dobutamine compensates deleterious hemodynamic and metabolic effects of vasopressin in the splanchnic region in endotoxin shock.	Dobutamine	0-10	vasopressin	Sus scrofa	72-83
15315609-5	2004	We aimed to keep systemic mean arterial pressure (MAP) >70 mmHg by vasopressin; the goal of dobutamine infusion was to prevent decrease in cardiac output often associated with vasopressin infusion.	Dobutamine	95-105	vasopressin	Sus scrofa	179-190
15315609-11	2004	Vasopressin also induced splanchnic lactate release and arterial hyperlactatemia, which were not observed when dobutamine was combined with vasopressin.	Dobutamine	111-121	vasopressin	Sus scrofa	0-11
15315609-12	2004	CONCLUSION: Dobutamine prevents adverse hemodynamic and metabolic effects of vasopressin in septic shock.	Dobutamine	12-22	vasopressin	Sus scrofa	77-88
15311061-6	2004	The beta1-adrenoceptor agonist dobutamine had a relaxing effect on the ureter only at high concentrations (over 1 x 10 M).	Dobutamine	31-41	adrenoceptor beta 1	Homo sapiens	4-22
15252280-3	2004	Dobutamine (a beta 1-agonist) or salbutamol (a beta 2-agonist) reversed the memory impairment induced by baclofen without exhibiting intrinsic actions on memory when administered alone.	Dobutamine	0-10	histocompatibility 2, class II antigen A, beta 1	Mus musculus	12-18
15193679-3	2004	METHODS: In 14 patients, HHM was diagnosed by dobutamine echocardiography, radionuclide ventriculography, and thallium-201 scintigraphy.	Dobutamine	46-56	cyclin D1 binding protein 1	Homo sapiens	25-28
15179140-7	2004	beta1-Receptor agonists dobutamine and xamoterol induced HO-1 dose dependently, whereas the beta1-receptor antagonist metoprolol attenuated HO-1 induction by beta1-receptor agonists.	Dobutamine	24-34	heme oxygenase 1	Rattus norvegicus	57-61
15189931-14	2004	Dobutamine administration increased cardiac output and Ppa, and decreased PVR and Z(0), without changing Zc.	Dobutamine	0-10	PVR cell adhesion molecule	Homo sapiens	74-77
15138671-2	2004	The objective was to compare endocrine effects of equipotent inotropic doses of dopexamine, dobutamine and dopamine on prolactin and thyreotropin release perioperatively.	Dobutamine	92-102	prolactin	Homo sapiens	119-128
15138671-13	2004	CONCLUSIONS: In high-risk surgical patients dopexamine or dobutamine produced fewer effects on prolactin and thyreotropin serum concentrations in comparison with DA when used in equivalent dosages.	Dobutamine	58-68	prolactin	Homo sapiens	95-104
15179140-9	2004	Inhibition of protein kinase A (PKA) abolished induction by dobutamine and 8 Br-cAMP.	Dobutamine	60-70	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	14-30
15179140-9	2004	Inhibition of protein kinase A (PKA) abolished induction by dobutamine and 8 Br-cAMP.	Dobutamine	60-70	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	32-35
15179140-11	2004	In vivo infusion of dobutamine for 6 h induced HO-1 in rat livers.	Dobutamine	20-30	heme oxygenase 1	Rattus norvegicus	47-51
15019872-0	2004	Usefulness of plasma brain natriuretic peptide levels in predicting dobutamine-induced myocardial ischemia.	Dobutamine	68-78	natriuretic peptide B	Homo sapiens	21-46
15023079-3	2004	In the present study, PWR has been used to monitor the incorporation of the human beta(2)-adrenergic receptor into a solid-supported egg phosphatidylcholine lipid bilayer and to follow the binding of full agonists (isoproterenol, epinephrine), a partial agonist (dobutamine), an antagonist (alprenolol), and an inverse agonist (ICI-118,551) to the receptor.	Dobutamine	263-273	adrenoceptor beta 2	Homo sapiens	82-109
15019872-7	2004	The change in BNP levels with dobutamine stress was not associated with ischemia.	Dobutamine	30-40	natriuretic peptide B	Homo sapiens	14-17
15019872-9	2004	In this pilot study, resting BNP was predictive of dobutamine-induced ischemia.	Dobutamine	51-61	natriuretic peptide B	Homo sapiens	29-32
15030423-5	2004	To characterize beta2-agonist effects, a comparison was made with the beta1-selective agonist dobutamine.	Dobutamine	94-104	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	70-75
14750408-10	2004	Dobutamine stress echocardiography revealed myocardial ischemia in the infarct region in 30% in the Convex ST-E group and 75% in the Concave ST-E group(p < 0.05).	Dobutamine	0-10	sulfotransferase family 1E member 1	Homo sapiens	107-111
14665551-11	2004	The ZFP increased significantly with ephedrine (from 29 (10) to 44 (11) mm Hg) and dobutamine (from 35 (14) to 43 (10) mm Hg) but not dopexamine (from 3 (23) to 11 (22) mm Hg).	Dobutamine	83-93	zinc finger with KRAB and SCAN domains 7	Homo sapiens	4-7
15296120-7	2004	Prognostic value of dobutamine stress-echocardiography test was analyzed by Cox regression model and was 2.92, meaning that the risk of significant events was 2.92 times higher in the group of patients with positive findings of dobutamine stress-echocardiography test.	Dobutamine	20-30	cytochrome c oxidase subunit 8A	Homo sapiens	76-79
15296120-7	2004	Prognostic value of dobutamine stress-echocardiography test was analyzed by Cox regression model and was 2.92, meaning that the risk of significant events was 2.92 times higher in the group of patients with positive findings of dobutamine stress-echocardiography test.	Dobutamine	228-238	cytochrome c oxidase subunit 8A	Homo sapiens	76-79
15013120-1	2004	OBJECTIVES: We sought to evaluate the impact of dobutamine stress echocardiography (DSE) in patients with known rheumatic mitral stenosis (MS) in order to assess its safety, feasibility, and prognostic correlation to well-known clinical outcomes.	Dobutamine	48-58	dermatan sulfate epimerase	Homo sapiens	84-87
14750408-10	2004	Dobutamine stress echocardiography revealed myocardial ischemia in the infarct region in 30% in the Convex ST-E group and 75% in the Concave ST-E group(p < 0.05).	Dobutamine	0-10	sulfotransferase family 1E member 1	Homo sapiens	141-145
14583313-13	2003	However, only VEGF and FGF-2 were effective with regard to regional contractility under dobutamine stress and to left ventricular contractility.	Dobutamine	88-98	vascular endothelial growth factor A	Homo sapiens	14-18
14583313-13	2003	However, only VEGF and FGF-2 were effective with regard to regional contractility under dobutamine stress and to left ventricular contractility.	Dobutamine	88-98	fibroblast growth factor 2	Homo sapiens	23-28
12972869-5	2003	RESULTS: Compared with peak exercise, dobutamine infusion resulted in lower cardiac output (12 +/- 2 vs 16 +/- 4 l x min(-1), P < 0.0001), heart rates (163 +/- 7 vs 175 +/- 12 beats x min(-1), P < 0.0001), and systolic blood pressure (160 +/- 22 vs 185 +/- 20 mm Hg, P < or = 0.0001).	Dobutamine	38-48	CD59 molecule (CD59 blood group)	Homo sapiens	117-123
12750069-2	2003	We tested the hypothesis that the beta1-agonist dobutamine increases peripheral chemosensitivity in a double-blind placebo-controlled randomized and crossover study.	Dobutamine	48-58	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	34-39
12972869-5	2003	RESULTS: Compared with peak exercise, dobutamine infusion resulted in lower cardiac output (12 +/- 2 vs 16 +/- 4 l x min(-1), P < 0.0001), heart rates (163 +/- 7 vs 175 +/- 12 beats x min(-1), P < 0.0001), and systolic blood pressure (160 +/- 22 vs 185 +/- 20 mm Hg, P < or = 0.0001).	Dobutamine	38-48	CD59 molecule (CD59 blood group)	Homo sapiens	187-193
12818968-5	2003	The effect of dobutamine on MIP-1alpha and IL-8 synthesis was examined by using an enzyme-linked immunosorbent assay, and MIP-1alpha and IL-8 messenger RNA (mRNA) were examined by using reverse transcriptase-polymerase chain reaction.	Dobutamine	14-24	C-C motif chemokine ligand 3	Homo sapiens	28-38
12818968-6	2003	Dobutamine significantly inhibited LPS-induced MIP-1alpha and IL-8 production by THP-1 cells in a dose-dependent manner.	Dobutamine	0-10	C-C motif chemokine ligand 3	Homo sapiens	47-57
12818967-0	2003	Dobutamine inhibits monocyte chemoattractant protein-1 production and chemotaxis in human monocytes.	Dobutamine	0-10	C-C motif chemokine ligand 2	Homo sapiens	20-54
12818967-2	2003	We conducted this study to investigate the effects of dobutamine and dopamine on lipopolysaccharide (LPS)-induced MCP-1 production in human monocytic THP-1 cells.	Dobutamine	54-64	C-C motif chemokine ligand 2	Homo sapiens	114-119
12818968-6	2003	Dobutamine significantly inhibited LPS-induced MIP-1alpha and IL-8 production by THP-1 cells in a dose-dependent manner.	Dobutamine	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	62-66
12818967-5	2003	Dobutamine inhibited LPS-induced production of MCP-1, as well as messenger RNA expression, in a dose-dependent manner, whereas dopamine had no significant effect.	Dobutamine	0-10	C-C motif chemokine ligand 2	Homo sapiens	47-52
12818967-6	2003	Furthermore, we demonstrated that dobutamine suppressed MCP-1-induced chemotaxis and peak [Ca(2+)](i) in monocytic THP-1 cells.	Dobutamine	34-44	C-C motif chemokine ligand 2	Homo sapiens	56-61
12818967-7	2003	These findings suggest that dobutamine may modulate monocyte activation, such as chemotaxis and [Ca(2+)](i), as well as MCP-1 production, during therapy for congestive heart failure.	Dobutamine	28-38	C-C motif chemokine ligand 2	Homo sapiens	120-125
12818967-9	2003	In this study, dobutamine was found to inhibit lipopolysaccharide-induced MCP-1 production and messenger RNA expression, as well as MCP-1-induced chemotaxis and peak [Ca(2+)](i), in human monocytes.	Dobutamine	15-25	C-C motif chemokine ligand 2	Homo sapiens	74-79
12818968-0	2003	Dobutamine modulates lipopolysaccharide-induced macrophage inflammatory protein-1alpha and interleukin-8 production in human monocytes.	Dobutamine	0-10	C-C motif chemokine ligand 3	Homo sapiens	48-86
12818968-0	2003	Dobutamine modulates lipopolysaccharide-induced macrophage inflammatory protein-1alpha and interleukin-8 production in human monocytes.	Dobutamine	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	91-104
12818968-3	2003	We conducted this study to investigate the effect of dobutamine on lipopolysaccharide (LPS)-induced MIP-1alpha and IL-8 production by human monocytic THP-1 cells.	Dobutamine	53-63	C-C motif chemokine ligand 3	Homo sapiens	100-110
12818968-3	2003	We conducted this study to investigate the effect of dobutamine on lipopolysaccharide (LPS)-induced MIP-1alpha and IL-8 production by human monocytic THP-1 cells.	Dobutamine	53-63	C-X-C motif chemokine ligand 8	Homo sapiens	115-119
12818968-8	2003	MIP-1alpha mRNA was also suppressed by 10 micro M dobutamine, whereas, at the same concentration, dobutamine had no significant effect on the IL-8 mRNA level.	Dobutamine	50-60	C-C motif chemokine ligand 3	Homo sapiens	0-10
12818968-9	2003	Moreover, we found that dobutamine suppressed the MIP-1alpha-induced chemotaxis in THP-1 differentiated macrophages.	Dobutamine	24-34	C-C motif chemokine ligand 3	Homo sapiens	50-60
12818968-10	2003	These findings suggest that dobutamine may inhibit macrophage chemotaxis, as well as MIP-1alpha and IL-8 production by monocytes.	Dobutamine	28-38	C-C motif chemokine ligand 3	Homo sapiens	85-95
12818968-10	2003	These findings suggest that dobutamine may inhibit macrophage chemotaxis, as well as MIP-1alpha and IL-8 production by monocytes.	Dobutamine	28-38	C-X-C motif chemokine ligand 8	Homo sapiens	100-104
12818968-13	2003	Our study suggests that dobutamine may inhibit macrophage chemotaxis, as well as lipopolysaccharide-induced MIP-1alpha and IL-8 production by human monocytes.	Dobutamine	24-34	C-C motif chemokine ligand 3	Homo sapiens	108-118
12818968-13	2003	Our study suggests that dobutamine may inhibit macrophage chemotaxis, as well as lipopolysaccharide-induced MIP-1alpha and IL-8 production by human monocytes.	Dobutamine	24-34	C-X-C motif chemokine ligand 8	Homo sapiens	123-127
12736183-7	2003	beta-Adrenergic agonists also stimulated GyK activity with the following relative magnitude of response: CL316243 (beta(3)) > isoproterenol (non-selective) > dobutamine (beta(1)).	Dobutamine	164-174	glycerol kinase	Rattus norvegicus	41-44
12817706-4	2002	Terbutaline (an agonist of beta2-adrenoceptor) and dobutamine (an agonist of beta1-adrenoceptor), both are able to increase intracellular cAMP via activation of adenylate cyclase, were examined in the anesthetized rat with endotoxemia.	Dobutamine	51-61	adrenoceptor beta 1	Rattus norvegicus	77-95
12712011-5	2003	RESULTS: During dobutamine pVel/pSR/epsilon were interpretable in >95% of segments at every stress stage, whereas in groups 1 and 2 pSR/epsilon responses were noninterpretable in >36% of segments (P <.0002).	Dobutamine	16-26	jumonji domain containing 6, arginine demethylase and lysine hydroxylase	Homo sapiens	32-35
12817706-8	2002	In addition, both terbutaline and dobutamine reduced the plasma TNF-alpha level, but only terbutaline attenuated the aortic O2*- production in these endotoxemic rats.	Dobutamine	34-44	tumor necrosis factor	Rattus norvegicus	64-73
12423672-6	2002	Norepinephrine, an alpha1 agonist phenylephrine, a beta1 agonist dobutamine and terbutaline suppressed the expressions of mRNAs encoding pro-inflammatory cytokines, interleukin-6 and tumor necrosis factor alpha.	Dobutamine	65-75	interleukin 6	Rattus norvegicus	165-210
12427596-5	2002	The dP/dt-EDV changed the most among parameters after atrial pacing and dobutamine infusion (percent change, 162.8 +/- 95.9% and 271.0 +/- 44.0%, respectively).	Dobutamine	72-82	endogenous sequence related to the Duplan murine retrovirus	Mus musculus	10-13
12462555-12	2002	Because glucose production is enhanced by alpha1- and beta2-adrenoceptor stimulation, we conclude that dobutamine is only a weak agonist at these adrenoceptors.	Dobutamine	103-113	adrenoceptor beta 2	Homo sapiens	42-72
12423672-7	2002	Release of tumor necrosis factor alpha and nitric oxide was suppressed by norepinephrine, phenylephrine, dobutamine and terbutaline.	Dobutamine	105-115	tumor necrosis factor	Rattus norvegicus	11-38
12423672-8	2002	An alpha2 agonist clonidine and dobutamine upregulated the expression of mRNA encoding catechol-O-methyl transferase, an important enzyme to degrade norepinephrine.	Dobutamine	32-42	catechol-O-methyltransferase	Rattus norvegicus	87-116
12098582-8	2002	In addition, beta(1)-adrenoceptor stimulation by dobutamine (1-10 microM) protected hippocampal neurons against glutamate toxicity.	Dobutamine	49-59	adrenergic receptor, beta 1	Mus musculus	13-33
12356382-7	2002	A significant correlation was present among Em, Sm, and the number of mRNA copies of TNF-alpha and NOS2 at baseline and during infusion of dobutamine (r range -0.72 to -0.92, p <0.01 for all).	Dobutamine	139-149	tumor necrosis factor	Homo sapiens	85-94
12356382-7	2002	A significant correlation was present among Em, Sm, and the number of mRNA copies of TNF-alpha and NOS2 at baseline and during infusion of dobutamine (r range -0.72 to -0.92, p <0.01 for all).	Dobutamine	139-149	nitric oxide synthase 2	Homo sapiens	99-103
12237475-8	2002	Akt-transgenic mice also showed a remarkable increase in cardiac contractility compared with wild-type controls as demonstrated by the analysis of left ventricular (dP/dt(max)) in an invasive hemodynamic study, although with graded dobutamine infusion, the maximum response was not different from that in controls.	Dobutamine	232-242	thymoma viral proto-oncogene 1	Mus musculus	0-3
12171829-1	2002	BACKGROUND: We evaluated whether dobutamine gated blood pool scintigraphy (DOB-GBP) can predict improvement in cardiac sympathetic nerve activity and cardiac function after beta-blocker therapy in patients with dilated cardiomyopathy (DCM).	Dobutamine	33-43	transmembrane protein 132A	Homo sapiens	79-82
12067855-6	2002	The classical beta(1)-AR agonist dobutamine and the beta(2)-AR agonist clenbuterol also considerably diminished insulin-induced glucose uptake.	Dobutamine	33-43	adrenoceptor beta 1	Homo sapiens	14-24
12015925-3	2002	Our objective was to describe TnT behavior after dobutamine stress echocardiography (EDOB) and evaluate its usefulness for improving the diagnostic power of EDOB.Methods.	Dobutamine	49-59	troponin T1, slow skeletal type	Homo sapiens	30-33
12075262-1	2002	OBJECTIVE: Our objective was to compare the qualitative response to low-dose dobutamine by echocardiography (DSE) with the quantitative response of magnetic resonance myocardial tagging (DMRT) in the prediction and evaluation of functional improvement after reperfused myocardial infarction (MI).	Dobutamine	77-87	dermatan sulfate epimerase	Homo sapiens	109-112
12015925-11	2002	The rise in TnT levels during EDOB suggests that this test may produce myocardial damage associated with the appearance of contractility disorders during dobutamine infusion.	Dobutamine	154-164	troponin T1, slow skeletal type	Homo sapiens	12-15
11959654-5	2002	Demand-induced ischemia was produced with intravenous dobutamine (15 microg x kg(-1) x min(-1)) and 20% reduction in LAD flow for 20 min.	Dobutamine	54-64	CD59 molecule (CD59 blood group)	Homo sapiens	87-93
11923045-4	2002	METHODS: In 16 patients with documented coronary artery disease and impaired left ventricular function, HHM was preoperatively detected by thallium-201 scintigraphy, radionuclide ventriculography and low-dose dobutamine echocardiography.	Dobutamine	209-219	cyclin D1 binding protein 1	Homo sapiens	104-107
11868065-8	2002	The mean Sw1 and Sw2 increased significantly with 2 microg/kg/min and 5 microg/kg/min of dobutamine, respectively, in the viability (+) group.	Dobutamine	89-99	WD repeat domain 82 pseudogene 1	Homo sapiens	17-20
11907189-0	2002	Kinetic interactions of dopamine and dobutamine with human catechol-O-methyltransferase and monoamine oxidase in vitro.	Dobutamine	37-47	catechol-O-methyltransferase	Homo sapiens	59-87
11855668-1	2002	The present study was designed to examine whether long-term blockade of angiotensin-converting enzyme (ACE) with perindopril ameliorates dobutamine-induced myocardial ischemia in patients with coronary artery disease (CAD).	Dobutamine	137-147	angiotensin I converting enzyme	Homo sapiens	72-101
11855668-1	2002	The present study was designed to examine whether long-term blockade of angiotensin-converting enzyme (ACE) with perindopril ameliorates dobutamine-induced myocardial ischemia in patients with coronary artery disease (CAD).	Dobutamine	137-147	angiotensin I converting enzyme	Homo sapiens	103-106
11737966-0	2001	Relationship between dobutamine echocardiography and the elevation of cardiac troponin I in patients with acute coronary syndromes.	Dobutamine	21-31	troponin I3, cardiac type	Homo sapiens	70-88
11599061-0	2001	Dobutamine stress cine-MRI of cardiac function in the hearts of adult cardiomyocyte-specific VEGF knockout mice.	Dobutamine	0-10	vascular endothelial growth factor A	Mus musculus	93-97
11605937-10	2001	Treatment of endotoxic mice with dobutamine significantly decreased interleukin-6 protein (P < 0.05) and mRNA (P < 0.05) expression.	Dobutamine	33-43	interleukin 6	Mus musculus	68-81
11605937-12	2001	Dobutamine decreased interleukin-10 expression, whereas dopexamine did not.	Dobutamine	0-10	interleukin 10	Mus musculus	21-35
11605937-13	2001	In endotoxemic mice, both dobutamine and dopexamine decreased induction of macrophage inflammatory protein-2 mRNA (P < 0.05) and reduced the fraction of neutrophils in lung lavage fluid (P < 0.05).	Dobutamine	26-36	chemokine (C-X-C motif) ligand 2	Mus musculus	75-108
11737966-6	2001	The occurrence of positive dobutamine echocardiography in patients with elevated cTnI was significantly higher than in those with normal cTnI (86.5% vs. 67.5%, P = 0.042).	Dobutamine	27-37	troponin I3, cardiac type	Homo sapiens	81-85
11737966-6	2001	The occurrence of positive dobutamine echocardiography in patients with elevated cTnI was significantly higher than in those with normal cTnI (86.5% vs. 67.5%, P = 0.042).	Dobutamine	27-37	troponin I3, cardiac type	Homo sapiens	137-141
11737966-8	2001	When compared with patients with normal cTnI, patients with elevated cTnI had a lower ischemic threshold during dobutamine echocardiography, and more frequently had baseline echocardiographic wall-motion abnormalities, a history of myocardial infarction, and a positive dobutamine echocardiography.	Dobutamine	112-122	troponin I3, cardiac type	Homo sapiens	69-73
11737966-8	2001	When compared with patients with normal cTnI, patients with elevated cTnI had a lower ischemic threshold during dobutamine echocardiography, and more frequently had baseline echocardiographic wall-motion abnormalities, a history of myocardial infarction, and a positive dobutamine echocardiography.	Dobutamine	270-280	troponin I3, cardiac type	Homo sapiens	69-73
11737966-9	2001	Using multivariate analysis, we found that only a lower dobutamine echocardiography ischemic threshold (P = 0.0008) and baseline wall-motion abnormalities (P = 0.0004) were associated independently with the elevation of cTnI.	Dobutamine	56-66	troponin I3, cardiac type	Homo sapiens	220-224
11465229-4	2001	After a resting Doppler echocardiogram, a dobutamine infusion was started at a rate of 5 microg x kg(-1) x min(-1) and increased to 30 microg x kg(-1) x min(-1) at 15-minute intervals.	Dobutamine	42-52	CD59 molecule (CD59 blood group)	Homo sapiens	107-113
11489778-9	2001	Both basal LV +dP/dt and its response to dobutamine were significantly increased in iNOS(-/-) compared with the wild-type mice (P<0.05).	Dobutamine	41-51	nitric oxide synthase 2, inducible	Mus musculus	84-88
11481219-3	2001	In normal conscious dogs chronically instrumented for left ventricular pressure-dimension analysis, PDE5A inhibition by EMD82639 had modest basal effects but markedly blunted dobutamine-enhanced systolic and diastolic function.	Dobutamine	175-185	phosphodiesterase 5A	Canis lupus familiaris	100-105
11505119-15	2001	The release of hepatic TNF-alpha after 12 hrs of dobutamine treatment was twice as high (p <.05) as during enoximone.	Dobutamine	49-59	tumor necrosis factor	Homo sapiens	23-32
11241017-4	2001	RESULTS: CREB(A133) mice displayed significantly lower values of LV fiber shortening velocities over a wide range of afterloads, and they displayed smaller dobutamine-induced shifts from baseline contractility relations.	Dobutamine	156-166	cAMP responsive element binding protein 1	Mus musculus	9-18
11325192-2	2001	Several purported agonists, including isoproterenol, epinephrine, norepinephine, dobutamine, salbutamol, and terbutaline, exhibited dual-affinity displacement curves, which is characteristic of agonist binding to betaAR.	Dobutamine	81-91	adrenoceptor beta 2	Homo sapiens	213-219
11288970-2	2001	HYPOTHESIS: We hypothesized that the inotropic support afforded by dobutamine may serve as a bridge to the introduction and intensification of angiotensin-converting enzyme (ACE) inhibitor-nitrate therapy.	Dobutamine	67-77	angiotensin I converting enzyme	Homo sapiens	143-172
11288970-2	2001	HYPOTHESIS: We hypothesized that the inotropic support afforded by dobutamine may serve as a bridge to the introduction and intensification of angiotensin-converting enzyme (ACE) inhibitor-nitrate therapy.	Dobutamine	67-77	angiotensin I converting enzyme	Homo sapiens	174-177
11288970-12	2001	CONCLUSIONS: Of the patients on dobutamine inotropic support, 70% were successfully transitioned to ACE inhibitor-nitrate therapy, with improved symptoms and LVEF, and with reduced hospitalizations and follow-up dobutamine or transplant.	Dobutamine	32-42	angiotensin I converting enzyme	Homo sapiens	100-103
11288970-12	2001	CONCLUSIONS: Of the patients on dobutamine inotropic support, 70% were successfully transitioned to ACE inhibitor-nitrate therapy, with improved symptoms and LVEF, and with reduced hospitalizations and follow-up dobutamine or transplant.	Dobutamine	212-222	angiotensin I converting enzyme	Homo sapiens	100-103
11406479-6	2001	In normal dogs, intracoronary SNP blunted the inotropic response to Dob (% Delta dP/dt 93 +/- 6% saline vs. 71 +/- 5% SNP, P < 0.05), whereas intracoronary BNP had no effect.	Dobutamine	68-71	natriuretic peptide B	Canis lupus familiaris	159-162
11344226-2	2001	The beta(1)-adrenoceptor study was performed in 9 obese and 10 lean men and consisted of 4 30-min periods during which subjects received consecutive infusions of 0, 3, 6, and 9 microg/kg fat-free mass (FFM).min dobutamine.	Dobutamine	211-221	adrenoceptor beta 1	Homo sapiens	4-24
11139781-5	2001	The beta1-adrenergic agonist dobutamine and the beta-2 agonist terbutaline also (both at 10(-5) M) significantly stimulated PYY secretion, from 29+/-1 to 79+/-12 fmol/2 min and from 19+/-1 to 73+/-13 fmol/2 min respectively (n=7, P<0.05).	Dobutamine	29-39	peptide YY	Rattus norvegicus	124-127
11215320-1	2001	The seven O-methylated analogs of dobutamine [(+/-)-4-[2-[[3-(p-hydroxyphenyl)-1-methylpropyl]amino]ethyl]pyrocatechol, CAS 34368-04-2), a trihydroxy secondary amine, can be considered potential impurities of the latter, the ultimate step of the synthesis of dobutamine being the deprotection of the three phenolic groups.	Dobutamine	34-44	BCAR1 scaffold protein, Cas family member	Homo sapiens	120-123
11118019-2	2000	We used microdialysis to study the in situ lipolytic effects of dobutamine (selective beta1-agonist) and terbutaline (selective beta2-agonist) on glycerol release (lipolytic index) in abdominal subcutaneous AT in 10 obese girls aged 13-17 years, BMI 38 +/- 2.1 kg/m2, and in 7 lean girls aged 11-17 years, BMI 21 +/- 1.1 kg/m2, and compared them with 10 obese women aged 21-39 years, BMI 36 +/- 1.6 kg/m2, and 10 lean women aged 18-42 years, BMI 21 +/- 0.4 kg/m2.	Dobutamine	64-74	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	86-91
11087255-12	2000	Analyses of glucose uptake and glycolytic intermediates revealed sustained enhancement of glycolysis by low-dose dobutamine, but glycolysis became limited at glyceraldehyde 3-phosphate dehydrogenase during high-dose dobutamine treatment.	Dobutamine	216-226	glyceraldehyde-3-phosphate dehydrogenase	Canis lupus familiaris	158-198
10827139-14	2000	Caveolin-3 abundance positively correlated with L-NMMA augmentation of dobutamine inotropic responses in HF (r = 0.9, P = 0.03; n = 4).	Dobutamine	71-81	caveolin 3	Canis lupus familiaris	0-10
11009478-6	2000	In LV crude homogenate, the thapsigargin-sensitive, Ca(2+)-ATPase activity-cAMP relationships was significantly less increased by milrinone compared with dobutamine (P < 0.05), indicating the higher sensitivity of the SR Ca(2+)-ATPase activity on cAMP by milrinone than by dobutamine.	Dobutamine	154-164	cathelicidin antimicrobial peptide	Homo sapiens	75-79
11009478-6	2000	In LV crude homogenate, the thapsigargin-sensitive, Ca(2+)-ATPase activity-cAMP relationships was significantly less increased by milrinone compared with dobutamine (P < 0.05), indicating the higher sensitivity of the SR Ca(2+)-ATPase activity on cAMP by milrinone than by dobutamine.	Dobutamine	276-286	cathelicidin antimicrobial peptide	Homo sapiens	75-79
11482713-10	2000	CONCLUSION: In asymptomatic or slightly symptomatic patients with surgically corrected TGA dobutamine had a positive inotropic effect on RV, but the increased contractility was not accompanied by an appropriate increase in SV.	Dobutamine	91-101	T-box transcription factor 1	Homo sapiens	87-90
19081329-8	2000	Dobutamine stress testing induced a significant decrease in ANF in all dogs in ELVD.	Dobutamine	0-10	natriuretic peptide A	Canis lupus familiaris	60-63
11071301-10	2000	During dobutamine infusion, eFS was significantly lower in groups Hc and Hn (54.1+/-9.2 and 54.1+/-7.9%, respectively) than that observed in group N (61.7+/-7.4%).	Dobutamine	7-17	embryonal Fyn-associated substrate	Homo sapiens	28-31
11071301-11	2000	In addition, eFS was highly correlated with circumferential end-systolic wall stress (ESS) during dobutamine infusion in the three groups.	Dobutamine	98-108	embryonal Fyn-associated substrate	Homo sapiens	13-16
10681485-6	2000	METHODS: Seventy five patients with previous myocardial infarction were studied in a low dose (up to 20 microg(-1) x kg(-1) x min(-1)) dobutamine stress echocardiography study.	Dobutamine	135-145	CD59 molecule (CD59 blood group)	Homo sapiens	126-132
10731471-4	2000	The beta(1)-adrenoceptor agonist dobutamine induced less relaxation in intact arteries from oestrus rats than did isoprenaline, and dobutamine-induced relaxation was markedly less in intact segments from OVX compared with oestrus rats.	Dobutamine	33-43	adrenoceptor beta 1	Rattus norvegicus	4-24
10630826-9	1999	Dobutamine is a beta1-, beta2-, and alpha1-adrenergic agonist.	Dobutamine	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	16-21
10598598-6	1999	RESULTS: Dobutamine increased cardiac index (3.0+/-0.6 to 4.4+/-1.0 l x min(-1)m(-2), mean +/- SD; P < 0.05), splanchnic blood flow (from 0.8+/-0.2 to 1.0 + 0.2 l x min(-1)m(-2); P < 0.05), femoral blood flow (from 0.2+/-0.1 to 0.3+/-0.1 l x min(-1)m(-2); P < 0.05), and the arterial-gastric mucosal Pco2 gap (from 11.4+/-9.5 to 11.9+/-8.0 mmHg; P < 0.05).	Dobutamine	9-19	CD59 molecule (CD59 blood group)	Homo sapiens	72-78
10598598-6	1999	RESULTS: Dobutamine increased cardiac index (3.0+/-0.6 to 4.4+/-1.0 l x min(-1)m(-2), mean +/- SD; P < 0.05), splanchnic blood flow (from 0.8+/-0.2 to 1.0 + 0.2 l x min(-1)m(-2); P < 0.05), femoral blood flow (from 0.2+/-0.1 to 0.3+/-0.1 l x min(-1)m(-2); P < 0.05), and the arterial-gastric mucosal Pco2 gap (from 11.4+/-9.5 to 11.9+/-8.0 mmHg; P < 0.05).	Dobutamine	9-19	CD59 molecule (CD59 blood group)	Homo sapiens	168-174
10598598-6	1999	RESULTS: Dobutamine increased cardiac index (3.0+/-0.6 to 4.4+/-1.0 l x min(-1)m(-2), mean +/- SD; P < 0.05), splanchnic blood flow (from 0.8+/-0.2 to 1.0 + 0.2 l x min(-1)m(-2); P < 0.05), femoral blood flow (from 0.2+/-0.1 to 0.3+/-0.1 l x min(-1)m(-2); P < 0.05), and the arterial-gastric mucosal Pco2 gap (from 11.4+/-9.5 to 11.9+/-8.0 mmHg; P < 0.05).	Dobutamine	9-19	CD59 molecule (CD59 blood group)	Homo sapiens	168-174
10598598-7	1999	Dobutamine increased systemic oxygen consumption (from 132+/-14 to 146+/-13 ml x min(-1) x m(-2); P < 0.05) but not splanchnic or femoral oxygen consumption.	Dobutamine	0-10	CD59 molecule (CD59 blood group)	Homo sapiens	81-87
11227720-6	2000	The VPF at the peak of dobutamine infusion were significantly different from the values observed under basal conditions in Group 1 (105.1 +/- 25.0 cm/s, p < 0.001) whereas this difference was not significant in Group 2 (67.4 +/- 19.3 cm/s, NS).	Dobutamine	23-33	vascular endothelial growth factor A	Homo sapiens	4-7
10630826-9	1999	Dobutamine is a beta1-, beta2-, and alpha1-adrenergic agonist.	Dobutamine	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	24-29
10630826-9	1999	Dobutamine is a beta1-, beta2-, and alpha1-adrenergic agonist.	Dobutamine	0-10	adrenoceptor alpha 1D	Homo sapiens	36-42
10630826-11	1999	We propose that the drop in blood pressure with dobutamine in this patient was caused by a fall in systemic vascular resistance due to vascular beta2-adrenergic receptor activation.	Dobutamine	48-58	adrenoceptor beta 2	Homo sapiens	144-169
10551583-3	1999	METHODS: One hundred patients received sequential 3-min infusions of dobutamine at 0-40 microg x kg(-1) x min(-1) immediately after cardiopulmonary bypass.	Dobutamine	69-79	CD59 molecule (CD59 blood group)	Homo sapiens	106-112
10620742-3	1999	ANIMALS AND METHODS: The beta1-adrenoceptor agonist dobutamine or the selective beta2-adrenoceptor agonist terbutaline was continuously infused individually into the systemic circulation of 15 anesthetized pigs for 20 mins in 5 and 15 microgram/kg/min doses.	Dobutamine	52-62	adrenoceptor beta 1	Sus scrofa	25-43
10551583-10	1999	Systemic vascular resistance initially increased with dobutamine 10 microg x kg(-1) x min(-1) and remained constant with larger doses.	Dobutamine	54-64	CD59 molecule (CD59 blood group)	Homo sapiens	86-92
10754593-3	1999	Increase in both serum growth hormone levels (from 0.3 to 0.8 microg/l) and serum IGF-1 levels (from 130 to 300ng/ml) was noted, in association with clinical status improvement, better optimization of heart failure treatment and discontinuation of dobutamine infusion.	Dobutamine	248-258	growth hormone 1	Homo sapiens	23-37
10552089-8	1999	8+/-0.06 ml min(-1) g(-1) at rest and 1.48+/-0.15 ml min(-1) g(-1) during dobutamine stress.	Dobutamine	74-84	CD59 molecule (CD59 blood group)	Homo sapiens	53-59
10754593-3	1999	Increase in both serum growth hormone levels (from 0.3 to 0.8 microg/l) and serum IGF-1 levels (from 130 to 300ng/ml) was noted, in association with clinical status improvement, better optimization of heart failure treatment and discontinuation of dobutamine infusion.	Dobutamine	248-258	insulin like growth factor 1	Homo sapiens	82-87
10484566-0	1999	Dobutamine as selective beta(1)-adrenoceptor agonist in in vivo studies on human thermogenesis and lipid utilization.	Dobutamine	0-10	adrenoceptor beta 1	Homo sapiens	24-44
10548200-0	1999	Dopexamine increases splanchnic blood flow but decreases gastric mucosal pH in severe septic patients treated with dobutamine.	Dobutamine	115-125	glucose-6-phosphate isomerase	Homo sapiens	73-75
10520782-0	1999	Improvement of myocardial blood flow to ischemic regions by angiotensin-converting enzyme inhibition with quinaprilat IV: a study using [15O] water dobutamine stress positron emission tomography.	Dobutamine	148-158	angiotensin I converting enzyme	Homo sapiens	60-89
10520782-7	1999	In contrast, MBF in ischemic regions increased significantly after acute ACE inhibition with quinaprilat during repetitive dobutamine stress (1.10 +/- 0.13 vs. 1.69 +/- 0.17 ml/min/g, p < 0.015).	Dobutamine	123-133	angiotensin I converting enzyme	Homo sapiens	73-76
10484381-1	1999	Epinephrine and beta-adrenergic agonists (beta1 and beta2 for isoproterenol, beta1 for dobutamine, beta2 for salbutamol) stimulated K+ (or 86Rb) influx mediated by the Na+-K+-2Cl- cotransporter and the Na+-K+ pump in isolated colonic crypt cells.	Dobutamine	87-97	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	77-82
10465291-5	1999	Even the established beta1-agonist dobutamine acted through beta3-receptors in the mature brown adipocytes.	Dobutamine	35-45	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	21-26
10465291-5	1999	Even the established beta1-agonist dobutamine acted through beta3-receptors in the mature brown adipocytes.	Dobutamine	35-45	eukaryotic translation elongation factor 1 beta 2 pseudogene 2	Homo sapiens	60-65
10484566-7	1999	Therefore, we conclude that dobutamine can be used as a selective beta(1)-adrenoceptor agonist at dosages </=10 microg x kg(-1) x min(-1) in in vivo studies on human thermogenesis and lipid utilization.	Dobutamine	28-38	CD59 molecule (CD59 blood group)	Homo sapiens	133-139
10484566-1	1999	The use of dobutamine as selective beta(1)-adrenoceptor agonist in in vivo studies on human thermogenesis and lipid utilization was investigated in 20 men.	Dobutamine	11-21	adrenoceptor beta 1	Homo sapiens	35-55
10484566-2	1999	At 2.5, 5, and 10 microg x kg(-1) x min(-1), dobutamine induced significant increases in energy expenditure, lipid oxidation, and lipolysis.	Dobutamine	45-55	CD59 molecule (CD59 blood group)	Homo sapiens	36-42
10484566-3	1999	The beta(1)-adrenoceptor antagonist atenolol (bolus: 42.5 microg/kg, infusion: 1.02 microg x kg(-1) x min(-1)) blocked all dobutamine-induced effects on thermogenesis and lipid utilization.	Dobutamine	123-133	adrenoceptor beta 1	Homo sapiens	4-24
10484566-3	1999	The beta(1)-adrenoceptor antagonist atenolol (bolus: 42.5 microg/kg, infusion: 1.02 microg x kg(-1) x min(-1)) blocked all dobutamine-induced effects on thermogenesis and lipid utilization.	Dobutamine	123-133	CD59 molecule (CD59 blood group)	Homo sapiens	102-108
10484566-7	1999	Therefore, we conclude that dobutamine can be used as a selective beta(1)-adrenoceptor agonist at dosages </=10 microg x kg(-1) x min(-1) in in vivo studies on human thermogenesis and lipid utilization.	Dobutamine	28-38	adrenoceptor beta 1	Homo sapiens	66-86
10441688-5	1999	The ANP, BNP, and cGMP concentrations decreased in 11 of the 14 patients during dobutamine infusion.	Dobutamine	80-90	natriuretic peptide B	Homo sapiens	9-12
10441688-12	1999	In conclusion, rapid changes in ANP, BNP, and cGMP concentrations during dobutamine infusion reflect the changes in atrial and ventricle pressure and volume overload.	Dobutamine	73-83	natriuretic peptide B	Homo sapiens	37-40
10462014-9	1999	The plasma concentrations of endothelin-1 and 6-keto-prostaglandin F1alpha were significantly increased after DOB stress in the ischemia group, but the serum concentration of NO did not increase.	Dobutamine	110-113	endothelin 1	Homo sapiens	29-41
10371662-6	1999	Prenalterol and dobutamine, both purported to be beta-1 adrenergic receptor agonists, partially substituted for clenbuterol, but at relatively high doses.	Dobutamine	16-26	adrenoceptor beta 1	Rattus norvegicus	49-75
10513074-7	1999	Dobutamine infusion, but not amrinone, increased gastric pHi, as well as cardiac index and oxygen delivery.	Dobutamine	0-10	glucose-6-phosphate isomerase	Homo sapiens	57-60
10513074-8	1999	CONCLUSIONS: An improvement in gastric pHi associated with an increase in oxygen delivery, was observed with dobutamine.	Dobutamine	109-119	glucose-6-phosphate isomerase	Homo sapiens	39-42
9882778-10	1999	Among the 4 patients with persistent dobutamine-induced STE, 1 patient had persistent ischemia and 2 showed worsening of resting regional function.	Dobutamine	37-47	sulfotransferase family 1E member 1	Homo sapiens	56-59
10338466-4	1999	In vivo contractile response to the beta1AR agonist dobutamine, measured by a high-fidelity left ventricular micromanometer, was enhanced in mice lacking the dbh gene.	Dobutamine	52-62	adrenergic receptor, beta 1	Mus musculus	36-43
10382089-4	1999	Dobutamine (up to 40 micrograms kg-1 min-1)-atropine (up to 1 mg) stress echocardiography in conjunction with stress-reinjection 201Tl SPET was performed for the evaluation of myocardial ischaemia in 90 patients with previous myocardial infarction who underwent coronary angiography.	Dobutamine	0-10	CD59 molecule (CD59 blood group)	Homo sapiens	37-42
10353179-9	1999	Comparing the wall motion score index at rest with the index after DSE 5 and 10 micrograms.kg-1.min-1 dobutamine and after HBO2, there was significant improvement (P < 0.005).	Dobutamine	102-112	CD59 molecule (CD59 blood group)	Homo sapiens	96-101
10353179-10	1999	Differences between DSE 5 micrograms.kg-1.min-1 dobutamine and DSE 10 micrograms.kg-1.min-1 dobutamine and between HBO2 and DSE 10 micrograms.kg-1.min-1 dobutamine were also significant (P < 0.005).	Dobutamine	92-102	CD59 molecule (CD59 blood group)	Homo sapiens	86-91
10353179-10	1999	Differences between DSE 5 micrograms.kg-1.min-1 dobutamine and DSE 10 micrograms.kg-1.min-1 dobutamine and between HBO2 and DSE 10 micrograms.kg-1.min-1 dobutamine were also significant (P < 0.005).	Dobutamine	92-102	CD59 molecule (CD59 blood group)	Homo sapiens	86-91
10353179-10	1999	Differences between DSE 5 micrograms.kg-1.min-1 dobutamine and DSE 10 micrograms.kg-1.min-1 dobutamine and between HBO2 and DSE 10 micrograms.kg-1.min-1 dobutamine were also significant (P < 0.005).	Dobutamine	92-102	CD59 molecule (CD59 blood group)	Homo sapiens	86-91
10353179-10	1999	Differences between DSE 5 micrograms.kg-1.min-1 dobutamine and DSE 10 micrograms.kg-1.min-1 dobutamine and between HBO2 and DSE 10 micrograms.kg-1.min-1 dobutamine were also significant (P < 0.005).	Dobutamine	92-102	CD59 molecule (CD59 blood group)	Homo sapiens	86-91
9882778-11	1999	Although dobutamine-induced STE in patients with old Q-wave infarction referred for CABG cannot identify patients with a higher prevalence of ischemia, the lack of reinduction of this pattern after CABG correlates with absent reinduction of ischemia in most of patients.	Dobutamine	9-19	sulfotransferase family 1E member 1	Homo sapiens	28-31
10072193-3	1999	In contrast, endothelin-1-induced effects were increased (p<0.05) by microinjections into the superior colliculus of prazosin (2.4 nmol) (49 +/- 7%, n=5), an alpha1-adrenoceptor antagonist; dobutamine (4 nmol) (51 +/- 9%, n=5), a beta1-adrenoceptor agonist or isoprenaline (1 nmol) (49 +/- 6%, n=5), a beta1/beta2-adrenoceptor agonist.	Dobutamine	193-203	endothelin 1	Rattus norvegicus	13-25
9843731-6	1998	beta2-Adrenoceptor stimulation with terbutaline induced a concentration-dependent increase in skeletal muscle glycerol levels and in tissue blood flow, whereas perfusion with beta1- or beta3-adrenoceptor agonists (dobutamine or CGP-12177) did not influence the glycerol concentration or blood flow.	Dobutamine	214-224	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	175-180
9843736-6	1998	The lipolytic effects of epinephrine, isoprenaline (beta-adrenoceptor agonist), and dobutamine (beta1-adrenoceptor agonist) were significantly increased (P < 0.05) but not those of procaterol (beta2-adrenoceptor agonist).	Dobutamine	84-94	adrenoceptor beta 1	Homo sapiens	96-114
9843736-6	1998	The lipolytic effects of epinephrine, isoprenaline (beta-adrenoceptor agonist), and dobutamine (beta1-adrenoceptor agonist) were significantly increased (P < 0.05) but not those of procaterol (beta2-adrenoceptor agonist).	Dobutamine	84-94	adrenoceptor beta 2	Homo sapiens	196-214
9884482-0	1998	Changes of endothelin-1 and atrial natriuretic peptide during dobutamine stress echocardiography.	Dobutamine	62-72	endothelin 1	Homo sapiens	11-23
9884482-1	1998	The aim of this study was to test the hypothesis that plasma endothelin-1 (ET-1) and atrial natriuretic peptide (ANP) concentrations in patients with ischemic heart disease are related either to myocardial ischemia or left ventricular (LV) dysfunction during dobutamine stress echocardiography.	Dobutamine	259-269	endothelin 1	Homo sapiens	61-73
9884482-11	1998	During peak dobutamine infusion, the ET-1 concentration dropped 8.7% from the baseline in group I, 10.2% in group II, and 10.5% in group III.	Dobutamine	12-22	endothelin 1	Homo sapiens	37-41
9588422-7	1998	RESULTS: In vitro we found a synergistic increase in epinephrine-induced CD62 expression in the presence of dobutamine.	Dobutamine	108-118	selectin P	Homo sapiens	73-77
9781735-8	1998	Dobutamine can significantly increase SBF and usually increases pHi.	Dobutamine	0-10	glucose-6-phosphate isomerase	Homo sapiens	64-67
9781735-14	1998	Among the catecholamines, dopamine is the least likely, and dobutamine the most likely, to increase pHi.	Dobutamine	60-70	glucose-6-phosphate isomerase	Homo sapiens	100-103
9756384-5	1998	Similar maximal stimulations were obtained with beta1-, beta2- or beta3-adrenoceptor selective agonists (dobutamine 5.1+/-0.3, terbutaline 5.3+/-0.3 and CL 316,243 4.8+/-0.9 fold, respectively); in BAT of beta3-adrenoceptor knockout mice, the beta1- and beta2-responses were fully conserved.	Dobutamine	105-115	adrenergic receptor, beta 3	Mus musculus	66-84
9716364-4	1998	The beta1-adrenoceptor agonist, dobutamine, produced relaxation of rat ureter.	Dobutamine	32-42	adrenoceptor beta 1	Rattus norvegicus	4-22
9673814-2	1998	In order to examine the possible involvement of the endothelium and K+ channel activation in the relaxation induced by dobutamine, a beta 1-adrenoceptor agonist, in rat isolated mesenteric arteries, the effects of inhibitors of nitric oxide (NO) activity, blockers of K+ channels and high extracellular K+ were studied by measuring isometric tension in both endothelium-intact and -denuded arteries.	Dobutamine	119-129	adrenoceptor beta 1	Rattus norvegicus	133-152
9673814-6	1998	The relaxation induced by dobutamine was inhibited by the beta 1-adrenoceptor antagonist CGP 20712A (3 mumol/L) but not by the beta 2-adrenoceptor antagonist ICI 118,551 (3 mumol/L) in endothelium-denuded arteries.	Dobutamine	26-36	adrenoceptor beta 1	Rattus norvegicus	58-77
11367717-1	1998	OBJECTIVE: To assess the safety and accuracy of dobutamine stress 99mTc-MIBI perfusion tomography (DST) for detecting coronary artery disease(CAD).	Dobutamine	48-58	dystonin	Homo sapiens	99-102
9597418-5	1998	Dobutamine was infused up to 40 mu.kg.l-1 min-1 in 3 min stages.	Dobutamine	0-10	CD59 molecule (CD59 blood group)	Homo sapiens	42-47
11367717-1	1998	OBJECTIVE: To assess the safety and accuracy of dobutamine stress 99mTc-MIBI perfusion tomography (DST) for detecting coronary artery disease(CAD).	Dobutamine	48-58	aconitate decarboxylase 1	Homo sapiens	142-145
9396426-13	1997	The hyperemic response to dobutamine is in excess of that predicted by rate-pressure product and reflects the unmeasured inotropic, oxygen-wasting, and beta2-agonist effects of the drug.	Dobutamine	26-36	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	152-157
9386153-6	1997	After dobutamine infusion, blood flow increased less in contractile reserve-negative (0.63+/-0.38 mL x g(-1) x min(-1)) than in contractile reserve-positive (1.28+/-0.65 mL x g(-1) x min(-1)) and normal segments (1.93+/-0.83 mL x g(-1) x min(-1), P<.0001).	Dobutamine	6-16	CD59 molecule (CD59 blood group)	Homo sapiens	111-117
9386153-6	1997	After dobutamine infusion, blood flow increased less in contractile reserve-negative (0.63+/-0.38 mL x g(-1) x min(-1)) than in contractile reserve-positive (1.28+/-0.65 mL x g(-1) x min(-1)) and normal segments (1.93+/-0.83 mL x g(-1) x min(-1), P<.0001).	Dobutamine	6-16	CD59 molecule (CD59 blood group)	Homo sapiens	183-189
9386153-6	1997	After dobutamine infusion, blood flow increased less in contractile reserve-negative (0.63+/-0.38 mL x g(-1) x min(-1)) than in contractile reserve-positive (1.28+/-0.65 mL x g(-1) x min(-1)) and normal segments (1.93+/-0.83 mL x g(-1) x min(-1), P<.0001).	Dobutamine	6-16	CD59 molecule (CD59 blood group)	Homo sapiens	183-189
9386153-8	1997	Myocardial oxygen consumption with dobutamine increased less in contractile reserve-negative (0.060+/-0.013 min(-1)) than in contractile reserve-positive (0.077+/-0.016 min(-1)) and normal segments (0.092+/-0.024 min(-1), P<.0001).	Dobutamine	35-45	CD59 molecule (CD59 blood group)	Homo sapiens	108-114
9386153-8	1997	Myocardial oxygen consumption with dobutamine increased less in contractile reserve-negative (0.060+/-0.013 min(-1)) than in contractile reserve-positive (0.077+/-0.016 min(-1)) and normal segments (0.092+/-0.024 min(-1), P<.0001).	Dobutamine	35-45	CD59 molecule (CD59 blood group)	Homo sapiens	169-175
9386153-8	1997	Myocardial oxygen consumption with dobutamine increased less in contractile reserve-negative (0.060+/-0.013 min(-1)) than in contractile reserve-positive (0.077+/-0.016 min(-1)) and normal segments (0.092+/-0.024 min(-1), P<.0001).	Dobutamine	35-45	CD59 molecule (CD59 blood group)	Homo sapiens	169-175
9374150-9	1997	Flap flow, on the other hand, is increased only with dobutamine but remains unchanged with dopamine despite increased cardiac output.	Dobutamine	53-63	arachidonate 5-lipoxygenase activating protein	Sus scrofa	0-4
9374150-11	1997	Flap flow also decreases relative to cardiac output with both dopamine and dobutamine.	Dobutamine	75-85	arachidonate 5-lipoxygenase activating protein	Sus scrofa	0-4
9295336-5	1997	The coupling efficiencies for betaAR agonist activation of adenylyl cyclase relative to epinephrine (100%) were 42% for fenoterol, 4.9% for albuterol, 2.5% for dobutamine, and 1.1% for ephedrine.	Dobutamine	160-170	adrenoceptor beta 2	Homo sapiens	30-36
9387890-5	1997	On the other hand, the beta1-adrenoceptor agonist dobutamine induced expression of this mRNA only in the meninges.	Dobutamine	50-60	adrenoceptor beta 1	Rattus norvegicus	23-41
9295336-6	1997	At concentrations of these agonists yielding >90% receptor occupancy, the rate and extent (0-30 min) of agonist-induced desensitization of betaAR activation of adenylyl cyclase followed the same order as coupling efficiency, i.e. epinephrine >/= fenoterol > albuterol > dobutamine > ephedrine.	Dobutamine	282-292	adrenoceptor beta 2	Homo sapiens	142-148
8997289-5	1996	In accord with our hypothesis, malonyl CoA decreased significantly with dobutamine in both groups, providing a possible mechanism for increased fatty acid oxidation through relieved inhibition on CPT I.	Dobutamine	72-82	carnitine palmitoyltransferase 1B	Sus scrofa	196-201
9264490-4	1997	At the peak of rapid atrial pacing and during dobutamine stress, LAD/LCX(CF) was reversed in HOCM patients (from 1.25+/-0.11 to 0.82+/-0.07 and 0.79+/-0.06, respectively), whereas it remained unchanged in control subjects (from 1.0+/-0.1 to 1.0+/-0.05 and 1.0+/-0.05, respectively; P<.001).	Dobutamine	46-56	dihydrolipoamide dehydrogenase	Homo sapiens	65-76
9227545-3	1997	The ESPVR was shifted upward in an enhanced contractility by dobutamine and downward in a depressed contractility by propranolol; ESP at a midrange V of 0.1 ml/g LV on each ESPVR increased from 131 +/- 11 to 192 +/- 17 mmHg and decreased from 136 +/- 10 to 110 +/- 7 mmHg, respectively.	Dobutamine	61-71	protein tyrosine phosphatase, receptor type, V	Rattus norvegicus	4-7
9124918-4	1997	Dobutamine infusion was started at a rate of 5 microg x kg(-1) x min(-1) and increased to 10 and 20 microg x kg(-1) x min(-1) at 15-minute intervals.	Dobutamine	0-10	CD59 molecule (CD59 blood group)	Homo sapiens	65-71
9083230-12	1997	In the norepinephrine-dobutamine group pHi (from 7.30 +/- 0.11 to 7.35 +/- 0.07) and the PCO2 gap (from 10 +/- 3.0 to 4 +/- 2.0 mmHg) were normalized within 6 h (p < 0.01).	Dobutamine	22-32	glucose-6-phosphate isomerase	Homo sapiens	39-42
9002984-5	1997	The beta 3-, beta L-, and beta 2-adrenoceptor agonists BRL 37344, dobutamine, and terbutaline inhibited ob gene expression in mouse brown adipocytes differentiated in culture with EC50 values of 0.3, 1.0, and 85 nM, respectively.	Dobutamine	66-76	adrenergic receptor, beta 2	Mus musculus	4-45
8994422-5	1997	In the presence of dobutamine, intracoronary substance P caused a greater fall in left ventricular end-systolic pressure (transplantation control, -9 +/- 11 versus transplantation dobutamine, -20 +/- 18 mm Hg [P < .05]; cardiomyopathy control, -4 +/- 1 versus cardiomyopathy dobutamine, -10 +/- 3 mm Hg [P < .05]) and in left ventricular peak systolic pressure (transplantation control, -14 +/- 10 versus transplantation dobutamine, -30 +/- 22 mm Hg [P < .01]; cardiomyopathy control, -9 +/- 7 versus cardiomyopathy dobutamine, -15 +/- 6 mm Hg [P = .1]).	Dobutamine	19-29	tachykinin precursor 1	Homo sapiens	45-56
8994422-5	1997	In the presence of dobutamine, intracoronary substance P caused a greater fall in left ventricular end-systolic pressure (transplantation control, -9 +/- 11 versus transplantation dobutamine, -20 +/- 18 mm Hg [P < .05]; cardiomyopathy control, -4 +/- 1 versus cardiomyopathy dobutamine, -10 +/- 3 mm Hg [P < .05]) and in left ventricular peak systolic pressure (transplantation control, -14 +/- 10 versus transplantation dobutamine, -30 +/- 22 mm Hg [P < .01]; cardiomyopathy control, -9 +/- 7 versus cardiomyopathy dobutamine, -15 +/- 6 mm Hg [P = .1]).	Dobutamine	180-190	tachykinin precursor 1	Homo sapiens	45-56
8994422-5	1997	In the presence of dobutamine, intracoronary substance P caused a greater fall in left ventricular end-systolic pressure (transplantation control, -9 +/- 11 versus transplantation dobutamine, -20 +/- 18 mm Hg [P < .05]; cardiomyopathy control, -4 +/- 1 versus cardiomyopathy dobutamine, -10 +/- 3 mm Hg [P < .05]) and in left ventricular peak systolic pressure (transplantation control, -14 +/- 10 versus transplantation dobutamine, -30 +/- 22 mm Hg [P < .01]; cardiomyopathy control, -9 +/- 7 versus cardiomyopathy dobutamine, -15 +/- 6 mm Hg [P = .1]).	Dobutamine	180-190	tachykinin precursor 1	Homo sapiens	45-56
8994422-5	1997	In the presence of dobutamine, intracoronary substance P caused a greater fall in left ventricular end-systolic pressure (transplantation control, -9 +/- 11 versus transplantation dobutamine, -20 +/- 18 mm Hg [P < .05]; cardiomyopathy control, -4 +/- 1 versus cardiomyopathy dobutamine, -10 +/- 3 mm Hg [P < .05]) and in left ventricular peak systolic pressure (transplantation control, -14 +/- 10 versus transplantation dobutamine, -30 +/- 22 mm Hg [P < .01]; cardiomyopathy control, -9 +/- 7 versus cardiomyopathy dobutamine, -15 +/- 6 mm Hg [P = .1]).	Dobutamine	180-190	tachykinin precursor 1	Homo sapiens	45-56
8994422-5	1997	In the presence of dobutamine, intracoronary substance P caused a greater fall in left ventricular end-systolic pressure (transplantation control, -9 +/- 11 versus transplantation dobutamine, -20 +/- 18 mm Hg [P < .05]; cardiomyopathy control, -4 +/- 1 versus cardiomyopathy dobutamine, -10 +/- 3 mm Hg [P < .05]) and in left ventricular peak systolic pressure (transplantation control, -14 +/- 10 versus transplantation dobutamine, -30 +/- 22 mm Hg [P < .01]; cardiomyopathy control, -9 +/- 7 versus cardiomyopathy dobutamine, -15 +/- 6 mm Hg [P = .1]).	Dobutamine	180-190	tachykinin precursor 1	Homo sapiens	45-56
9013264-0	1996	Interleukin-6 correlates with hemodynamic impairment during dobutamine administration in chronic heart failure.	Dobutamine	60-70	interleukin 6	Homo sapiens	0-13
9013264-7	1996	In conclusion, in this pilot study IL6 correlates with the severity of chronic heart failure during low dose dobutamine infusion.	Dobutamine	109-119	interleukin 6	Homo sapiens	35-38
9202046-2	1997	This was associated with marked beta-adrenergic receptor (beta-AR) desensitization in vivo, as determined by a blunted inotropic response to dobutamine.	Dobutamine	141-151	adrenergic receptor, beta 1	Mus musculus	32-56
9202046-2	1997	This was associated with marked beta-adrenergic receptor (beta-AR) desensitization in vivo, as determined by a blunted inotropic response to dobutamine.	Dobutamine	141-151	adrenergic receptor, beta 1	Mus musculus	58-65
9209250-7	1997	Plasma renin activity was significantly increased during dobutamine and fenoterol infusion.	Dobutamine	57-67	renin	Homo sapiens	7-12
9183605-5	1997	Most dobutamine stress protocols start at an infusion rate of 5 micrograms.kg-1.min-1 and increase to a peak dose of 40 or 50 micrograms.kg-1.min-1; to further increase heart rate, a bolus injection of 0.25-1.0 mg atropine is added.	Dobutamine	5-15	CD59 molecule (CD59 blood group)	Homo sapiens	80-85
9183619-7	1997	Dobutamine is infused at low rates of 2.5 to 20 micrograms.kg-1.min-1 to detect myocardial viability.	Dobutamine	0-10	CD59 molecule (CD59 blood group)	Homo sapiens	64-69
9043840-3	1997	AIMS: The present study aimed to assess the effects of non-beta-blocker antianginal therapy on dobutamine (up to 40 micrograms.kg-1.min-1)-atropine (up to 1 mg) stress.	Dobutamine	95-105	CD59 molecule (CD59 blood group)	Homo sapiens	132-137
9014976-9	1997	When Cox analysis was performed, dobutamine echocardiography had an independent prognostic value both for all events (RR 2.88, 95% CI 1.37 to 6.08) and for hard events (RR 6.56, 95% CI 1.42 to 30.46).	Dobutamine	33-43	cytochrome c oxidase subunit 8A	Homo sapiens	5-8
9057076-8	1997	Angiotensin II reduced the increase in LVP, LV dP/dt(max), and HR elicited by isoproterenol and dobutamine but did not affect responses to salbutamol.	Dobutamine	96-106	angiotensinogen	Rattus norvegicus	0-14
8960434-6	1996	Dobutamine was progressively increased (5-40 micrograms.kg-1.min-1) and atropine was injected in 30 patients.	Dobutamine	0-10	CD59 molecule (CD59 blood group)	Homo sapiens	61-66
8960434-8	1996	RESULTS: The mean peak dobutamine dose was 32 +/- 11 micrograms.kg-1.min-1.	Dobutamine	23-33	CD59 molecule (CD59 blood group)	Homo sapiens	69-74
8997289-7	1996	Dobutamine infusion resulted in similar increases in cardiac contractility, oxygen consumption, and glucose uptake in both groups despite reductions of 50-65% in GLUT-4 and GLUT-1 protein in the diabetic group.	Dobutamine	0-10	solute carrier family 2 member 4	Sus scrofa	162-168
8997289-7	1996	Dobutamine infusion resulted in similar increases in cardiac contractility, oxygen consumption, and glucose uptake in both groups despite reductions of 50-65% in GLUT-4 and GLUT-1 protein in the diabetic group.	Dobutamine	0-10	glucose transport protein	Sus scrofa	173-179
8914702-6	1996	Maximal out flow blood Doppler velocity during dobutamine infusion correlated moderately with percent fractional shortening of the left ventricle (r = .53; P < .01) and D1/D2 (r = .60; P < .0001).	Dobutamine	47-57	leiomodin 1	Homo sapiens	172-177
8951574-9	1996	Pretreatment with intravenous dobutamine augmented the drop in LV end-systolic pressures observed during bi-coronary infusion of substance P.	Dobutamine	30-40	tachykinin precursor 1	Homo sapiens	129-140
8977994-11	1996	Dobutamine infusion increased heart rate (to about 190 x min-1 and CI by 30% in normovolemia and hypovolemia, while ITBV remained basically unchanged.	Dobutamine	0-10	CD59 molecule (CD59 blood group)	Homo sapiens	57-62
8910155-7	1996	Compared with the enoximone (enox)-treated group, the administration of dobutamine (dob) resulted in significantly (p < 0.05) greater increases in mean arterial pressure (dob: 18 +/- 9% v enox: -2 +/- 7%), heart rate (dob: 24 +/- 13% v enox: 3 +/- 5%) and pulmonary artery pressure (dob: 5 +/- 10% v enox: -4 +/- 9%).	Dobutamine	72-82	ecto-NOX disulfide-thiol exchanger 2	Homo sapiens	191-199
8910155-7	1996	Compared with the enoximone (enox)-treated group, the administration of dobutamine (dob) resulted in significantly (p < 0.05) greater increases in mean arterial pressure (dob: 18 +/- 9% v enox: -2 +/- 7%), heart rate (dob: 24 +/- 13% v enox: 3 +/- 5%) and pulmonary artery pressure (dob: 5 +/- 10% v enox: -4 +/- 9%).	Dobutamine	72-75	ecto-NOX disulfide-thiol exchanger 2	Homo sapiens	191-199
8910155-7	1996	Compared with the enoximone (enox)-treated group, the administration of dobutamine (dob) resulted in significantly (p < 0.05) greater increases in mean arterial pressure (dob: 18 +/- 9% v enox: -2 +/- 7%), heart rate (dob: 24 +/- 13% v enox: 3 +/- 5%) and pulmonary artery pressure (dob: 5 +/- 10% v enox: -4 +/- 9%).	Dobutamine	84-87	ecto-NOX disulfide-thiol exchanger 2	Homo sapiens	191-199
8910155-7	1996	Compared with the enoximone (enox)-treated group, the administration of dobutamine (dob) resulted in significantly (p < 0.05) greater increases in mean arterial pressure (dob: 18 +/- 9% v enox: -2 +/- 7%), heart rate (dob: 24 +/- 13% v enox: 3 +/- 5%) and pulmonary artery pressure (dob: 5 +/- 10% v enox: -4 +/- 9%).	Dobutamine	84-87	ecto-NOX disulfide-thiol exchanger 2	Homo sapiens	191-199
8910155-7	1996	Compared with the enoximone (enox)-treated group, the administration of dobutamine (dob) resulted in significantly (p < 0.05) greater increases in mean arterial pressure (dob: 18 +/- 9% v enox: -2 +/- 7%), heart rate (dob: 24 +/- 13% v enox: 3 +/- 5%) and pulmonary artery pressure (dob: 5 +/- 10% v enox: -4 +/- 9%).	Dobutamine	84-87	ecto-NOX disulfide-thiol exchanger 2	Homo sapiens	191-199
9005168-0	1996	[Acute changes in the hemodynamic profile and circulating levels of atrial natriuretic peptide induced by dobutamine in severe heart failure].	Dobutamine	106-116	natriuretic peptide A	Homo sapiens	68-94
8857434-5	1996	INTERVENTIONS: The effect of dobutamine infusion (6 mu g kg-1 min-1) on systemic and regional oxygen transport was studied in ten patients, with six patients serving as controls.	Dobutamine	29-39	CD59 molecule (CD59 blood group)	Homo sapiens	62-67
8844233-6	1996	Patients treated with dobutamine showed significant increases in CI and LVSWI and significant falls in SVRI and PAWP at 2 and 6 h after institution of therapy, and there was a significant rise in PaO2/fiO2 ratio to 27.8 kPa at 6 h. NPO was generally associated with severe depression of myocardial function and elevation of pulmonary vascular pressures.	Dobutamine	22-32	WBP2 N-terminal like	Homo sapiens	112-116
8697482-6	1996	In the control group, dobutamine produced a significant decrease in both end-diastolic and end-systolic volumes, with percent changes from rest to peak of 24 +/- 5% and 29 +/- 5% respectively, and an average increase of 70 +/- 20% in the SBP/ESVI ratio.	Dobutamine	22-32	selenium binding protein 1	Homo sapiens	238-241
8829879-12	1996	VO2 increased more with dobutamine than with nitroprusside (from 138 +/- 14 to 149 +/- 20 ml min-1 m-2, P < 0.001, and from 131 +/- 14 to 138 +/- 17 ml min-1 m-2, P < 0.001, respectively).	Dobutamine	24-34	CD59 molecule (CD59 blood group)	Homo sapiens	155-160
8829879-13	1996	However, DO2 also increased more with dobutamine than with nitroprusside (from 531 +/- 186 to 702 +/- 274 ml min-1 m-2, P < 0.001, and from 523 +/- 107 to 610 +/- 122 ml min-1 m-2, P < 0.001, respectively).	Dobutamine	38-48	CD59 molecule (CD59 blood group)	Homo sapiens	109-114
8583814-3	1996	Dobutamine infusion was started at a rate of 5 micrograms.kg-1.min-1 and increased to 10 and 20 micrograms.kg-1.min-1 at 15-minute intervals.	Dobutamine	0-10	CD59 molecule (CD59 blood group)	Homo sapiens	63-68
8857434-8	1996	Dobutamine increased cardiac output (3.2 +/- 0.6 vs 4.4 +/- 0.7 l x min-1 x min-2; P <0.05), splanchnic blood flow (0.68 +/- 0.28 vs 0.91 +/- 0.28 l x min-1 x m-2; p <0.05) and femoral blood flow (0.25 +/- 0.08 vs 0.32 +/- 0.11 l x min-1 x m-2; p <0.05).	Dobutamine	0-10	CD59 molecule (CD59 blood group)	Homo sapiens	68-73
8857434-8	1996	Dobutamine increased cardiac output (3.2 +/- 0.6 vs 4.4 +/- 0.7 l x min-1 x min-2; P <0.05), splanchnic blood flow (0.68 +/- 0.28 vs 0.91 +/- 0.28 l x min-1 x m-2; p <0.05) and femoral blood flow (0.25 +/- 0.08 vs 0.32 +/- 0.11 l x min-1 x m-2; p <0.05).	Dobutamine	0-10	CD59 molecule (CD59 blood group)	Homo sapiens	76-81
8857434-8	1996	Dobutamine increased cardiac output (3.2 +/- 0.6 vs 4.4 +/- 0.7 l x min-1 x min-2; P <0.05), splanchnic blood flow (0.68 +/- 0.28 vs 0.91 +/- 0.28 l x min-1 x m-2; p <0.05) and femoral blood flow (0.25 +/- 0.08 vs 0.32 +/- 0.11 l x min-1 x m-2; p <0.05).	Dobutamine	0-10	CD59 molecule (CD59 blood group)	Homo sapiens	154-159
8857434-8	1996	Dobutamine increased cardiac output (3.2 +/- 0.6 vs 4.4 +/- 0.7 l x min-1 x min-2; P <0.05), splanchnic blood flow (0.68 +/- 0.28 vs 0.91 +/- 0.28 l x min-1 x m-2; p <0.05) and femoral blood flow (0.25 +/- 0.08 vs 0.32 +/- 0.11 l x min-1 x m-2; p <0.05).	Dobutamine	0-10	CD59 molecule (CD59 blood group)	Homo sapiens	154-159
8857434-11	1996	Systemic oxygen consumption increased in response to dobutamine (141 +/- 11 vs 149 +/- 11 ml x min-1 x m-2; P <0.05) but did not change in the control group.	Dobutamine	53-63	CD59 molecule (CD59 blood group)	Homo sapiens	95-100
7574946-3	1995	Dobutamine infusion was started at a rate of 5 micrograms.kg-1.min-2 and increased to 10 and 20 micrograms.kg-1.min-2 at 15-minute intervals.	Dobutamine	0-10	CD59 molecule (CD59 blood group)	Homo sapiens	63-68
8717145-6	1996	The mean maximal dobutamine dose was 41,4 +/- 10 mu g/kg center dot min(-1).	Dobutamine	17-27	CD59 molecule (CD59 blood group)	Homo sapiens	68-74
8907433-4	1995	In this work the possibility that a beta3-adrenoceptor plays a significant role in the control of lipid mobilization is studied and also its importance in comparison to beta1- and beta2-adrenoceptors in isolated human fat cells, is evaluated, by measuring the in vitro lipolysis induced by dobutamine, salbutamol, metaproterenol, BRL 37344 and CGP 12177A.	Dobutamine	290-300	eukaryotic translation elongation factor 1 beta 2 pseudogene 2	Homo sapiens	36-41
7586371-11	1995	Treatment with ACE inhibitors attenuated the reduction in cardiac output and stroke volume indices and improved the inotropic response to dobutamine and isoprenaline and reversed partially the cardiac norepinephrine content in the CHF rat.	Dobutamine	138-148	angiotensin I converting enzyme	Rattus norvegicus	15-18
8881872-6	1995	RESULTS: Dobutamine increased heart rate (rest = 69 +/- 9 vs dobutamine = 138 +/- 13 beats.min-1; P < 0.01), whereas systolic blood pressure did not change significantly (rest = 136 +/- 15 vs dobutamine = 150 +/- 25 mmHg, P = ns).	Dobutamine	9-19	CD59 molecule (CD59 blood group)	Homo sapiens	91-96
8664455-1	1995	OBJECTIVE: The purpose was to study whether the hemodynamic benefit of a catabolic catecholamine (dobutamine) induces a certain oxygen cost for the myocardial energy demand and whether this effect would be less pronounced if an anabolic intervention, such as the administration of insulin, was used.	Dobutamine	98-108	insulin	Homo sapiens	281-288
7621647-4	1995	During infusion of dobutamine up to 40 micrograms kg-1 min-1, arterial pressure was maintained near baseline levels, whereas heart rate and cardiac index increased, more so in group 1 (mean: 89 and 79%) than in group 2 (58 and 52%; P < 0.05 vs. group 1).	Dobutamine	19-29	CD59 molecule (CD59 blood group)	Homo sapiens	55-60
8582395-8	1995	During dobutamine infusion, exercise resulted in a further increase in heart rate from 108 +/- 11 to 122 +/- 17 mmHg (P < 0.05), in cardiac output from 7.4 +/- 0.9 to 10.3 +/- 2.5 l.min-1 (P < 0.05), and in left ventricular dP/dtmax from 2181 +/- 220 to 2620 +/- 214 mmHg.s-1 (P < 0.05).	Dobutamine	7-17	CD59 molecule (CD59 blood group)	Homo sapiens	185-190
7654481-0	1995	Evaluation of cardiac beta 1-adrenergic sensitivity with dobutamine in healthy volunteers.	Dobutamine	57-67	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	22-28
7654481-3	1995	We set up a non-invasive test in healthy volunteers to evaluate beta 1-adrenergic reactivity using dobutamine as a preferential agonist.	Dobutamine	99-109	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	64-70
7654481-13	1995	We conclude that the left ventricular contractile response assessed by QS2i provided the best parameter for evaluation of beta 1-adrenergic cardiac effects either with dobutamine or with isoprenaline.	Dobutamine	168-178	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	122-128
7554756-9	1995	An exercise load of 50 W and a dobutamine infusion of 15 micrograms min-1 kg-1 gave the following results respectively: heart rate, 120.3 +/- 3.0 beats/min versus 110.2 +/- 3.0 beats/min; SD, 16.0 +/- 1.1 ms versus 16.3 +/- 2.5 ms; low-frequency component, 4.3 +/- 0.3 ln-ms2 versus 4.4 +/- 0.3 ln-ms2 and high-frequency component, 2.6 +/- 0.3 ln-ms2 versus 2.2 +/- 0.3 ln-ms2.	Dobutamine	31-41	CD59 molecule (CD59 blood group)	Homo sapiens	68-78
7718371-3	1995	We measured changes in gastric intramucosal pH, splanchnic blood flow and oxygen transport in response to increased systemic flow induced by dobutamine (mean 4.4 (range 3.0-7.0) micrograms kg-1 min-1) after coronary artery bypass.	Dobutamine	141-151	CD59 molecule (CD59 blood group)	Homo sapiens	194-199
7738189-8	1995	When adipose tissue was pretreated with the beta 1/beta 2-selective adrenoceptor blocker propranolol the glycerol increasing effect of dobutamine or terbutaline was inhibited by 80-85% but the glycerol response to CGP 12177 was not influenced.	Dobutamine	135-145	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	44-57
7810640-6	1994	Tissue cAPK activity was positively correlated with renin secretion associated with dobutamine.	Dobutamine	84-94	renin	Homo sapiens	52-57
8847943-5	1995	Dobutamine substantially increased systolic blood pressure corresponding to its beta 1-adrenoceptor agonist propriety.	Dobutamine	0-10	adrenoceptor beta 1	Homo sapiens	80-99
7810640-10	1994	Dobutamine-induced renin secretion was attenuated by selective inhibitors of cAPK regulatory and catalytic subunits.	Dobutamine	0-10	renin	Homo sapiens	19-24
7867239-6	1994	Corrected Doppler-derived dP/dtmax for LV end-diastolic volume using Teichholz"s method significantly increased by inotropic stimulation with dobutamine (p < 0.01); however, it remained unchanged by augmentation of afterload with angiotensin II.	Dobutamine	142-152	angiotensinogen	Homo sapiens	233-247
8049810-2	1994	In the present study we measured changes in gastric pHi with a tonometer in septic patients after a short-term infusion of dobutamine.	Dobutamine	123-133	glucose-6-phosphate isomerase	Homo sapiens	52-55
8049810-10	1994	Gastric pHi increased in both groups when dobutamine was infused at 5 micrograms/kg/min (p < 0.01), and then again at 10 micrograms/kg/min (p < 0.05).	Dobutamine	42-52	glucose-6-phosphate isomerase	Homo sapiens	8-11
8151405-3	1994	Dobutamine is a predominant beta-1 agonist that increases heart rate, myocardial contractility and systolic blood pressure.	Dobutamine	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	28-34
7895322-9	1994	Dobutamine induced a significant increase in active renin levels and a decrease in the regression slope between renin and PRA.	Dobutamine	0-10	renin	Homo sapiens	52-57
7895322-9	1994	Dobutamine induced a significant increase in active renin levels and a decrease in the regression slope between renin and PRA.	Dobutamine	0-10	renin	Homo sapiens	112-117
7895322-16	1994	These levels were not modified by a dobutamine-induced beta-2 stimulation.	Dobutamine	36-46	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	55-61
8176104-1	1994	OBJECTIVES: The purpose of this study was to determine whether intravenous sonicated dextrose albumin could improve endocardial border resolution during dobutamine stress echocardiography.	Dobutamine	153-163	albumin	Homo sapiens	94-101
8176104-3	1994	Because a sonicated mixture of albumin with dextrose results in better transpulmonary passage than sonicated albumin alone, this agent could be utilized to further improve endocardial border resolution during dobutamine stress echocardiography.	Dobutamine	209-219	albumin	Homo sapiens	31-38
8176104-4	1994	METHODS: We gave intravenous injections of sonicated dextrose and albumin to 50 patients undergoing dobutamine stress echocardiography.	Dobutamine	100-110	albumin	Homo sapiens	66-73
8176104-9	1994	CONCLUSIONS: Intravenous sonicated dextrose albumin improves endocardial border resolution during dobutamine stress echocardiography.	Dobutamine	98-108	albumin	Homo sapiens	44-51
7958736-8	1994	SNP inhibited the relaxation to dobutamine, a beta 1-adrenoceptor agonist but not that to terbutaline, a beta 2-adrenoceptor agonist.	Dobutamine	32-42	adrenoceptor beta 1	Rattus norvegicus	46-65
7913341-3	1994	To discriminate between those alternatives, dose-dependency studies were addressed to assess the abilities of the selective beta-adrenergic agonists dobutamine (beta 1) and salbutamol (beta 2) to induce plasma membrane desialylation and DNA synthesis.	Dobutamine	149-159	hemoglobin, beta adult major chain	Mus musculus	161-167
8120022-2	1994	Following butyrate treatment, EC50 values of beta 1- and beta 2-selective agonists, dobutamine and fenoterol, were decreased, whereas that of the beta 3-selective agonist BRL37344 was increased.	Dobutamine	84-94	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	45-63
8227796-8	1993	RESULTS: The mean (+/- SD) C-11 clearance rate significantly increased with dobutamine from 0.105 +/- 0.027 to 0.155 +/- 0.023 min-1 (p = 0.001).	Dobutamine	76-86	RNA polymerase III subunit K	Homo sapiens	27-31
8005123-9	1994	Peak rate-pressure product during steady-state dobutamine infusion (18.493 +/- 4.315 mmHg.min-1) was significantly lower (P < 0.01) than during EST (21.316 +/- 4.937 mmHg.min-1).	Dobutamine	47-57	CD59 molecule (CD59 blood group)	Homo sapiens	90-95
7826649-7	1994	By avoiding volume overload (CVP < or = 10 mmHg) at weaning off ECC and by lowering the systemic vascular resistance and, thus, LV afterload (approximately 8 micrograms.kg-1 min-1 dobutamine), the LV developed systemic pressure (70 +/- 7 vs. 41 +/- 4 mmHg) at unchanged diastolic LV end-diastolic pressure (LVedP) (10 +/- 3 mmHg).	Dobutamine	183-193	CD59 molecule (CD59 blood group)	Homo sapiens	177-182
8438699-1	1993	The myocardial clearance rate of C-11 palmitate as an index of fatty acid oxidation was assessed by means of positron emission tomography (PET) at rest and during dobutamine infusion in seven normal subjects and 10 patients with coronary artery disease.	Dobutamine	163-173	RNA polymerase III subunit K	Homo sapiens	33-37
8262081-4	1993	Seven CHF patients received a continuous intravenous infusion of dobutamine (5 micrograms.kg-1 x min-1) for 96 h. Blood samples were obtained before and every 24 h after starting the therapy.	Dobutamine	65-75	CD59 molecule (CD59 blood group)	Homo sapiens	97-102
8491224-7	1993	Fourteen patients were able to tolerate dobutamine 20 micrograms kg-1 min-1.	Dobutamine	40-50	CD59 molecule (CD59 blood group)	Homo sapiens	70-75
8508864-9	1993	Dobutamine also significantly increased heart rate from a mean of 108 beats.min-1 to 117 beats.min-1 (P < 0.001).	Dobutamine	0-10	CD59 molecule (CD59 blood group)	Homo sapiens	76-81
8508864-9	1993	Dobutamine also significantly increased heart rate from a mean of 108 beats.min-1 to 117 beats.min-1 (P < 0.001).	Dobutamine	0-10	CD59 molecule (CD59 blood group)	Homo sapiens	95-100
8096781-7	1993	The beta 1-adrenoceptor agonist, dobutamine (10(-9)-10(-5) M), relaxed arteries precontracted with K+.	Dobutamine	33-43	adrenoceptor beta 1	Rattus norvegicus	4-23
8064586-3	1993	During dobutamine infusion, the clearance rate constant of C-11 acetate increased significantly (0.063 +/- 0.014 vs 0.109 +/- 0.016, p < 0.002) in good correlation with the rate-pressure product (r = 0.83).	Dobutamine	7-17	RNA polymerase III subunit K	Homo sapiens	59-63
8374553-6	1993	Dobutamine is a sympathomimetic drug (beta 1 agonist) that increases myocardial contractility and at high doses also systolic arterial blood pressure and heart rate.	Dobutamine	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	38-44
1469631-5	1992	In contrast, PVN microinjections of both the beta 1 adrenoceptor agonist dobutamine and the beta 2 adrenoceptor agonist salbutamol significantly reduced basal plasma AVP.	Dobutamine	73-83	adrenoceptor beta 1	Rattus norvegicus	45-64
1480569-3	1992	A single and brief infusion of dobutamine--a synthetic catecholamine and potent beta 1-adrenoreceptor agonist--provides a clinical improvement which may last for several weeks.	Dobutamine	31-41	adrenoceptor beta 1	Homo sapiens	80-101
1466438-1	1992	The report describes a patient during induction of anaesthesia for coronary artery by-pass grafting, in whom the infusion of dobutamine at a rate of 5 micrograms.kg-1.min-1 resulted in unanticipated severe hypertension.	Dobutamine	125-135	CD59 molecule (CD59 blood group)	Homo sapiens	167-172
1389847-2	1992	Nine healthy, adult, non-obese, male physicians were infused with an incremental infusion of dobutamine starting at 2.5 micrograms kg-1 min-1 increasing to 5.0 and then 7.5 micrograms kg-1 min-1 for 15 min each.	Dobutamine	93-103	CD59 molecule (CD59 blood group)	Homo sapiens	136-141
1325107-3	1992	After a left main intracoronary infusion of dobutamine (25 to 200 micrograms.min-1), beta-adrenergic contractile responsiveness was assessed as the net increase in peak positive LV dp/dt (delta LV dp/dt).	Dobutamine	44-54	CD59 molecule (CD59 blood group)	Homo sapiens	77-82
1354251-4	1992	Epinine evoked positive inotropic effects through stimulation of beta-1 and beta-2 adrenoceptors to about the same degree, whereas dobutamine acted mainly at beta-1 adrenoceptors but had a significant beta-2 adrenoceptor component.	Dobutamine	131-141	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	158-164
1623750-5	1992	In the dobutamine low pHi group, pHi increased significantly from 7.16 +/- 0.03 to 7.24 +/- 0.03 (n = 9, p less than 0.05).	Dobutamine	7-17	glucose-6-phosphate isomerase	Homo sapiens	22-25
1623750-5	1992	In the dobutamine low pHi group, pHi increased significantly from 7.16 +/- 0.03 to 7.24 +/- 0.03 (n = 9, p less than 0.05).	Dobutamine	7-17	glucose-6-phosphate isomerase	Homo sapiens	33-36
1310921-4	1992	The energy expenditure increased and was 33% higher than control (P less than 0.001) at 10 micrograms of dobutamine min-1 kg-1.	Dobutamine	105-115	CD59 molecule (CD59 blood group)	Homo sapiens	116-126
1412379-5	1992	There is a significant increase in coronary bypass flow induced by both rates of 0.4 and 0.8 microgram x kg-1 x min-1 dobutamine, but there was no significant effect on bypass flow induced by dopamine.	Dobutamine	118-128	CD59 molecule (CD59 blood group)	Homo sapiens	112-117
1412379-8	1992	A significant increase in rate of contraction and relaxation was only induced by the higher dosage of 0.8 microgram x kg-1 x min-1 dobutamine.	Dobutamine	131-141	CD59 molecule (CD59 blood group)	Homo sapiens	125-130
1323000-4	1992	Dobutamine, a beta 1-AR full agonist, mediated delta Vcfc was 92-97% of that of isoproterenol.	Dobutamine	0-10	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	14-20
1310921-5	1992	The respiratory exchange ratio decreased from 0.85 (SEM 0.02) before infusion to 0.80 (SEM 0.01) at 10 micrograms of dobutamine min-1 kg-1, but did not alter during the placebo infusion (P less than 0.001).	Dobutamine	117-127	CD59 molecule (CD59 blood group)	Homo sapiens	128-138
1310921-11	1992	The plasma insulin concentration increased at 2 and 5 micrograms of dobutamine min-1 kg-1 (P less than 0.001) with no further rise at 10 micrograms of dobutamine min-1 kg-1.	Dobutamine	68-78	CD59 molecule (CD59 blood group)	Homo sapiens	79-89
1577035-2	1992	Dobutamine was infused at incremental doses (up to a maximum of 40 micrograms kg-1 min-1) in 52 patients with chest pain; all the patients underwent coronary angiography; significant coronary artery disease was quantitatively defined as greater than or equal to 50% diameter stenosis.	Dobutamine	0-10	CD59 molecule (CD59 blood group)	Homo sapiens	83-88
1777350-8	1991	PET with C-11 palmitate at control and during dobutamine infusion is considered to be promising in assessing metabolic reserve in the myocardium.	Dobutamine	46-56	aldo-keto reductase family 1 member C4	Homo sapiens	9-13
1681086-4	1991	Noradrenaline or isoprenaline in the absence and presence of a selective beta-2 receptor antagonist, or the selective beta-1 adrenergic agonist dobutamine, caused a 2- to 2.5-fold transient lipolytic response which also peaked at 30 min but then (within 3 hr) declined to the base-line level.	Dobutamine	144-154	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	118-124
1655438-2	1991	For this purpose, a four-point dose-response curve was prepared for dobutamine starting with an initial dose of 2.5 micrograms kg-1 min-1, which was increased by 2.5 micrograms kg-1 min-1 at a time up to altogether 10 micrograms kg-1 min-1.	Dobutamine	68-78	CD59 molecule (CD59 blood group)	Homo sapiens	132-137
1655438-2	1991	For this purpose, a four-point dose-response curve was prepared for dobutamine starting with an initial dose of 2.5 micrograms kg-1 min-1, which was increased by 2.5 micrograms kg-1 min-1 at a time up to altogether 10 micrograms kg-1 min-1.	Dobutamine	68-78	CD59 molecule (CD59 blood group)	Homo sapiens	182-187
1655438-2	1991	For this purpose, a four-point dose-response curve was prepared for dobutamine starting with an initial dose of 2.5 micrograms kg-1 min-1, which was increased by 2.5 micrograms kg-1 min-1 at a time up to altogether 10 micrograms kg-1 min-1.	Dobutamine	68-78	CD59 molecule (CD59 blood group)	Homo sapiens	182-187
1859148-3	1991	Dobutamine is a synthetic catecholamine that acts on alpha-1, beta-1 and beta-2 adrenergic receptors.	Dobutamine	0-10	adrenoceptor alpha 1D	Homo sapiens	53-68
1859148-3	1991	Dobutamine is a synthetic catecholamine that acts on alpha-1, beta-1 and beta-2 adrenergic receptors.	Dobutamine	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	73-79
1676248-9	1991	Cardiovascular collapse was treated with dobutamine (10 micrograms.kg-1.min-1).	Dobutamine	41-51	CD59 molecule (CD59 blood group)	Homo sapiens	72-77
1832602-1	1991	The influence of two cardiac inotropic drugs, dobutamine and salbutamol, on plasma atrial natriuretic factor (ANF) was investigated in 20 patients with congestive heart failure.	Dobutamine	46-56	natriuretic peptide A	Homo sapiens	83-108
1832602-1	1991	The influence of two cardiac inotropic drugs, dobutamine and salbutamol, on plasma atrial natriuretic factor (ANF) was investigated in 20 patients with congestive heart failure.	Dobutamine	46-56	natriuretic peptide A	Homo sapiens	110-113
1824930-2	1991	The CPAP added to inotropic support (enoximone plus dobutamine) and intraaortic balloon pumping dramatically increased SvO2 in relation to both an increase in cardiac output and a decrease in VO2 secondary to respiratory work reduction, validating the initial hypotheses.	Dobutamine	52-62	centromere protein J	Homo sapiens	4-8
1978808-10	1990	Other beta-sympathomimetic agents such as dopamine, dobutamine, fenoterol, salbutamol, and terbutaline also stimulated myocardial G-6-PDH activity in a time- and dose-related manner.	Dobutamine	52-62	glucose-6-phosphate dehydrogenase	Rattus norvegicus	130-137
1833898-6	1991	Dobutamine was administered in a dose of 4-7 micrograms.kg-1.min-1 over the same period.	Dobutamine	0-10	CD59 molecule (CD59 blood group)	Homo sapiens	61-66
2248392-1	1990	Using implanted pulsed Doppler microprobes sutured on saphenous bypass grafts in ten patients we studied, 6 h after cardiac surgery, the effects of 5 and 10 micrograms.kg-1.min-1 of dobutamine on mean (Qm), systolic (Qs), and diastolic (Qd) coronary bypass graft flows, as well as on coronary systolic (integral of Qs) and diastolic (integral of Qd) blood volumes entering the myocardium per cardiac beat.	Dobutamine	182-192	CD59 molecule (CD59 blood group)	Homo sapiens	173-178
2358560-5	1990	During combined fentanyl-midazolam and clonidine infusion, cardiovascular depression gradually developed over several days necessitating the institution of a dobutamine infusion (dose: 8-12 micrograms kg-1 min-1).	Dobutamine	158-168	CD59 molecule (CD59 blood group)	Homo sapiens	206-211
2364711-4	1990	Dobutamine infusion resulted in a significant decrease in PEPI (from 108 +/- 16 [SEM] to 95 +/- 17 msec; p less than .01) and in PEP/LVET ratio (from 0.55 +/- 0.16 [SEM] to 0.45 +/- 0.17; p less than .01), and in a significant increase in LVETI (from 255 +/- 15.7 [SEM] to 264 +/- 16.2 msec; p less than .01).	Dobutamine	0-10	progestagen associated endometrial protein	Homo sapiens	58-61
2318228-2	1990	Dobutamine-ECG test (dose of 5, 10, 15 and 20 micrograms kg-1 min-1 every 5 min) was performed 5 to 12 days after the beginning of the symptoms of AMI, and coronary angiography within the first month.	Dobutamine	0-10	CD59 molecule (CD59 blood group)	Homo sapiens	62-67
1981809-8	1990	Dobutamine, believed to preferentially stimulate beta 1-receptors, inhibited active tension in a concentration-dependent manner (10(-7)-10(-4) M).	Dobutamine	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	49-55
34297830-8	2021	In 9- to 10-week-old hUgcg-/- mice, contractile capacity in response to dobutamine stress was reduced.	Dobutamine	72-82	UDP-glucose ceramide glucosyltransferase	Homo sapiens	21-26
25887954-10	2015	Pretreatment with nifedipine not only significantly blocked the enhancing effects of DOB on LPS-induced elevation in cytosolic Ca(2+) concentration and CaMKII phosphorylation in cardiomyocytes, but also partly reversed the effects of DOB on caspase-9 and caspase-3/7 activities in LPS-treated cardiomyocytes.	Dobutamine	85-88	toll-like receptor 4	Mus musculus	92-95
25887954-10	2015	Pretreatment with nifedipine not only significantly blocked the enhancing effects of DOB on LPS-induced elevation in cytosolic Ca(2+) concentration and CaMKII phosphorylation in cardiomyocytes, but also partly reversed the effects of DOB on caspase-9 and caspase-3/7 activities in LPS-treated cardiomyocytes.	Dobutamine	85-88	calcium/calmodulin-dependent protein kinase II gamma	Mus musculus	152-158
25887954-10	2015	Pretreatment with nifedipine not only significantly blocked the enhancing effects of DOB on LPS-induced elevation in cytosolic Ca(2+) concentration and CaMKII phosphorylation in cardiomyocytes, but also partly reversed the effects of DOB on caspase-9 and caspase-3/7 activities in LPS-treated cardiomyocytes.	Dobutamine	85-88	caspase 9	Mus musculus	241-250
25887954-10	2015	Pretreatment with nifedipine not only significantly blocked the enhancing effects of DOB on LPS-induced elevation in cytosolic Ca(2+) concentration and CaMKII phosphorylation in cardiomyocytes, but also partly reversed the effects of DOB on caspase-9 and caspase-3/7 activities in LPS-treated cardiomyocytes.	Dobutamine	85-88	caspase 3	Mus musculus	255-264
25887954-10	2015	Pretreatment with nifedipine not only significantly blocked the enhancing effects of DOB on LPS-induced elevation in cytosolic Ca(2+) concentration and CaMKII phosphorylation in cardiomyocytes, but also partly reversed the effects of DOB on caspase-9 and caspase-3/7 activities in LPS-treated cardiomyocytes.	Dobutamine	85-88	toll-like receptor 4	Mus musculus	281-284
25887954-10	2015	Pretreatment with nifedipine not only significantly blocked the enhancing effects of DOB on LPS-induced elevation in cytosolic Ca(2+) concentration and CaMKII phosphorylation in cardiomyocytes, but also partly reversed the effects of DOB on caspase-9 and caspase-3/7 activities in LPS-treated cardiomyocytes.	Dobutamine	234-237	toll-like receptor 4	Mus musculus	92-95
34716983-1	2022	BACKGROUND AND AIM: The aim of this study was to assess the nature of myocardial dysfunction in the cardiac syndrome x (CSX) and insignificant coronary artery disease (ICAD) using dobutamine stress echocardiography (DSE) and coronary calcium scoring (CAC).	Dobutamine	180-190	NK2 homeobox 5	Homo sapiens	120-123
2196538-4	1990	The overuse of dobutamine, if it does exist, must be dealt with by pharmacy departments in an informed, yet unbiased fashion, to aid in preventing the continued escalation of health care costs.	Dobutamine	15-25	activation induced cytidine deaminase	Homo sapiens	129-132
25887954-7	2015	RESULTS: LPS induced apoptosis in adult mouse ventricular myocytes, dobutamine (DOB), a beta1-AR agonist, promoted apoptosis, caspase-8, 9 and 3 activation and increased cytosolic Ca(2+) concentration in LPS-challenged cardiomyocytes.	Dobutamine	68-78	adrenergic receptor, beta 1	Mus musculus	94-96
25887954-7	2015	RESULTS: LPS induced apoptosis in adult mouse ventricular myocytes, dobutamine (DOB), a beta1-AR agonist, promoted apoptosis, caspase-8, 9 and 3 activation and increased cytosolic Ca(2+) concentration in LPS-challenged cardiomyocytes.	Dobutamine	68-78	caspase 8	Mus musculus	126-135
25887954-7	2015	RESULTS: LPS induced apoptosis in adult mouse ventricular myocytes, dobutamine (DOB), a beta1-AR agonist, promoted apoptosis, caspase-8, 9 and 3 activation and increased cytosolic Ca(2+) concentration in LPS-challenged cardiomyocytes.	Dobutamine	68-78	toll-like receptor 4	Mus musculus	204-207
25887954-7	2015	RESULTS: LPS induced apoptosis in adult mouse ventricular myocytes, dobutamine (DOB), a beta1-AR agonist, promoted apoptosis, caspase-8, 9 and 3 activation and increased cytosolic Ca(2+) concentration in LPS-challenged cardiomyocytes.	Dobutamine	80-83	adrenergic receptor, beta 1	Mus musculus	94-96
25887954-7	2015	RESULTS: LPS induced apoptosis in adult mouse ventricular myocytes, dobutamine (DOB), a beta1-AR agonist, promoted apoptosis, caspase-8, 9 and 3 activation and increased cytosolic Ca(2+) concentration in LPS-challenged cardiomyocytes.	Dobutamine	80-83	caspase 8	Mus musculus	126-135
25887954-7	2015	RESULTS: LPS induced apoptosis in adult mouse ventricular myocytes, dobutamine (DOB), a beta1-AR agonist, promoted apoptosis, caspase-8, 9 and 3 activation and increased cytosolic Ca(2+) concentration in LPS-challenged cardiomyocytes.	Dobutamine	80-83	toll-like receptor 4	Mus musculus	204-207
25887954-8	2015	DOB also up-regulated TNF-alpha expression, decreased Bcl-2 levels, promoted Bax translocation to mitochondria, mitochondrial membrane potential loss and cytochrome c release as well as IkappaBalpha, p38 MAPK, JNK and Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) phosphorylation in LPS-treated cardiomyocytes.	Dobutamine	0-3	tumor necrosis factor	Mus musculus	22-31
25887954-8	2015	DOB also up-regulated TNF-alpha expression, decreased Bcl-2 levels, promoted Bax translocation to mitochondria, mitochondrial membrane potential loss and cytochrome c release as well as IkappaBalpha, p38 MAPK, JNK and Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) phosphorylation in LPS-treated cardiomyocytes.	Dobutamine	0-3	B cell leukemia/lymphoma 2	Mus musculus	54-59
25887954-8	2015	DOB also up-regulated TNF-alpha expression, decreased Bcl-2 levels, promoted Bax translocation to mitochondria, mitochondrial membrane potential loss and cytochrome c release as well as IkappaBalpha, p38 MAPK, JNK and Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) phosphorylation in LPS-treated cardiomyocytes.	Dobutamine	0-3	BCL2-associated X protein	Mus musculus	77-80
25887954-8	2015	DOB also up-regulated TNF-alpha expression, decreased Bcl-2 levels, promoted Bax translocation to mitochondria, mitochondrial membrane potential loss and cytochrome c release as well as IkappaBalpha, p38 MAPK, JNK and Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) phosphorylation in LPS-treated cardiomyocytes.	Dobutamine	0-3	mitogen-activated protein kinase 14	Mus musculus	200-203
25887954-8	2015	DOB also up-regulated TNF-alpha expression, decreased Bcl-2 levels, promoted Bax translocation to mitochondria, mitochondrial membrane potential loss and cytochrome c release as well as IkappaBalpha, p38 MAPK, JNK and Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) phosphorylation in LPS-treated cardiomyocytes.	Dobutamine	0-3	mitogen-activated protein kinase 8	Mus musculus	210-213
25887954-8	2015	DOB also up-regulated TNF-alpha expression, decreased Bcl-2 levels, promoted Bax translocation to mitochondria, mitochondrial membrane potential loss and cytochrome c release as well as IkappaBalpha, p38 MAPK, JNK and Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) phosphorylation in LPS-treated cardiomyocytes.	Dobutamine	0-3	calcium/calmodulin-dependent protein kinase II gamma	Mus musculus	218-263
25887954-8	2015	DOB also up-regulated TNF-alpha expression, decreased Bcl-2 levels, promoted Bax translocation to mitochondria, mitochondrial membrane potential loss and cytochrome c release as well as IkappaBalpha, p38 MAPK, JNK and Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) phosphorylation in LPS-treated cardiomyocytes.	Dobutamine	0-3	calcium/calmodulin-dependent protein kinase II gamma	Mus musculus	265-271
25887954-8	2015	DOB also up-regulated TNF-alpha expression, decreased Bcl-2 levels, promoted Bax translocation to mitochondria, mitochondrial membrane potential loss and cytochrome c release as well as IkappaBalpha, p38 MAPK, JNK and Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) phosphorylation in LPS-treated cardiomyocytes.	Dobutamine	0-3	toll-like receptor 4	Mus musculus	292-295
25887954-9	2015	PKA inhibitor abolished the effects of DOB on caspase-9 activation, Bcl-2 levels as well as JNK and p38 MAPK phosphorylation, but not on IkappaBalpha phosphorylation, TNF-alpha expression and caspase-8 activation in LPS-stimulated cardiomyocytes.	Dobutamine	39-42	caspase 9	Mus musculus	46-55
25887954-9	2015	PKA inhibitor abolished the effects of DOB on caspase-9 activation, Bcl-2 levels as well as JNK and p38 MAPK phosphorylation, but not on IkappaBalpha phosphorylation, TNF-alpha expression and caspase-8 activation in LPS-stimulated cardiomyocytes.	Dobutamine	39-42	B cell leukemia/lymphoma 2	Mus musculus	68-73
16040714-4	2005	The peak positive rate of change of LV pressure (LV +dP/dt) was measured in response to intravenous dobutamine (Dob-1).	Dobutamine	100-110	Mtr4 exosome RNA helicase	Homo sapiens	112-117
34487814-9	2022	Dobutamine and nitroprusside treatment decreased the transrenal gradient of ACE (p=0.012, p<0.0001 respectively), aldosterone (p=0.005, p=0.030) and PRA (p=0.014, p=0.002) in patients with HF only.	Dobutamine	0-10	angiotensin I converting enzyme	Homo sapiens	76-79
34551626-0	2021	The beta3 Adrenergic Receptor Antagonist L-748,337 Attenuates Dobutamine-Induced Cardiac Inefficiency While Preserving Inotropy in Anesthetized Pigs.	Dobutamine	62-72	beta-3 adrenergic receptor	Sus scrofa	4-29
34524268-7	2021	However, DOB (10.0 mug/kg) increased serum IL-10 level and improved survival in septic rats.	Dobutamine	9-12	interleukin 10	Rattus norvegicus	43-48
35437830-2	2022	METHODS: Alleles in the known genetic single nucleotide polymorphisms in beta1 and beta2 adrenoceptor (AR) genes and Gs protein alpha-subunit gene (GNAS) possibly affecting inotropic effect were identified in patients of neonatal dobutamine pharmacokinetic-pharmacodynamic study.	Dobutamine	230-240	BCL2 related protein A1	Homo sapiens	73-78
35437830-2	2022	METHODS: Alleles in the known genetic single nucleotide polymorphisms in beta1 and beta2 adrenoceptor (AR) genes and Gs protein alpha-subunit gene (GNAS) possibly affecting inotropic effect were identified in patients of neonatal dobutamine pharmacokinetic-pharmacodynamic study.	Dobutamine	230-240	adrenoceptor beta 2	Homo sapiens	83-101
35437830-2	2022	METHODS: Alleles in the known genetic single nucleotide polymorphisms in beta1 and beta2 adrenoceptor (AR) genes and Gs protein alpha-subunit gene (GNAS) possibly affecting inotropic effect were identified in patients of neonatal dobutamine pharmacokinetic-pharmacodynamic study.	Dobutamine	230-240	GNAS complex locus	Homo sapiens	148-152
35437830-5	2022	Dobutamine plasma concentration and exposure time respective HR (adjusted to gestational age) is dependent on beta1-AR Arg389Gly polymorphism so that in G/G (Gly) homozygotes and G/C heterozygotes dobutamine increases HR more than in C/C (Arg) homozygotes, with parameter estimate (95% CI) of 38.3 (15.8 - 60.7) bpm per AUC of 100 mug L-1 h, p=0.0008.	Dobutamine	0-10	adrenoceptor beta 1	Homo sapiens	110-118
35437830-5	2022	Dobutamine plasma concentration and exposure time respective HR (adjusted to gestational age) is dependent on beta1-AR Arg389Gly polymorphism so that in G/G (Gly) homozygotes and G/C heterozygotes dobutamine increases HR more than in C/C (Arg) homozygotes, with parameter estimate (95% CI) of 38.3 (15.8 - 60.7) bpm per AUC of 100 mug L-1 h, p=0.0008.	Dobutamine	197-207	adrenoceptor beta 1	Homo sapiens	110-118
35437830-7	2022	CONCLUSION: In critically ill neonates, beta1-AR Arg389Gly and GNAS c.393C>T polymorphisms may play a role in the haemodynamic response to dobutamine during the first hours and days of life.	Dobutamine	139-149	adrenoceptor beta 1	Homo sapiens	40-48
35437830-7	2022	CONCLUSION: In critically ill neonates, beta1-AR Arg389Gly and GNAS c.393C>T polymorphisms may play a role in the haemodynamic response to dobutamine during the first hours and days of life.	Dobutamine	139-149	GNAS complex locus	Homo sapiens	63-67
35262701-18	2022	adipocytes, DOB and LUB + DOB increased HSL gene expression (P = 0.001) and LUB + SAL depressed adipose triglyceride lipase expression below control levels (P = 0.001).	Dobutamine	12-15	lipase E, hormone sensitive type	Bos taurus	40-43
35262701-18	2022	adipocytes, DOB and LUB + DOB increased HSL gene expression (P = 0.001) and LUB + SAL depressed adipose triglyceride lipase expression below control levels (P = 0.001).	Dobutamine	26-29	lipase E, hormone sensitive type	Bos taurus	40-43
2712404-4	1989	The administration of 10.6 +/- 0.5 micrograms.kg-1.min-1 dobutamine (starting dose: 6 micrograms.kg-1.min-1) was started when the cardiac index (CI) was less than 3.3 l.min-1.m-2 after vascular filling with plasma expanders.	Dobutamine	57-67	CD59 molecule (CD59 blood group)	Homo sapiens	51-56
35216120-7	2022	Interestingly, OCT1 substrates exhibiting stronger OCT1 inhibition were mainly biaromatic beta-agonistic drugs, such as dobutamine, fenoterol, ractopamine and ritodrine.	Dobutamine	120-130	solute carrier family 22 member 1	Homo sapiens	15-19
35216120-7	2022	Interestingly, OCT1 substrates exhibiting stronger OCT1 inhibition were mainly biaromatic beta-agonistic drugs, such as dobutamine, fenoterol, ractopamine and ritodrine.	Dobutamine	120-130	solute carrier family 22 member 1	Homo sapiens	51-55
2679978-7	1989	Forty-five patients were infused dobutamine 7 micrograms.kg-1.min-1 (group D) from 10 min.	Dobutamine	33-43	CD59 molecule (CD59 blood group)	Homo sapiens	62-67
2679978-13	1989	With dobutamine, haemodynamic parameters returned to preoperative values and heart rate increased by 12 b.min-1.	Dobutamine	5-15	CD59 molecule (CD59 blood group)	Homo sapiens	106-111
2736968-3	1989	Dobutamine increased HR, CI, SI, stroke work, DO2, VO2, and Qsp while decreasing PAWP and SVRI and PVRI.	Dobutamine	0-10	WBP2 N-terminal like	Homo sapiens	81-85
2736968-7	1989	These data are consistent with the hypothesis that the beta 2-adrenergic action of dobutamine vasodilates the previously constricted peripheral circulation, enhances tissue perfusion by improving micro-circulatory flow distribution, and improves DO2 and VO2.	Dobutamine	83-93	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	55-61
2712404-4	1989	The administration of 10.6 +/- 0.5 micrograms.kg-1.min-1 dobutamine (starting dose: 6 micrograms.kg-1.min-1) was started when the cardiac index (CI) was less than 3.3 l.min-1.m-2 after vascular filling with plasma expanders.	Dobutamine	57-67	CD59 molecule (CD59 blood group)	Homo sapiens	102-107
2712404-4	1989	The administration of 10.6 +/- 0.5 micrograms.kg-1.min-1 dobutamine (starting dose: 6 micrograms.kg-1.min-1) was started when the cardiac index (CI) was less than 3.3 l.min-1.m-2 after vascular filling with plasma expanders.	Dobutamine	57-67	CD59 molecule (CD59 blood group)	Homo sapiens	102-107
3407597-7	1988	Plasma renin activity increased with both agents (dobutamine +38%, p less than 0.06; dopexamine hydrochloride +41%, p less than 0.05).	Dobutamine	50-60	renin	Homo sapiens	7-12
2544635-7	1989	Both drugs similarly increased cardiac output: +2.61.min-1 +/- 1.4 for DP and 2.21.min-1 +/- 1.5 for DB.	Dobutamine	101-103	CD59 molecule (CD59 blood group)	Homo sapiens	83-88
3569349-4	1987	While there was no change of STI in group I, dobutamine infusion resulted in a significant decrease in PEPI (from 102 +/- 4.8 to 87.8 +/- 4.2; mean +/- SEM; P less than 0.01) and of PEP/LVET (from 0.56 +/- 0.05 to 0.45 +/- 0.05; mean +/- SEM; P less than 0.01) and in a significant increase of LVETI (from 237.6 +/- 5.6 to 253.3 +/- 5.2; mean +/- SEM; P less than 0.01) in group II.	Dobutamine	45-55	progestagen associated endometrial protein	Homo sapiens	182-190
2839569-8	1988	Thus, the beta 1-adrenoceptor activity of dopamine and dobutamine augmented the contractile state of the myocardium.	Dobutamine	55-65	adrenoceptor beta 1	Homo sapiens	10-29
3677352-7	1987	In two patients, an inverse linear relationship was demonstrated between decreases in Tau and increases in contractile state produced by an infusion of dobutamine, as shown by correlation of Tln and TD with (+)dP/dt/DP40 (r = -.88 and -.83, respectively).	Dobutamine	152-162	intercellular adhesion molecule 5	Homo sapiens	191-194
3310640-7	1987	It has recently been suggested that the inotropic activity of dobutamine results from combined beta 1- and alpha 1-adrenoceptor stimulation in the myocardium, and that this activity could explain, at least in part, the inotropic selectivity of the compound.	Dobutamine	62-72	adrenoceptor beta 1	Homo sapiens	95-127
3310640-8	1987	Furthermore, in the vasculature, the beta 2-adrenoceptor-mediated vasodilatory effect of dobutamine is exactly offset by the alpha 1-adrenoceptor-mediated vasoconstrictor activity, such that net changes in blood pressure are minimal following the administration of dobutamine.	Dobutamine	89-99	adrenoceptor beta 2	Homo sapiens	37-56
3310640-8	1987	Furthermore, in the vasculature, the beta 2-adrenoceptor-mediated vasodilatory effect of dobutamine is exactly offset by the alpha 1-adrenoceptor-mediated vasoconstrictor activity, such that net changes in blood pressure are minimal following the administration of dobutamine.	Dobutamine	265-275	adrenoceptor beta 2	Homo sapiens	37-56
3308346-6	1987	Plasma renin activity rose significantly with dobutamine and further increased with amrinone.	Dobutamine	46-56	renin	Homo sapiens	7-12
3446365-3	1987	When dobutamine was infused at 10 micrograms.kg-1.min-1 seven out of 10 patients had power output values above the defined limits, implying that the technique can identify correctly in vivo the direct positive inotropic effects of dobutamine in the presence of its vasodilating activity.	Dobutamine	5-15	CD59 molecule (CD59 blood group)	Homo sapiens	50-55
3446365-3	1987	When dobutamine was infused at 10 micrograms.kg-1.min-1 seven out of 10 patients had power output values above the defined limits, implying that the technique can identify correctly in vivo the direct positive inotropic effects of dobutamine in the presence of its vasodilating activity.	Dobutamine	231-241	CD59 molecule (CD59 blood group)	Homo sapiens	50-55
3039539-2	1987	In addition, the effects of dobutamine and of clenbuterol are impaired by betaxolol (1 and 4 mg/kg) and unchanged by ICI 118,551 (1 and 4 mg/kg) beta-blocking drugs respectively selective for beta 1 and beta 2 receptors.	Dobutamine	28-38	hemoglobin, beta adult major chain	Mus musculus	192-198
2906100-5	1988	The electrophoretic profiles of GP in DOB-evoked saliva were similar to those in TER-evoked saliva, and included two characteristic main bands of GP I (130 KDa) and GP IV (21.5 KDa) from the acinar cells and a minor band of GP III (31 KDa) which originated in the cells of the granular tubules.	Dobutamine	38-41	glucose-6-phosphate isomerase	Rattus norvegicus	146-150
2906100-5	1988	The electrophoretic profiles of GP in DOB-evoked saliva were similar to those in TER-evoked saliva, and included two characteristic main bands of GP I (130 KDa) and GP IV (21.5 KDa) from the acinar cells and a minor band of GP III (31 KDa) which originated in the cells of the granular tubules.	Dobutamine	38-41	CD36 molecule	Rattus norvegicus	165-170
6150925-5	1984	Compared with the latter, the beta 1-selective agonist dobutamine increases myocardial contractile force and cardiac output with less beta 2-mediated vasodilation and hypotension.	Dobutamine	55-65	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	30-36
2942027-6	1986	Plasma renin activity increased significantly with dobutamine (from 11.3 +/- 13.5 to 17.8 +/- 15.0 ng/ml/hour, p less than 0.01) and with enoximone (from 13.6 +/- 18.3 to 16.6 +/- 18.8 ng/ml/hour, 0.05 less than p less than 0.1).	Dobutamine	51-61	renin	Homo sapiens	7-12
2942027-10	1986	Further, dobutamine, like other beta agonists, provokes renin secretion and may do so to a greater extent than enoximone.	Dobutamine	9-19	renin	Homo sapiens	56-61
3515823-10	1986	Plasma renin activity (PRA) rose significantly (P less than 0.05) at the highest infusion rate of dobutamine.	Dobutamine	98-108	renin	Homo sapiens	7-12
2868577-1	1986	Isoprenaline, isoetharine, rimiterol, dobutamine and nadolol were investigated as substrates for purified pig-liver catechol-O-methyltransferase using a sensitive spectrophotometric assay.	Dobutamine	38-48	catechol-O-methyltransferase	Sus scrofa	116-144
2868577-3	1986	On the basis of the apparent first-order rate constant, rimiterol was found to be a 1.5-fold and dobutamine a 5-fold better substrate for catechol-O-methyltransferase than isoprenaline; isoetharine shows no improvement over isoprenaline.	Dobutamine	97-107	catechol-O-methyltransferase	Sus scrofa	138-166
3001267-8	1985	In contrast, (+)-dobutamine, which possesses predominantly beta-1 and beta-2 adrenoceptor agonist activity, elicited only a modest increase in cardiac output which was due both to an increase in heart rate and stroke volume.	Dobutamine	13-27	adrenoceptor beta 2	Rattus norvegicus	70-89
4057075-2	1985	The (-)-enantiomer of dobutamine, which is predominantly an alpha-1 adrenoceptor agonist, displayed greater inotropic selectivity than the (+)-enantiomer, which is predominantly a beta-1 and beta-2 adrenoceptor agonist.	Dobutamine	22-32	adrenoceptor beta 2	Rattus norvegicus	191-210
2864131-2	1985	Both the beta1 agonist dobutamine and the beta2 agonist terbutaline relaxed coronary arteries partially contracted by 25 mM of KCl.	Dobutamine	23-33	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	9-14
2864131-3	1985	Dobutamine contracted small coronary arteries at 10(-5) M concentrations, then relaxed them at 10(-4) M. The beta1-adrenoceptor antagonist metoprolol contracted coronary arteries relaxed by either dobutamine or terbutaline, but the beta2 antagonist H35/25 did so only in high and probably nonselective concentrations.	Dobutamine	0-10	adrenoceptor beta 1	Homo sapiens	109-127
2864131-3	1985	Dobutamine contracted small coronary arteries at 10(-5) M concentrations, then relaxed them at 10(-4) M. The beta1-adrenoceptor antagonist metoprolol contracted coronary arteries relaxed by either dobutamine or terbutaline, but the beta2 antagonist H35/25 did so only in high and probably nonselective concentrations.	Dobutamine	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	232-237
2864131-3	1985	Dobutamine contracted small coronary arteries at 10(-5) M concentrations, then relaxed them at 10(-4) M. The beta1-adrenoceptor antagonist metoprolol contracted coronary arteries relaxed by either dobutamine or terbutaline, but the beta2 antagonist H35/25 did so only in high and probably nonselective concentrations.	Dobutamine	0-10	H3.5 histone	Homo sapiens	249-255
2864131-3	1985	Dobutamine contracted small coronary arteries at 10(-5) M concentrations, then relaxed them at 10(-4) M. The beta1-adrenoceptor antagonist metoprolol contracted coronary arteries relaxed by either dobutamine or terbutaline, but the beta2 antagonist H35/25 did so only in high and probably nonselective concentrations.	Dobutamine	197-207	adrenoceptor beta 1	Homo sapiens	109-127
2986993-6	1985	In contrast, (+)-dobutamine, which possesses predominantly beta 1-and beta 2-adrenoceptor agonist activity, elicited only a modest increase in cardiac output which was due entirely to increased heart rate since stroke volume was not increased.	Dobutamine	13-27	adrenoceptor beta 1	Rattus norvegicus	59-89
6084778-4	1984	The beta 1-agonist dobutamine and the beta 2-agonists fenoterol and procaterol activated adenylate cyclase with an intrinsic activity of 0.5-0.7 (isoprenaline = 1.0).	Dobutamine	19-29	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	4-10
6084778-6	1984	On the contrary, combination of dobutamine (100 microM) and procaterol (10 microM) resulted in activation of adenylate cyclase which was not different from that evoked by saturating concentration of isoprenaline (10 microM), indicating that dobutamine (beta 1) and procaterol (beta 2) produce adenylate cyclase activation through stimulation of different beta-adrenoceptor subtypes.	Dobutamine	32-42	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	253-259
6084778-6	1984	On the contrary, combination of dobutamine (100 microM) and procaterol (10 microM) resulted in activation of adenylate cyclase which was not different from that evoked by saturating concentration of isoprenaline (10 microM), indicating that dobutamine (beta 1) and procaterol (beta 2) produce adenylate cyclase activation through stimulation of different beta-adrenoceptor subtypes.	Dobutamine	32-42	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	277-283
3037572-12	1987	Since the (-)-enantiomer of dobutamine has little or no beta 2-adrenoceptor agonist activity, the beta 2-adrenoceptor-mediated effect of (+/-)-dobutamine must result from the (+)-enantiomer as has been previously proposed.	Dobutamine	137-153	beta-2 adrenergic receptor	Canis lupus familiaris	98-117
3932470-9	1985	In contrast to the exercise control group, the saline and dobutamine groups developed orthostatic hypotension, tachycardia, and accentuation of the renin-aldosterone response over the 3-wk treatment period; for the saline group, this is best explained by the observed fall in blood volume and for the dobutamine group, by the blunting of vascular vasoconstrictive responses.	Dobutamine	58-68	renin	Homo sapiens	148-153
6150925-5	1984	Compared with the latter, the beta 1-selective agonist dobutamine increases myocardial contractile force and cardiac output with less beta 2-mediated vasodilation and hypotension.	Dobutamine	55-65	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	134-140
6263950-3	1981	For beta adrenergic receptors identified by (-) [(3)H]dihydroalprenolol (DHA), dobutamine had significantly greater affinity for the beta(1) subtype (K(D) = 2.5 muM in rat heart and 2.6 muM in turkey erythrocyte) than for the beta(2) subtype (K(D) = 14.8 muM in frog heart and 25.4 muM in rat lung) (P &lt; 0.001).	Dobutamine	79-89	latexin	Homo sapiens	161-164
6090958-10	1984	All three compounds elicited beta 2-adrenoceptor mediated inhibition of tone in rat uterus, with the rank order of potency being ASL-7022 greater than dobutamine greater than dopamine.	Dobutamine	151-161	adrenoceptor beta 2	Rattus norvegicus	29-48
6325661-7	1984	Based on ratios of relative potencies for alpha adrenoceptor-mediated vasopressor effects and beta-2 adrenoceptor-mediated vasodepressor effects, it appears that dobutamine possesses an equal balance between its vasopressor and vasodepressor potencies, such that the net effect in the vasculature is a physiological antagonism with little or no change in blood pressure, consistent with clinical observations and experiments in animals.	Dobutamine	162-172	adrenoceptor beta 2	Rattus norvegicus	94-113
6115050-1	1981	Multiple injections of dobutamine, a selective adrenergic beta-1 receptor agonist, or isoproterenol, a nonselective beta receptor agonist, produced significant dose-dependent enlargement of the submandibular glands of male rats.	Dobutamine	23-33	adrenoceptor beta 1	Rattus norvegicus	47-73
6149303-7	1984	The selective beta-2 adrenergic receptor agonists, salbutamol (3 X 10(-8) to 3 X 10(-7) M) and terbutaline (10(-7) to 3 X 10(-7) M), caused significantly greater enhancement of the PNS response in preparations from SHR than in those from WKY, whereas the selective beta-1 agonist, dobutamine, caused only inhibition of the PNS responses in preparations from both WKY and SHR.	Dobutamine	281-291	adrenoceptor beta 2	Rattus norvegicus	14-40
6705283-3	1984	Each patient underwent a continuous infusion of dobutamine from 2.5 to 10 micrograms/kg min-1 with dosage increments of 2.5 micrograms/kg at 15-minute intervals.	Dobutamine	48-58	CD59 molecule (CD59 blood group)	Homo sapiens	88-93
6705283-8	1984	However, 5 patients showed a decreased myocardial lactate extraction after 10 micrograms/kg min-1 of intravenous dobutamine, 3 from group I and 2 from group II.	Dobutamine	113-123	CD59 molecule (CD59 blood group)	Homo sapiens	92-97
6199596-3	1984	In phentolamine-treated cats, reductions in arterial pressure and total peripheral resistance produced by infusions of dobutamine were little affected by the beta 2-adrenoceptor-selective antagonist butoxamine, but were antagonized by atenolol.	Dobutamine	119-129	adrenoceptor beta 2	Felis catus	158-177
6625384-3	1983	Dobutamine"s effects are mediated by strong beta 1 adrenergic receptor stimulation and mild stimulation of beta 2 and alpha 1 receptors.	Dobutamine	0-10	adrenoceptor beta 1	Homo sapiens	44-70
6263950-3	1981	For beta adrenergic receptors identified by (-) [(3)H]dihydroalprenolol (DHA), dobutamine had significantly greater affinity for the beta(1) subtype (K(D) = 2.5 muM in rat heart and 2.6 muM in turkey erythrocyte) than for the beta(2) subtype (K(D) = 14.8 muM in frog heart and 25.4 muM in rat lung) (P &lt; 0.001).	Dobutamine	79-89	latexin	Homo sapiens	186-189
6263950-3	1981	For beta adrenergic receptors identified by (-) [(3)H]dihydroalprenolol (DHA), dobutamine had significantly greater affinity for the beta(1) subtype (K(D) = 2.5 muM in rat heart and 2.6 muM in turkey erythrocyte) than for the beta(2) subtype (K(D) = 14.8 muM in frog heart and 25.4 muM in rat lung) (P &lt; 0.001).	Dobutamine	79-89	latexin	Homo sapiens	186-189
6263950-3	1981	For beta adrenergic receptors identified by (-) [(3)H]dihydroalprenolol (DHA), dobutamine had significantly greater affinity for the beta(1) subtype (K(D) = 2.5 muM in rat heart and 2.6 muM in turkey erythrocyte) than for the beta(2) subtype (K(D) = 14.8 muM in frog heart and 25.4 muM in rat lung) (P &lt; 0.001).	Dobutamine	79-89	latexin	Homo sapiens	186-189
6781663-0	1981	Effect of dobutamine on insulin requirement in diabetic ketoacidosis.	Dobutamine	10-20	insulin	Homo sapiens	24-31
6778182-3	1980	The average PEP/LVET declined significantly (p &lt; 0.001) at three days, four and nine weeks, and at 10 months after the discontinuation of dobutamine infusion.	Dobutamine	141-151	progestagen associated endometrial protein	Homo sapiens	12-15
33851400-9	2021	End-systolic elastance (Ees) was overall reduced (compared with data from the literature) and showed significant increase under dobutamine (0.80 +- 0.44 to 1.89 +- 0.72 mm Hg/mL, p <= 0.001), whereas end-diastolic elastance (Eed) was not significantly influenced (0.11 +- 0.70 to 0.13 +- 0.15 mm Hg/mL, p = 0.454).	Dobutamine	128-138	embryonic ectoderm development	Homo sapiens	225-228
649837-2	1978	The dosage of dobutamine started from 2.5 mcg kg-1 min-1 and was increased stepwise to 5, 7.5, 10, 12.5 and 15 mcg kg-1 min-1.	Dobutamine	14-24	CD59 molecule (CD59 blood group)	Homo sapiens	51-56
649837-2	1978	The dosage of dobutamine started from 2.5 mcg kg-1 min-1 and was increased stepwise to 5, 7.5, 10, 12.5 and 15 mcg kg-1 min-1.	Dobutamine	14-24	CD59 molecule (CD59 blood group)	Homo sapiens	120-125
649837-13	1978	We conclude that in patients with depressed cardiac function dobutamine at low doses of 2.5 mcg kg-1 min-1 decreases afterload and filling pressures.	Dobutamine	61-71	CD59 molecule (CD59 blood group)	Homo sapiens	101-106
7002564-4	1980	Dobutamine stimulated renin release, which might partly be the cause of the increased systolic arterial pressure.	Dobutamine	0-10	renin	Homo sapiens	22-27
35061-3	1978	Doses of dobutamine of 5 or 7.5 microgram.kg-1.min-1 corrected the IC, PCP and TPR.	Dobutamine	9-19	CD59 molecule (CD59 blood group)	Homo sapiens	47-52
35061-4	1978	Dobutamine ameliorated the SI and SWILV in an increasing fashion up to a dose of 10 microgram.kg-1.min-1 only and without restoring them to the control values of the pre-operative period.	Dobutamine	0-10	CD59 molecule (CD59 blood group)	Homo sapiens	99-104
35061-7	1978	Tests of vascular filling (pre-charge tests) carried out in the second group of patients under 10 microgram,kg-1.min-1 of dobutamine and in a third group under 15 microgram.kg-1.min-1 showed a good cardiac adaptation to filling, equal or superior to that of the pre-operative period.	Dobutamine	122-132	CD59 molecule (CD59 blood group)	Homo sapiens	113-118
35061-8	1978	It also appeared that the amelioration of CF obtained with a moderate vascular filling (300 ml of low molecular weight dextran) under 10 microgram.kg-1.min-1 of dobutamine is greatly superior to the amelioration obtained by 10 to 15 microgram.kg-1.min-1 of dobutamine.	Dobutamine	161-171	CD59 molecule (CD59 blood group)	Homo sapiens	152-157
33904806-0	2021	In vitro effects of epinephrine, norepinephrine, and dobutamine on lipopolysaccharide-stimulated production of tumor necrosis factor-alpha, interleukin-6, and interleukin-10 in blood from healthy dogs.	Dobutamine	53-63	tumor necrosis factor	Canis lupus familiaris	111-138
33986192-9	2021	However, loss of lipin 1 dampened the cardiac ionotropic response to dobutamine and exercise endurance in association with reduced protein kinase A signaling.	Dobutamine	69-79	lipin 1	Mus musculus	17-24
33904806-0	2021	In vitro effects of epinephrine, norepinephrine, and dobutamine on lipopolysaccharide-stimulated production of tumor necrosis factor-alpha, interleukin-6, and interleukin-10 in blood from healthy dogs.	Dobutamine	53-63	interleukin 10	Canis lupus familiaris	159-173
33904806-1	2021	OBJECTIVE: To determine the in vitro effects of epinephrine, norepinephrine, and dobutamine on lipopolysaccharide (LPS)-stimulated production of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-10 (IL-10) in blood from healthy dogs.	Dobutamine	81-91	tumor necrosis factor	Canis lupus familiaris	145-172
33480422-8	2021	While MET treatment reduced myocardial nitrates, only MET treatment completely restored microvessel dilation to dobutamine (DOB) stimulation in the absence of NO and prostanoids (combined inhibition), indicating that MET restored the coronary flow reserve attributable to endothelium-derived hyperpolarisation (EDH).	Dobutamine	112-122	MET proto-oncogene, receptor tyrosine kinase	Rattus norvegicus	54-57
32929770-0	2021	Quantifying the effect of dobutamine stress on myocardial Pi and pH in healthy volunteers: A 31 P MRS study at 7T.	Dobutamine	26-36	phenylalanine hydroxylase	Homo sapiens	65-67
33662683-8	2021	For instance, three drugs Benserazide, Dobutamine and Masoprocol showed a superior consensus enrichment against the PLpro conformations.	Dobutamine	39-49	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	116-121
33662683-9	2021	Further MD simulations for these drugs complexed with PLpro suggested the superior stability and binding of dobutamine and masoprocol inside the binding site compared to Benserazide.	Dobutamine	108-118	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	54-59
33534612-4	2021	Unexpectedly, pre-treatment of cells with IgG3(+) serum or purified IgG3(+) autoantibodies impaired dobutamine-mediated adenylyl cyclase (AC) activity and cAMP generation while enhancing biased beta-arrestin recruitment and ERK activation.	Dobutamine	100-110	immunoglobulin heavy constant gamma 3 (G3m marker)	Homo sapiens	42-46
33534612-4	2021	Unexpectedly, pre-treatment of cells with IgG3(+) serum or purified IgG3(+) autoantibodies impaired dobutamine-mediated adenylyl cyclase (AC) activity and cAMP generation while enhancing biased beta-arrestin recruitment and ERK activation.	Dobutamine	100-110	immunoglobulin heavy constant gamma 3 (G3m marker)	Homo sapiens	68-72
33534612-4	2021	Unexpectedly, pre-treatment of cells with IgG3(+) serum or purified IgG3(+) autoantibodies impaired dobutamine-mediated adenylyl cyclase (AC) activity and cAMP generation while enhancing biased beta-arrestin recruitment and ERK activation.	Dobutamine	100-110	mitogen-activated protein kinase 1	Homo sapiens	224-227
33480422-8	2021	While MET treatment reduced myocardial nitrates, only MET treatment completely restored microvessel dilation to dobutamine (DOB) stimulation in the absence of NO and prostanoids (combined inhibition), indicating that MET restored the coronary flow reserve attributable to endothelium-derived hyperpolarisation (EDH).	Dobutamine	112-122	MET proto-oncogene, receptor tyrosine kinase	Rattus norvegicus	54-57
31867674-7	2020	In TERT-hBA, UCP1 mRNA expression was stimulated 11.0-fold by dibutyryl cAMP (dbcAMP), 8.0-fold to 8.4-fold by isoproterenol (ISO; a pan-ADRB agonist), and 6.1-fold to 12.7-fold by dobutamine (ADRB1 agonist), whereas neither procaterol (ADRB2 agonist), CL314.432, or Mirabegron (ADRB3 agonists) affected UCP1.	Dobutamine	181-191	uncoupling protein 1	Homo sapiens	13-17
33100271-5	2021	MET (1-10 micromol/L) prevented beta1AR-mediated increases in diameter elicited by dobutamine in cannulated rat CA.	Dobutamine	83-93	MET proto-oncogene, receptor tyrosine kinase	Rattus norvegicus	0-3
33100271-7	2021	Acute oral administration of MET (30 mg/kg) to rats in doses that attenuated resting heart rate and dobutamine-induced tachycardia also blunted beta1AR-mediated dilation of CA.	Dobutamine	100-110	MET proto-oncogene, receptor tyrosine kinase	Rattus norvegicus	29-32
32868321-5	2020	Mechanisms of dobutamine-induced CS are not fully understood and include endothelial dysfunction leading to deficient nitric oxide-mediated coronary vasodilation in response to increased myocardial oxygen demand as well as imbalance between beta1 and beta2 adrenergic effects of dobutamine.	Dobutamine	14-24	citrate synthase	Homo sapiens	33-35
32868321-5	2020	Mechanisms of dobutamine-induced CS are not fully understood and include endothelial dysfunction leading to deficient nitric oxide-mediated coronary vasodilation in response to increased myocardial oxygen demand as well as imbalance between beta1 and beta2 adrenergic effects of dobutamine.	Dobutamine	14-24	BCL2 related protein A1	Homo sapiens	241-246
32868321-5	2020	Mechanisms of dobutamine-induced CS are not fully understood and include endothelial dysfunction leading to deficient nitric oxide-mediated coronary vasodilation in response to increased myocardial oxygen demand as well as imbalance between beta1 and beta2 adrenergic effects of dobutamine.	Dobutamine	14-24	ATPase H+ transporting V0 subunit a2	Homo sapiens	251-256
32868321-5	2020	Mechanisms of dobutamine-induced CS are not fully understood and include endothelial dysfunction leading to deficient nitric oxide-mediated coronary vasodilation in response to increased myocardial oxygen demand as well as imbalance between beta1 and beta2 adrenergic effects of dobutamine.	Dobutamine	279-289	citrate synthase	Homo sapiens	33-35
32868321-6	2020	Dobutamine-induced CS has also been much more frequently reported in patients from Asian descent with VSA.	Dobutamine	0-10	citrate synthase	Homo sapiens	19-21
33432967-8	2021	While MET treatment reduced myocardial nitrates, only MET treatment completely restored microvessel dilation to dobutamine stimulation in the absence of NO and prostanoids (combined inhibition), indicating that MET restored the coronary flow reserve attributable to endothelium-derived hyperpolarisation.	Dobutamine	112-122	MET proto-oncogene, receptor tyrosine kinase	Rattus norvegicus	54-57
33432967-8	2021	While MET treatment reduced myocardial nitrates, only MET treatment completely restored microvessel dilation to dobutamine stimulation in the absence of NO and prostanoids (combined inhibition), indicating that MET restored the coronary flow reserve attributable to endothelium-derived hyperpolarisation.	Dobutamine	112-122	MET proto-oncogene, receptor tyrosine kinase	Rattus norvegicus	54-57
32868321-1	2020	A 53-year-old woman with atypical chest pain underwent a dobutamine stress echocardiogram (DSE) and developed a coronary spasm (CS) with severe pain and dramatic ST-segment elevation 9 min after dobutamine infusion was discontinued.	Dobutamine	195-205	citrate synthase	Homo sapiens	128-130
32868321-4	2020	Retrospectively, we found that the patient had vasospastic angina (VSA), a condition that has been strongly associated with the development of dobutamine-induced CS.	Dobutamine	143-153	citrate synthase	Homo sapiens	162-164
32835622-0	2022	Possible inhibition mechanism of dobutamine hydrochloride as potent inhibitor for human glucose-6-phosphate dehydrogenase enzyme.	Dobutamine	33-57	glucose-6-phosphate dehydrogenase	Homo sapiens	88-121
32835622-8	2022	We also found that dobutamine hydrochloride inhibits the hG6PD enzyme"s activity by causing structural alterations in substrate and coenzyme binding sites.	Dobutamine	19-43	glucose-6-phosphate dehydrogenase	Homo sapiens	57-62
31551025-7	2020	Finally, our data suggested that compounds "structures.722" (dobutamine) and "M2" are suitable candidates to inhibit MT2-MMP for further examination in the laboratory.	Dobutamine	61-71	matrix metallopeptidase 15	Homo sapiens	117-124
29768300-4	2018	We have previously shown that the ADRB1 389 polymorphism affects the response to incremental dose infusion of the ADRB agonist dobutamine.	Dobutamine	127-137	adrenoceptor beta 1	Homo sapiens	34-39
31841026-7	2020	Renin (P&lt;.05), angiotensin II (P&lt;.005) and aldosterone (P&lt;.05) increased after dobutamine infusion.	Dobutamine	88-98	angiotensinogen	Homo sapiens	18-32
31841026-9	2020	A combined treatment of dobutamine and terlipressin had a positive effect on CO (1.19 L/min, P&lt;.05) and increased renin (P&lt;.005), angiotensin II (P&lt;.005) and aldosterone (P&lt;.05), but it had no significant effects on MAP or GFR.	Dobutamine	24-34	angiotensinogen	Homo sapiens	136-150
30734585-8	2019	The contractile reserve assessed by low-dose dobutamine stress echocardiography and "perfusion-metabolism mismatch" assessed by positron emission tomography, which are the characteristics of viable myocardium in hibernation, were observed in the PEDF overexpressed ischemic heart.	Dobutamine	45-55	serpin family F member 1	Rattus norvegicus	246-250
29976618-5	2018	The lack of ADAMTS13 drastically increased the propensity for ventricular arrhythmias during dobutamine-induced stress in diabetic mice.	Dobutamine	93-103	a disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 motif, 13	Mus musculus	12-20
29064277-5	2018	Significant increments in hs-cTnT were documented after exercise test (from 15.9+-11.9 ng/l to 19.5+-13.6 ng/l, p&lt;0.0001) and dobutamine test (from 20.6+-20.8 ng/l to 37.8+-31.1 ng/l, p=0.0006), in absence of changes in CK-MB according to each stressor.	Dobutamine	129-139	troponin T2, cardiac type	Homo sapiens	29-33
29970875-7	2018	Low-dose dobutamine MRI will be applied for the assessment of viable myocardium, microcirculation perfusion, and left ventricular remodeling, and the concentrations of angiogenic cytokine, vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (bFGF) will be investigated at baseline and at 1- and 12-month follow-up.	Dobutamine	9-19	vascular endothelial growth factor A	Homo sapiens	225-229
29970875-7	2018	Low-dose dobutamine MRI will be applied for the assessment of viable myocardium, microcirculation perfusion, and left ventricular remodeling, and the concentrations of angiogenic cytokine, vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (bFGF) will be investigated at baseline and at 1- and 12-month follow-up.	Dobutamine	9-19	fibroblast growth factor 2	Homo sapiens	236-266
29970875-7	2018	Low-dose dobutamine MRI will be applied for the assessment of viable myocardium, microcirculation perfusion, and left ventricular remodeling, and the concentrations of angiogenic cytokine, vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (bFGF) will be investigated at baseline and at 1- and 12-month follow-up.	Dobutamine	9-19	fibroblast growth factor 2	Homo sapiens	268-272
30711447-6	2019	Intravenous treatment of mdx mice with rAAVrh74.MCK.GALGT2 at 2 months of age significantly improved stroke volume and cardiac output compared to mock-treated mice analyzed at 17 months, both at rest and after stimulation with dobutamine.	Dobutamine	227-237	creatine kinase, muscle	Mus musculus	48-51
30711447-6	2019	Intravenous treatment of mdx mice with rAAVrh74.MCK.GALGT2 at 2 months of age significantly improved stroke volume and cardiac output compared to mock-treated mice analyzed at 17 months, both at rest and after stimulation with dobutamine.	Dobutamine	227-237	beta-1,4-N-acetyl-galactosaminyl transferase 2	Mus musculus	52-58
29912990-13	2018	Cmah-/-mdx mice showed an abnormal response to dobutamine stress test and this was completely ameliorated by PIP6a-PMO treatment.	Dobutamine	47-57	cytidine monophospho-N-acetylneuraminic acid hydroxylase	Mus musculus	0-4
29768300-5	2018	The aim of the current study was to determine whether the ADRB1 389 polymorphism affects the hemodynamic response to constant dose infusion of dobutamine in healthy patients.	Dobutamine	143-153	adrenoceptor beta 1	Homo sapiens	58-63
29306449-12	2018	In conclusion, in response to chronic exercise adrenaline-deficient Pnmt-KO mice show concentric LV hypertrophy and impaired response to dobutamine, suggesting an initial stage of pathological cardiac hypertrophic remodeling.	Dobutamine	137-147	phenylethanolamine-N-methyltransferase	Mus musculus	68-72
29611347-8	2018	The selective beta1-AR agonist dobutamine diminished preadipocyte proliferation both in vivo and in vitro, whereas the selective beta2-AR agonist, salbutamol, promoted proliferation in vitro, suggesting that the beta1-AR may mediate the inhibitory effect of NE on preadipocyte proliferation.	Dobutamine	31-41	adrenergic receptor, beta 1	Mus musculus	14-22
29523072-5	2018	Dobutamine depressed the inflammatory response by modifying the toll-like receptor-4 signalling pathways, including interferon regulatory factors and nuclear factor kappa B activation in experimental paradigm 1.	Dobutamine	0-10	toll-like receptor 4	Mus musculus	64-84
29523072-8	2018	Moreover, increased levels of SOD3 were verified on the protein level 24 h after OGD and control stimulation in cultures with or without preconditioning with LPS and dobutamine, respectively.	Dobutamine	166-176	superoxide dismutase 3, extracellular	Mus musculus	30-34
28894151-9	2017	However, in Scn5a+/DeltaKPQ mice, dobutamine delayed the changes in ventricular repolarisation following corresponding increases in ventricular rate.	Dobutamine	34-44	sodium channel, voltage-gated, type V, alpha	Mus musculus	12-17
30460079-3	2017	injections with dobutamine (beta1-adrenergic receptor agonist) or terbutaline (beta2-adrenergic receptor agonist) caused an elevation of the blood glucose level, whereas metoprolol (beta1-adrenergic receptor antagonist) or butoxamine (beta2-adrenergic receptor antagonist) did not.	Dobutamine	16-26	adrenergic receptor, beta 1	Mus musculus	28-53
30460079-3	2017	injections with dobutamine (beta1-adrenergic receptor agonist) or terbutaline (beta2-adrenergic receptor agonist) caused an elevation of the blood glucose level, whereas metoprolol (beta1-adrenergic receptor antagonist) or butoxamine (beta2-adrenergic receptor antagonist) did not.	Dobutamine	16-26	adrenergic receptor, beta 2	Mus musculus	235-260
28071680-9	2017	Treatment with dobutamine and 2-deoxy-D-glucose and glucose starvation induced the pYAP expression and prevented the cell migration and invasion induced by siRNA-LSR.	Dobutamine	15-25	lipolysis stimulated lipoprotein receptor	Homo sapiens	162-165
28220640-5	2017	The dobutamine-induced changes of all speckle tracking indices predicted cardiac mortality, while, among resting echocardiographic parameters, only RS and RSR predicted survival, after adjusting for age, sex, cardiomyopathy aetiology, NYHA class, AF, BNP levels, resting LVED, and LV outflow tract velocity-time integral, and their respective changes produced by dobutamine (P &lt; 0.05).	Dobutamine	4-14	natriuretic peptide B	Homo sapiens	251-254
28597800-0	2017	Effect of dobutamine stress echocardiography on serum heart fatty acid binding protein levels.	Dobutamine	10-20	fatty acid binding protein 3	Homo sapiens	54-86
28597800-3	2017	The aim of this study was to evaluate the effect of myocardial ischaemia induced by dobutamine stress echocardiography (DSE) on serum HFABP levels.	Dobutamine	84-94	fatty acid binding protein 3	Homo sapiens	134-139
27545647-10	2017	As shown by 31P-magnetic resonance spectroscopy in vivo, LV phosphocreatine/ATP ratio declined during dobutamine stress in Irp-targeted mice but remained stable in control mice.	Dobutamine	102-112	wingless-type MMTV integration site family, member 2	Mus musculus	123-126
28201733-1	2017	Aims: The benefit of the beta1-adrenergic receptor (beta1-AR) agonist dobutamine for treatment of acute heart failure in peripartum cardiomyopathy (PPCM) is controversial.	Dobutamine	70-80	adrenoceptor beta 1	Homo sapiens	52-60
28201733-13	2017	These cellular alterations may underlie the dobutamine-induced irreversible heart failure progression in PPCM patients who frequently display reduced cardiac STAT3 expression.	Dobutamine	44-54	signal transducer and activator of transcription 3	Homo sapiens	158-163
27840071-4	2017	In the current study, we probed the effects of the beta1-AR agonist dobutamine (Dobu) on GABAergic transmission onto pyramidal neurons in the PFC of juvenile rats.	Dobutamine	68-78	adrenoceptor beta 1	Rattus norvegicus	51-59
27840071-4	2017	In the current study, we probed the effects of the beta1-AR agonist dobutamine (Dobu) on GABAergic transmission onto pyramidal neurons in the PFC of juvenile rats.	Dobutamine	80-84	adrenoceptor beta 1	Rattus norvegicus	51-59
26941040-4	2016	Nonspecific adrenoceptor agonists including epinephrine, isoprotenerol, and the selective beta1 adrenoceptor agonist dobutamine were found to cause &gt; 90% encystment of Acanthamoeba trophozoites compared to &lt; 30% with the controls.	Dobutamine	117-127	adrenoceptor beta 1	Homo sapiens	90-108
27037808-7	2016	Both norepinephrine and dobutamine significantly reduced TNF-alpha and IL-6 production after ex vivo LPS stimulation of whole blood in a dose-dependent manner, and this effect was partially reversed by the presence of metoprolol.	Dobutamine	24-34	tumor necrosis factor	Homo sapiens	57-66
27037808-7	2016	Both norepinephrine and dobutamine significantly reduced TNF-alpha and IL-6 production after ex vivo LPS stimulation of whole blood in a dose-dependent manner, and this effect was partially reversed by the presence of metoprolol.	Dobutamine	24-34	interleukin 6	Homo sapiens	71-75
27207969-3	2016	METHODS AND RESULTS: Cardiomyocyte-restricted deletion of S1P1 in mice (S1P1 (alpha) (MHCC) (re)) resulted in progressive cardiomyopathy, compromised response to dobutamine, and premature death.	Dobutamine	162-172	sphingosine-1-phosphate receptor 1	Mus musculus	58-62
27284371-12	2016	Western blot analysis revealed that dobutamine induces expression of caspase-3 and caspase-9.	Dobutamine	36-46	caspase 3	Homo sapiens	69-78
27284371-12	2016	Western blot analysis revealed that dobutamine induces expression of caspase-3 and caspase-9.	Dobutamine	36-46	caspase 9	Homo sapiens	83-92
26380773-0	2015	Effect of dobutamine on lung aquaporin 5 in endotoxine shock-induced acute lung injury rabbit.	Dobutamine	10-20	aquaporin-5	Oryctolagus cuniculus	29-40
26635197-11	2016	Furthermore, unanaesthesized MyBPC(PKA-) and DBL(PKA-) mice displayed depressed maximum systolic pressure in response to dobutamine as measured using implantable telemetry devices.	Dobutamine	121-131	mcf.2 transforming sequence	Mus musculus	45-48
26313487-0	2015	Effects of sex and the common ADRB1 389 genetic polymorphism on the hemodynamic response to dobutamine.	Dobutamine	92-102	adrenoceptor beta 1	Homo sapiens	30-35
26313487-4	2015	The aim of this study was to determine whether the ADRB1 389 polymorphism affects the hemodynamic response to dobutamine in healthy individuals including men and women.	Dobutamine	110-120	adrenoceptor beta 1	Homo sapiens	51-56
26313487-9	2015	Renin response to dobutamine (DeltaRenin) was 3.9-fold greater in Arg389Arg than in Gly389Gly (PANOVA=0.032).	Dobutamine	18-28	renin	Homo sapiens	0-5
26313487-12	2015	CONCLUSION: In healthy individuals, HR and renin responses to dobutamine were more than three-fold greater among ADRB1 Arg389 compared with Gly389 homozygotes.	Dobutamine	62-72	renin	Homo sapiens	43-48
26313487-12	2015	CONCLUSION: In healthy individuals, HR and renin responses to dobutamine were more than three-fold greater among ADRB1 Arg389 compared with Gly389 homozygotes.	Dobutamine	62-72	adrenoceptor beta 1	Homo sapiens	113-118
26313487-13	2015	Future studies on the effect of the ADRB1 389 polymorphism on dobutamine stress echocardiography should compare Arg389 and Gly389 homozygotes.	Dobutamine	62-72	adrenoceptor beta 1	Homo sapiens	36-41
26913580-9	2015	In response to stimulation with dobutamine, Akt1/2/3 was phosphorylated in UROtsa, while ERK1/2 and p38 were phosphorylated in T24.	Dobutamine	32-42	AKT serine/threonine kinase 1	Homo sapiens	44-52
26913580-9	2015	In response to stimulation with dobutamine, Akt1/2/3 was phosphorylated in UROtsa, while ERK1/2 and p38 were phosphorylated in T24.	Dobutamine	32-42	mitogen-activated protein kinase 3	Homo sapiens	89-95
26913580-9	2015	In response to stimulation with dobutamine, Akt1/2/3 was phosphorylated in UROtsa, while ERK1/2 and p38 were phosphorylated in T24.	Dobutamine	32-42	mitogen-activated protein kinase 1	Homo sapiens	100-103
26913580-10	2015	MEK1/2 inhibition blocked basal and dobutamine-induced proliferation in T24 but only basal proliferation in UROtsa.	Dobutamine	36-46	mitogen-activated protein kinase kinase 1	Homo sapiens	0-6
27030626-3	2016	In addition, western blot analysis revealed that glucose transporter 4 (GLUT4) level in the adipocyte plasma membrane (PM) fraction was increased by treatment with 10 microM NE, 100 microM dobutamine (DOB, a ss1-AR agonist), or 0.1 microM CL316243 (CL, a ss3-AR agonist) for 30 min or with 10 mM AF for 20 min.	Dobutamine	189-199	solute carrier family 2 member 4	Rattus norvegicus	49-70
27030626-3	2016	In addition, western blot analysis revealed that glucose transporter 4 (GLUT4) level in the adipocyte plasma membrane (PM) fraction was increased by treatment with 10 microM NE, 100 microM dobutamine (DOB, a ss1-AR agonist), or 0.1 microM CL316243 (CL, a ss3-AR agonist) for 30 min or with 10 mM AF for 20 min.	Dobutamine	189-199	solute carrier family 2 member 4	Rattus norvegicus	72-77
27030626-3	2016	In addition, western blot analysis revealed that glucose transporter 4 (GLUT4) level in the adipocyte plasma membrane (PM) fraction was increased by treatment with 10 microM NE, 100 microM dobutamine (DOB, a ss1-AR agonist), or 0.1 microM CL316243 (CL, a ss3-AR agonist) for 30 min or with 10 mM AF for 20 min.	Dobutamine	201-204	solute carrier family 2 member 4	Rattus norvegicus	49-70
27030626-3	2016	In addition, western blot analysis revealed that glucose transporter 4 (GLUT4) level in the adipocyte plasma membrane (PM) fraction was increased by treatment with 10 microM NE, 100 microM dobutamine (DOB, a ss1-AR agonist), or 0.1 microM CL316243 (CL, a ss3-AR agonist) for 30 min or with 10 mM AF for 20 min.	Dobutamine	201-204	solute carrier family 2 member 4	Rattus norvegicus	72-77
26751789-11	2016	CONCLUSIONS: Higher visceral fat volumes are associated with reduced left ventricular myocardial perfusion at peak dose dobutamine stress in women but not in men.	Dobutamine	120-130	FAT atypical cadherin 1	Homo sapiens	29-32
26380773-1	2015	BACKGROUND: Dobutamine, a commonly used vasoactive drug, has been reported to reduce pulmonary edema and protect against acute lung injury (ALI) by up-regulating aquaporin 5 (AQP5) expressions.	Dobutamine	12-22	aquaporin-5	Oryctolagus cuniculus	162-173
26380773-1	2015	BACKGROUND: Dobutamine, a commonly used vasoactive drug, has been reported to reduce pulmonary edema and protect against acute lung injury (ALI) by up-regulating aquaporin 5 (AQP5) expressions.	Dobutamine	12-22	aquaporin-5	Oryctolagus cuniculus	175-179
26380773-12	2015	RESULTS: Dobutamine increased AQP5 protein expression and cAMP level in a dose-dependent manner.	Dobutamine	9-19	aquaporin-5	Oryctolagus cuniculus	30-34
26380773-16	2015	CONCLUSIONS: These results suggested that protective effect of dobutamine against endotoxin shock-induced ALI may be due to its ability of up-regulating AQP5 protein expression via increasing intracellular cAMP concentration.	Dobutamine	63-73	aquaporin-5	Oryctolagus cuniculus	153-157
25634756-4	2015	RESULTS: Significant increase of HO-1 was found in neonatal cultured cardiomyocytes treated with DOB, when compared to the control group.	Dobutamine	97-100	heme oxygenase 1	Rattus norvegicus	33-37
25955350-10	2015	Patients administered dobutamine had a higher acute change in hs-TnT levels 3 hours after testing than did those administered adenosine (21 vs 0 pg/mL, P &lt; 0.001).	Dobutamine	22-32	troponin T1, slow skeletal type	Homo sapiens	65-68
25759702-4	2015	Left ventricular (LV) hemodynamics were studied during administration of dobutamine (dobu), the highly specific irreversible inhibitor of nNOS L-VNIO [L-N5-(1-Imino-3-butenyl)-ornithine], or both at steady state and during preload reduction.	Dobutamine	73-83	nitric oxide synthase 1	Rattus norvegicus	138-142
25759702-4	2015	Left ventricular (LV) hemodynamics were studied during administration of dobutamine (dobu), the highly specific irreversible inhibitor of nNOS L-VNIO [L-N5-(1-Imino-3-butenyl)-ornithine], or both at steady state and during preload reduction.	Dobutamine	73-77	nitric oxide synthase 1	Rattus norvegicus	138-142
26451343-5	2015	Treatment with dobutamine, known to affect YAP, was shown to suppress proliferation in an Ocln-dependent manner.	Dobutamine	15-25	Yes1 associated transcriptional regulator	Homo sapiens	43-46
26451343-5	2015	Treatment with dobutamine, known to affect YAP, was shown to suppress proliferation in an Ocln-dependent manner.	Dobutamine	15-25	occludin	Homo sapiens	90-94
25634756-5	2015	Significant change for Nrf2 translocation was also revealed in neonatal cultured cardiomyocytes treated with DOB.	Dobutamine	109-112	NFE2 like bZIP transcription factor 2	Rattus norvegicus	23-27
25634756-6	2015	Insignificant decreases of NF-kappaB p65 activation and HMGB1 release were observed in H/R-induced neonatal cultured cardiomyocytes treated with DOB, when compared to the control group.	Dobutamine	145-148	synaptotagmin 1	Rattus norvegicus	37-40
25634756-6	2015	Insignificant decreases of NF-kappaB p65 activation and HMGB1 release were observed in H/R-induced neonatal cultured cardiomyocytes treated with DOB, when compared to the control group.	Dobutamine	145-148	high mobility group box 1	Rattus norvegicus	56-61
30534237-4	2014	A beta blocker, bisoprolol, was successfully introduced in this patient in combination with oral inotropic agents, pimobendan and digitalis after the prolonged use of intravenous dobutamine infusion, which might have been beneficial for this patient with burn-associated dilated cardiomyopathy not only to reduce regional myocardial ischemia but also to attenuate hypermetabolic state after severe burn injury.	Dobutamine	179-189	amyloid beta precursor protein	Homo sapiens	0-6
24162523-3	2014	The experimental results also show dobutamine as the most lipophilic compound in the case of RP-18 and CN stationary phases (RM0(RP-18) = 1.58 and RM(CN) = 1.21), while RP-8 indicates norepinephrine as the less lipophilic one (RM0(RP8) = -0.70).	Dobutamine	35-45	programmed cell death 2	Homo sapiens	169-173
24162523-3	2014	The experimental results also show dobutamine as the most lipophilic compound in the case of RP-18 and CN stationary phases (RM0(RP-18) = 1.58 and RM(CN) = 1.21), while RP-8 indicates norepinephrine as the less lipophilic one (RM0(RP8) = -0.70).	Dobutamine	35-45	programmed cell death 2	Homo sapiens	231-234
25493021-10	2014	The expression of YAP was detected mainly in the nucleus in the absence of dobutamine.	Dobutamine	75-85	Yes1 associated transcriptional regulator	Homo sapiens	18-21
25493021-11	2014	However, reduced expression of phosphorylated YAP was mainly found in the cytosol following treatment with dobutamine.	Dobutamine	107-117	Yes1 associated transcriptional regulator	Homo sapiens	46-49
25131356-0	2014	Effect of intravenous infusion of dobutamine hydrochloride on the development of early postoperative cognitive dysfunction in elderly patients via inhibiting the release of tumor necrosis factor-alpha.	Dobutamine	34-58	tumor necrosis factor	Homo sapiens	173-200
25131356-8	2014	Simultaneously, an increase of plasma TNF-alpha levels 30min after anesthesia was observed (41.34+-9.61 vs. 27.75+-5.45), which was significantly suppressed by the administration of low-dose dobutamine hydrochloride (29.23+-7.32 vs. 41.34+-9.61) but not by high-dose dobutamine hydrochloride (45.9+-12.11 vs. 41.34+-9.61).	Dobutamine	191-215	tumor necrosis factor	Homo sapiens	38-47
25131356-8	2014	Simultaneously, an increase of plasma TNF-alpha levels 30min after anesthesia was observed (41.34+-9.61 vs. 27.75+-5.45), which was significantly suppressed by the administration of low-dose dobutamine hydrochloride (29.23+-7.32 vs. 41.34+-9.61) but not by high-dose dobutamine hydrochloride (45.9+-12.11 vs. 41.34+-9.61).	Dobutamine	267-291	tumor necrosis factor	Homo sapiens	38-47
25131356-9	2014	Together, our data indicated that the plasma concentration of TNFalpha was engaged in the effect of dobutamine hydrochloride on POCD.	Dobutamine	100-124	tumor necrosis factor	Homo sapiens	62-70
24805304-6	2014	In contrast to esmolol, dobutamine increased the superoxide dismutase level and decreased the myeloperoxidase, malondialdehyde, and nitric oxide levels in CG-induced inflamed paws.	Dobutamine	24-34	myeloperoxidase	Rattus norvegicus	94-109
24727211-5	2014	We found that 1) the beta1-AR agonist Dobutamine (Dobu) suppressed the amplitude evoked excitatory postsynaptic currents (eEPSCs).	Dobutamine	38-48	adrenoceptor beta 1	Homo sapiens	21-29
24727211-5	2014	We found that 1) the beta1-AR agonist Dobutamine (Dobu) suppressed the amplitude evoked excitatory postsynaptic currents (eEPSCs).	Dobutamine	38-42	adrenoceptor beta 1	Homo sapiens	21-29
24828496-7	2014	Subsequently, treatment of TRPV5-expressing mouse DCT2/CNT primary cell cultures with the beta1-AR agonist dobutamine showed enhanced apical-to-basolateral transepithelial Ca(2+) transport.	Dobutamine	107-117	transient receptor potential cation channel, subfamily V, member 5	Mus musculus	27-32
25388343-5	2014	RESULTS: Dobutamine significantly reduced the myocardial infarct size (P &lt; 0.05), myocardial enzymes (LDH and CK) (P &lt; 0.05) and proinfiammation cytokines (TNF-alpha and IL-6), reduced oxidative stress (MDA and SOD) in a dose-dependent manner (all P &lt; 0.05).	Dobutamine	9-19	tumor necrosis factor	Rattus norvegicus	162-171
25388343-5	2014	RESULTS: Dobutamine significantly reduced the myocardial infarct size (P &lt; 0.05), myocardial enzymes (LDH and CK) (P &lt; 0.05) and proinfiammation cytokines (TNF-alpha and IL-6), reduced oxidative stress (MDA and SOD) in a dose-dependent manner (all P &lt; 0.05).	Dobutamine	9-19	interleukin 6	Rattus norvegicus	176-180
25388343-6	2014	Meanwhile, dobutamine significantly and dose-dependently mediated the induction of HO-1 (P &lt; 0.05), the expression of NF-kappaB (P &lt; 0.05) and HMGB1 (P &lt; 0.05).	Dobutamine	11-21	high mobility group box 1	Rattus norvegicus	149-154
24828496-7	2014	Subsequently, treatment of TRPV5-expressing mouse DCT2/CNT primary cell cultures with the beta1-AR agonist dobutamine showed enhanced apical-to-basolateral transepithelial Ca(2+) transport.	Dobutamine	107-117	adrenoceptor beta 1	Homo sapiens	90-98
24828496-8	2014	In human embryonic kidney (HEK293) cells, dobutamine was shown to stimulate cAMP production, signifying functional beta1-AR expression.	Dobutamine	42-52	adrenoceptor beta 1	Homo sapiens	115-123
24828496-9	2014	Fura-2 experiments demonstrated increased activity of TRPV5 in response to dobutamine, which could be prevented by the PKA inhibitor H89.	Dobutamine	75-85	transient receptor potential cation channel subfamily V member 5	Homo sapiens	54-59
24227727-6	2013	When paravascular CSF-ISF exchange was evaluated in real time using in vivo two-photon and ex vivo fluorescence imaging, we observed that internal carotid artery ligation slowed the rate of paravascular CSF-ISF exchange, while dobutamine increased the rate of paravascular CSF-ISF exchange.	Dobutamine	227-237	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	18-21
24447628-3	2014	Dobutamine also inhibits nuclear factor (NF)-kappaB in human T lymphocytes.	Dobutamine	0-10	nuclear factor kappa B subunit 1	Homo sapiens	25-51
24447628-12	2014	Dobutamine induced DNA-binding of HSF-1 and mRNA-expression of hsp70 and hsp90.	Dobutamine	0-10	heat shock transcription factor 1	Homo sapiens	34-39
24447628-12	2014	Dobutamine induced DNA-binding of HSF-1 and mRNA-expression of hsp70 and hsp90.	Dobutamine	0-10	heat shock protein family A (Hsp70) member 4	Homo sapiens	63-68
24447628-12	2014	Dobutamine induced DNA-binding of HSF-1 and mRNA-expression of hsp70 and hsp90.	Dobutamine	0-10	heat shock protein 90 alpha family class A member 1	Homo sapiens	73-78
24447628-14	2014	SIGNIFICANCE: Dobutamine protects from apoptotic cell death via the induction of Hsp70.	Dobutamine	14-24	heat shock protein family A (Hsp70) member 4	Homo sapiens	81-86
24503784-8	2014	CONCLUSIONS: The addition of dipeptidyl peptidase-4 inhibitor therapy with sitagliptin to the treatment regime of patients with type 2 diabetes mellitus and coronary artery disease is associated with a sustained improvement in myocardial performance during dobutamine stress and a reduction in postischemic stunning.	Dobutamine	257-267	dipeptidyl peptidase 4	Homo sapiens	29-51
24132816-1	2013	BACKGROUND: Patients with LBBB or ventricular pacemaker undergoing MPI are at risk for false positive MPI results in the setting of an elevated heart rate (HR) with exercise or dobutamine stress.	Dobutamine	177-187	mannose phosphate isomerase	Homo sapiens	67-70
24132816-1	2013	BACKGROUND: Patients with LBBB or ventricular pacemaker undergoing MPI are at risk for false positive MPI results in the setting of an elevated heart rate (HR) with exercise or dobutamine stress.	Dobutamine	177-187	mannose phosphate isomerase	Homo sapiens	102-105
23726240-0	2014	Dobutamine-mediated heme oxygenase-1 induction via P13K and p38 MAPK inhibits high mobility group box 1 protein release and attenuates rat myocardial ischemia/reperfusion injury in vivo.	Dobutamine	0-10	high mobility group box 1	Rattus norvegicus	78-103
24227727-6	2013	When paravascular CSF-ISF exchange was evaluated in real time using in vivo two-photon and ex vivo fluorescence imaging, we observed that internal carotid artery ligation slowed the rate of paravascular CSF-ISF exchange, while dobutamine increased the rate of paravascular CSF-ISF exchange.	Dobutamine	227-237	ATPase, H+ transporting, lysosomal V0 subunit A2	Mus musculus	22-25
24227727-6	2013	When paravascular CSF-ISF exchange was evaluated in real time using in vivo two-photon and ex vivo fluorescence imaging, we observed that internal carotid artery ligation slowed the rate of paravascular CSF-ISF exchange, while dobutamine increased the rate of paravascular CSF-ISF exchange.	Dobutamine	227-237	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	203-206
24227727-6	2013	When paravascular CSF-ISF exchange was evaluated in real time using in vivo two-photon and ex vivo fluorescence imaging, we observed that internal carotid artery ligation slowed the rate of paravascular CSF-ISF exchange, while dobutamine increased the rate of paravascular CSF-ISF exchange.	Dobutamine	227-237	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	203-206
23531454-0	2013	Dobutamine-mediated heme oxygenase-1 induction via PI3K and p38 MAPK inhibits high mobility group box 1 protein release and attenuates rat myocardial ischemia/reperfusion injury in vivo.	Dobutamine	0-10	heme oxygenase 1	Rattus norvegicus	20-36
23866734-1	2013	In patients with obstructive coronary artery disease, electrocardiographic (ECG) ST-segment elevation (STE) is frequently seen during dobutamine stress echocardiography (DSE) in leads overlying previous transmural left ventricular (LV) myocardial infarction.	Dobutamine	134-144	sulfotransferase family 1E member 1	Homo sapiens	103-106
23866734-8	2013	In conclusion, dobutamine-induced ECG STE in LV segments with normal baseline wall motion is a highly reliable marker of viable collateral-dependent myocardium.	Dobutamine	15-25	sulfotransferase family 1E member 1	Homo sapiens	38-41
23470310-2	2013	The purpose of this study was to evaluate the effects of a beta-1 adrenergic (Adrb1) agonist, dobutamine (DOB), on disuse-induced changes in bone integrity during 28 d of hindlimb unloading (HU).	Dobutamine	94-104	adrenoceptor beta 1	Rattus norvegicus	78-83
23470310-2	2013	The purpose of this study was to evaluate the effects of a beta-1 adrenergic (Adrb1) agonist, dobutamine (DOB), on disuse-induced changes in bone integrity during 28 d of hindlimb unloading (HU).	Dobutamine	106-109	adrenoceptor beta 1	Rattus norvegicus	78-83
23531454-0	2013	Dobutamine-mediated heme oxygenase-1 induction via PI3K and p38 MAPK inhibits high mobility group box 1 protein release and attenuates rat myocardial ischemia/reperfusion injury in vivo.	Dobutamine	0-10	mitogen activated protein kinase 14	Rattus norvegicus	60-68
23531454-0	2013	Dobutamine-mediated heme oxygenase-1 induction via PI3K and p38 MAPK inhibits high mobility group box 1 protein release and attenuates rat myocardial ischemia/reperfusion injury in vivo.	Dobutamine	0-10	high mobility group box 1	Rattus norvegicus	78-103
23531454-2	2013	The present study aimed to investigate whether dobutamine, a selective beta1-adrenergic receptor agonist, could inhibit HMGB1 release via beta1-adrenergic receptor-mediated HO-1 induction and attenuate myocardial ischemia/reperfusion (I/R) injury in rats.	Dobutamine	47-57	adrenoceptor beta 1	Rattus norvegicus	71-96
23531454-2	2013	The present study aimed to investigate whether dobutamine, a selective beta1-adrenergic receptor agonist, could inhibit HMGB1 release via beta1-adrenergic receptor-mediated HO-1 induction and attenuate myocardial ischemia/reperfusion (I/R) injury in rats.	Dobutamine	47-57	high mobility group box 1	Rattus norvegicus	120-125
23531454-2	2013	The present study aimed to investigate whether dobutamine, a selective beta1-adrenergic receptor agonist, could inhibit HMGB1 release via beta1-adrenergic receptor-mediated HO-1 induction and attenuate myocardial ischemia/reperfusion (I/R) injury in rats.	Dobutamine	47-57	adrenoceptor beta 1	Rattus norvegicus	138-163
23531454-2	2013	The present study aimed to investigate whether dobutamine, a selective beta1-adrenergic receptor agonist, could inhibit HMGB1 release via beta1-adrenergic receptor-mediated HO-1 induction and attenuate myocardial ischemia/reperfusion (I/R) injury in rats.	Dobutamine	47-57	heme oxygenase 1	Mus musculus	173-177
23531454-7	2013	RESULTS: Dobutamine significantly and dose-dependently attenuated myocardial I/R injury, reduced oxidative stress, and caused the induction of HO-1, the reduction of NF-kappaB activation and HMGB1 over expression.	Dobutamine	9-19	heme oxygenase 1	Rattus norvegicus	143-147
23531454-7	2013	RESULTS: Dobutamine significantly and dose-dependently attenuated myocardial I/R injury, reduced oxidative stress, and caused the induction of HO-1, the reduction of NF-kappaB activation and HMGB1 over expression.	Dobutamine	9-19	high mobility group box 1	Rattus norvegicus	191-196
23531454-9	2013	CONCLUSIONS: The present study demonstrated that dobutamine mediated the induction of HO-1 by selectively stimulating beta1-adrenergic receptor via PI3K and p38 MAPK, which inhibited HMGB1 release and attenuated rat myocardial I/R injury in vivo.	Dobutamine	49-59	heme oxygenase 1	Rattus norvegicus	86-90
23531454-9	2013	CONCLUSIONS: The present study demonstrated that dobutamine mediated the induction of HO-1 by selectively stimulating beta1-adrenergic receptor via PI3K and p38 MAPK, which inhibited HMGB1 release and attenuated rat myocardial I/R injury in vivo.	Dobutamine	49-59	adrenoceptor beta 1	Rattus norvegicus	118-143
23531454-9	2013	CONCLUSIONS: The present study demonstrated that dobutamine mediated the induction of HO-1 by selectively stimulating beta1-adrenergic receptor via PI3K and p38 MAPK, which inhibited HMGB1 release and attenuated rat myocardial I/R injury in vivo.	Dobutamine	49-59	mitogen activated protein kinase 14	Rattus norvegicus	157-165
23531454-9	2013	CONCLUSIONS: The present study demonstrated that dobutamine mediated the induction of HO-1 by selectively stimulating beta1-adrenergic receptor via PI3K and p38 MAPK, which inhibited HMGB1 release and attenuated rat myocardial I/R injury in vivo.	Dobutamine	49-59	high mobility group box 1	Rattus norvegicus	183-188
23666674-8	2013	Despite a lack of left ventricular hypertrophy, MyBP-C+/- hearts exhibited elevated end-diastolic pressure and decreased peak rate of LV pressure rise, which was normalized following dobutamine infusion.	Dobutamine	183-193	myosin binding protein C3	Homo sapiens	48-54
23698550-11	2013	Our results indicate that pretreatment with dobutamine may improve survival, liver function, and hepatic microcirculation after polymicrobial sepsis in rat via beta1-adrenoceptor activation.	Dobutamine	44-54	adrenoceptor beta 1	Rattus norvegicus	160-178
22609812-7	2012	Conversely, dobutamine was identified in a screen of known drugs as a compound that promotes cytoplasmic localization of YAP, thereby resulting in growth suppressing activity.	Dobutamine	12-22	Yes1 associated transcriptional regulator	Homo sapiens	121-124
23634242-9	2013	CONCLUSION: Erythropoietin activated mitochondrial protective mechanisms that helped maintain bioenergetic function enabling reversal of post-resuscitation myocardial dysfunction in the presence of dobutamine.	Dobutamine	198-208	erythropoietin	Rattus norvegicus	12-26
22537461-0	2012	Resting and dobutamine stress test induced serum concentrations of brain natriuretic peptide in German Shepherd dogs.	Dobutamine	12-22	natriuretic peptide B	Canis lupus familiaris	67-92
22537461-3	2012	The aim of this study is to measure BNP concentrations in healthy German Shepherd dogs of different ages as a baseline in resting and when conventional protocol of the dobutamine stress test (DST) is applied to dogs.	Dobutamine	168-178	natriuretic peptide B	Canis lupus familiaris	36-39
22761457-7	2012	Using this cell-based assay, they found that dobutamine, a beta-adrenergic receptor agonist, attenuated YAP-dependent transcription by inhibiting its nuclear translocation.	Dobutamine	45-55	Yes1 associated transcriptional regulator	Homo sapiens	104-107
23426115-1	2013	Dobutamine is a beta-adrenergic agonist with an affinity higher for receptor expressed in the heart (beta1) than for receptors expressed in the arteries (beta2).	Dobutamine	0-10	hemoglobin, beta adult major chain	Mus musculus	101-106
23426115-1	2013	Dobutamine is a beta-adrenergic agonist with an affinity higher for receptor expressed in the heart (beta1) than for receptors expressed in the arteries (beta2).	Dobutamine	0-10	hemoglobin, beta adult minor chain	Mus musculus	154-159
22728333-4	2012	infusion of norepinephrine (NE) or the beta(1) selective agonist dobutamine (DB) resulted in similar interscapular BAT (iBAT) thermal response in WT mice.	Dobutamine	65-75	hemoglobin, beta adult major chain	Mus musculus	39-46
22728333-5	2012	Secondly, mice with targeted disruption of the beta(1) gene (KO of beta(1) adrenergic receptor (beta(1)KO)) developed hypothermia during cold exposure and exhibited decreased iBAT thermal response to NE or DB infusion.	Dobutamine	206-208	hemoglobin, beta adult major chain	Mus musculus	47-54
22728333-5	2012	Secondly, mice with targeted disruption of the beta(1) gene (KO of beta(1) adrenergic receptor (beta(1)KO)) developed hypothermia during cold exposure and exhibited decreased iBAT thermal response to NE or DB infusion.	Dobutamine	206-208	adrenergic receptor, beta 1	Mus musculus	67-94
23130169-8	2012	Although the search revealed no additional, naturally occurring compounds, it identified dobutamine, isoproterenol, and alpha-methyldopa as substrates of renalase.	Dobutamine	89-99	renalase, FAD dependent amine oxidase	Homo sapiens	154-162
22471594-10	2012	Dobu, Epi, Nor, and LPS significantly increased BNP concentration but not TNF-alpha, IL-1beta, or IL-6.	Dobutamine	0-4	natriuretic peptide B	Homo sapiens	48-51
22471594-11	2012	CONCLUSIONS: In vitro, LPS, Dobu, Epi, and Nor induced BNP synthesis by human atrial myocardium.	Dobutamine	28-32	natriuretic peptide B	Homo sapiens	55-58
22131977-11	2011	A significant increase in MLC-2 phosphorylation was observed during dobutamine only in sham.	Dobutamine	68-78	myosin light chain 2	Sus scrofa	26-31
22414727-6	2012	In this article, we report the successful identification of six approved drugs out of the Drugbank as FXR modulators (ketoconazole, pentamidine, dobutamine, imatinib, papaverine and montelukast) by using a SOM for screening of the DrugBank database.	Dobutamine	145-155	nuclear receptor subfamily 1 group H member 4	Homo sapiens	102-105
21561896-0	2012	Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease.	Dobutamine	46-56	glucagon	Homo sapiens	70-93
21561896-3	2012	OBJECTIVE: To assess the hypothesis that intravenous infusion of GLP-1 would protect the heart from ischaemic left ventricular (LV) dysfunction during dobutamine stress echocardiography (DSE) in patients with coronary artery disease (CAD).	Dobutamine	151-161	glucagon	Homo sapiens	65-70
21561896-12	2012	CONCLUSION: Intravenous infusion of GLP-1 protects the heart from ischaemic LV dysfunction induced by dobutamine stress in patients with CAD.	Dobutamine	102-112	glucagon	Homo sapiens	36-41
21347606-8	2012	Dobutamine doses were positively associated and related to TNF-alpha plasma levels, independently of disease severity, hemodynamics, and outcome, in multivariable models.	Dobutamine	0-10	tumor necrosis factor	Homo sapiens	59-68
21347606-11	2012	Dobutamine treatment may contribute to circulating TNF-alpha and dopamine to IL-6, independently of activated neutrophils.	Dobutamine	0-10	tumor necrosis factor	Homo sapiens	51-60
21347606-11	2012	Dobutamine treatment may contribute to circulating TNF-alpha and dopamine to IL-6, independently of activated neutrophils.	Dobutamine	0-10	interleukin 6	Homo sapiens	77-81
22058155-12	2012	Mice deficient in nNOS demonstrate increased Bsl LTCC function and an attenuated contractile reserve to Dob, whereas eNOS(-/-) mice demonstrate normal LTCC and contractile function under all conditions.	Dobutamine	104-107	nitric oxide synthase 1, neuronal	Mus musculus	18-22
22580528-0	2012	Influence of 825 C&gt;T polymorphism of G protein beta3 subunit gene (GNB3) on hemodynamic response during dobutamine stress echocardiography.	Dobutamine	107-117	G protein subunit beta 3	Homo sapiens	40-55
22580528-0	2012	Influence of 825 C&gt;T polymorphism of G protein beta3 subunit gene (GNB3) on hemodynamic response during dobutamine stress echocardiography.	Dobutamine	107-117	G protein subunit beta 3	Homo sapiens	70-74
22580528-2	2012	The aim of this study was to determine an association between GNB3 825C&gt;T gene polymorphism, encoding the beta3-subunit of G protein, and heart rate (HR), systolic (SBP) and diastolic blood pressure (DBP) response to dobutamine during DSE.	Dobutamine	220-230	G protein subunit beta 3	Homo sapiens	62-66
22666095-5	2012	We show that treatment with dobutamine increased PPARdelta expression and cTnI phosphorylation in a time- and dose-dependent manner in neonatal rat cardiomyocytes.	Dobutamine	28-38	troponin I3, cardiac type	Rattus norvegicus	74-78
22666095-9	2012	Moreover, deletion of PPARdelta using siRNA generated the reduction of cTnI phosphorylation in cardiomyocytes treated with dobutamine.	Dobutamine	123-133	troponin I3, cardiac type	Rattus norvegicus	71-75
22570371-3	2012	METHODS AND RESULTS: Here, we show that miR-22-deficient mice are impaired in inotropic and lusitropic response to acute stress by dobutamine.	Dobutamine	131-141	microRNA 22	Mus musculus	40-46
21332948-2	2011	Resveratrol, catechin, silymarin, dobutamin, and curcumin showed K(I) values in the range of 4.47-9.47 mm for hCA I and of 2.86-7.44 mum against hCA II, respectively.	Dobutamine	34-43	carbonic anhydrase 1	Homo sapiens	110-115
21848869-3	2011	In addition, we also studied if beta1-adrenoceptor activation with the selective beta1 agonist dobutamine could improve deficits of prefrontal cortex long-term potentiation presenting these animals.	Dobutamine	95-105	adrenoceptor beta 1	Rattus norvegicus	32-50
21665956-7	2011	Mice deficient in dystrophin and, less so, delta-sarcoglycan have reduced survival during in vivo dobutamine stress testing compared to controls.	Dobutamine	98-108	dystrophin, muscular dystrophy	Mus musculus	18-28
21665956-7	2011	Mice deficient in dystrophin and, less so, delta-sarcoglycan have reduced survival during in vivo dobutamine stress testing compared to controls.	Dobutamine	98-108	sarcoglycan, delta (dystrophin-associated glycoprotein)	Mus musculus	43-60
21311897-2	2011	The Arg389Gly polymorphism of the beta(1)AR gene has recently been shown to determine the responsiveness to catecholamines in vitro, and we previously reported that dobutamine induced an augmented contractile response in humans homozygous for the Arg389 allele.	Dobutamine	165-175	adrenoceptor beta 1	Homo sapiens	34-43
21586534-0	2011	A cell-based assay to screen stimulators of the Hippo pathway reveals the inhibitory effect of dobutamine on the YAP-dependent gene transcription.	Dobutamine	95-105	Yes1 associated transcriptional regulator	Homo sapiens	113-116
21586534-7	2011	Using this method, we found that dobutamine inhibits the YAP-dependent gene transcription.	Dobutamine	33-43	Yes1 associated transcriptional regulator	Homo sapiens	57-60
21586534-8	2011	Contrary to our expectations, the effect of dobutamine is independent of the Hippo pathway but our method opens the possibility to discover Hippo pathway stimulators or Hippo-independent YAP inhibitors.	Dobutamine	44-54	Yes1 associated transcriptional regulator	Homo sapiens	187-190
21763292-6	2011	This conclusion was supported by the finding that dobutamine but not salbutamol increased HO-1 expression in both RAW 264.7 cells.	Dobutamine	50-60	heme oxygenase 1	Mus musculus	90-94
21561432-8	2011	Dobutamine, a member of this group, had 70% of the adrenaline (epinephrine) effect on arrestin via beta1-AR, but acted as a competitive antagonist of adrenaline via beta2-AR.	Dobutamine	0-10	adrenoceptor beta 1	Homo sapiens	99-107
21561432-8	2011	Dobutamine, a member of this group, had 70% of the adrenaline (epinephrine) effect on arrestin via beta1-AR, but acted as a competitive antagonist of adrenaline via beta2-AR.	Dobutamine	0-10	adrenoceptor beta 2	Homo sapiens	165-173
21332948-2	2011	Resveratrol, catechin, silymarin, dobutamin, and curcumin showed K(I) values in the range of 4.47-9.47 mm for hCA I and of 2.86-7.44 mum against hCA II, respectively.	Dobutamine	34-43	carbonic anhydrase 2	Homo sapiens	145-151
21061196-6	2011	Using this method, we studied the distribution of tyrosine phosphorylated signal transducer and activator of transcription 3 (PY-STAT3) in LV tissue of animals treated with the beta-agonist dobutamine.	Dobutamine	190-200	signal transducer and activator of transcription 3	Homo sapiens	74-124
21626318-4	2011	This systematic review found positive effects of PMX-DHP on mean arterial pressure and dopamine/ dobutamine use, PaO2/FiO2 ratio, endotoxin removal, and mortality.	Dobutamine	97-107	dihydropyrimidinase	Homo sapiens	53-56
21305273-0	2011	Effect of the ADRB1 1165C&gt;G and 145A&gt;G polymorphisms on hemodynamic response during dobutamine stress echocardiography.	Dobutamine	90-100	adrenoceptor beta 1	Homo sapiens	14-19
21297144-5	2011	RESULTS: Preoperative BNP levels correlate with longer ICU stay (P = 0.003), longer ventilator use (P = 0.018) and duration of dobutamine use (P &lt; 0.001).	Dobutamine	127-137	natriuretic peptide B	Homo sapiens	22-25
21297144-6	2011	The receiver-operating characteristic curve demonstrated BNP levels &gt;190 pg/ml as predictor of ICU &gt;5 days and BNP levels &gt;20.5 pg/ml correlated with dobutamine use, with areas under the curve of 0.712 and 0.842, respectively.	Dobutamine	159-169	natriuretic peptide B	Homo sapiens	117-120
21320508-8	2011	In contrast to ET-1 stimulation, the positive inotropic effect of beta(1)-adrenergic receptor agonist dobutamine (250nmol/L) was significantly augmented by N-acetylcysteine and apocynin.	Dobutamine	102-112	adrenoceptor beta 1	Rattus norvegicus	66-93
21305273-1	2011	PURPOSE: The aim of this study was to determine an association between the ADRB1 1165C&gt;G and 145A&gt;G polymorphisms and hemodynamic response [heart rate (HR), systolic (SBP) and diastolic (DBP) blood pressure] to dobutamine during dobutamine stress echocardiography (DSE).	Dobutamine	217-227	adrenoceptor beta 1	Homo sapiens	75-80
21305273-1	2011	PURPOSE: The aim of this study was to determine an association between the ADRB1 1165C&gt;G and 145A&gt;G polymorphisms and hemodynamic response [heart rate (HR), systolic (SBP) and diastolic (DBP) blood pressure] to dobutamine during dobutamine stress echocardiography (DSE).	Dobutamine	235-245	adrenoceptor beta 1	Homo sapiens	75-80
21156182-10	2011	However, the dobutamine-induced increase in overall cTnI phosphorylation and cTnI phosphorylation at protein kinase A (PKA)-sites (Ser23/24) was less in MI compared to sham.	Dobutamine	13-23	protein kinase cAMP-activated catalytic subunit alpha	Sus scrofa	101-117
20821015-0	2011	Functional effects of beta1-adrenoceptor polymorphisms on the hemodynamic response to dobutamine with and without beta-blocker administration.	Dobutamine	86-96	adrenoceptor beta 1	Homo sapiens	22-40
21371608-6	2011	Upon enzymatic characterization, purified COMT displayed methylating activity toward dopamine, dopa, and catecholestrogens, as well as three representative catechol drugs, methyldopa, dobutamine, and isoproterenol.	Dobutamine	184-194	catechol-O-methyltransferase b	Danio rerio	42-46
21156182-10	2011	However, the dobutamine-induced increase in overall cTnI phosphorylation and cTnI phosphorylation at protein kinase A (PKA)-sites (Ser23/24) was less in MI compared to sham.	Dobutamine	13-23	protein kinase cAMP-activated catalytic subunit alpha	Sus scrofa	119-122
21228877-5	2011	Here we present four crystal structures of the thermostabilized turkey (Meleagris gallopavo) beta(1)-adrenergic receptor (beta(1)AR-m23) bound to the full agonists carmoterol and isoprenaline and the partial agonists salbutamol and dobutamine.	Dobutamine	232-242	beta-1 adrenergic receptor	Meleagris gallopavo	93-131
21125687-4	2011	Nevertheless, rac dobutamine is still frequently used as a tool for classification of beta-adrenoceptors.	Dobutamine	18-28	AKT serine/threonine kinase 1	Homo sapiens	14-17
21172031-12	2010	Dobutamine remained neuroprotective in slices exposed to pure OGD as well as in TNFR1-/- and TNFR2-/- slices exposed to LPS followed by OGD.	Dobutamine	0-10	tumor necrosis factor receptor superfamily, member 1a	Mus musculus	80-85
19735400-6	2009	Both mean and maximum blood flow increased significantly in the anastomosed artery at dobutamine infusions of 4 and 6 microg x kg(-1) x min(-1) and this was accompanied by increased cardiac output.	Dobutamine	86-96	CD59 molecule (CD59 blood group)	Homo sapiens	136-142
20970750-8	2010	In contrast, supplemental AVP further worsened the shock state by decreasing CO (70 +- 6 mL/kg) and SVO2 (45 +- 5%) compared with Dobu alone.	Dobutamine	130-134	vasopressin	Sus scrofa	26-29
20566195-8	2010	RESULTS: The expression of E-selectin on endothelium following stimulation with interleukin-1 is attenuated by the inotropes dopamine or dobutamine, but not by epinephrine.	Dobutamine	137-147	selectin E	Homo sapiens	27-37
20566195-8	2010	RESULTS: The expression of E-selectin on endothelium following stimulation with interleukin-1 is attenuated by the inotropes dopamine or dobutamine, but not by epinephrine.	Dobutamine	137-147	interleukin 1 alpha	Homo sapiens	80-93
21132126-1	2010	We have shown that in isolated human atrial strips the beta1-adrenoceptor agonist dobutamine can induce spontaneous, stable and durable rhythmic contractions.	Dobutamine	82-92	adrenoceptor beta 1	Homo sapiens	55-73
20211301-6	2010	RESULTS: At peak dobutamine infusion, SBP amplification averaged 14.9 mm Hg, with a maximum difference of 43 mm Hg.	Dobutamine	17-27	selenium binding protein 1	Homo sapiens	38-41
20075143-0	2010	DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease.	Dobutamine	68-78	dipeptidyl peptidase 4	Homo sapiens	0-5
20075143-3	2010	We assessed the hypothesis that increasing the plasma concentration of GLP-1 by DPP-4 inhibition would protect the heart from ischemic left ventricular (LV) dysfunction during dobutamine stress echocardiography in patients with coronary artery disease.	Dobutamine	176-186	glucagon	Homo sapiens	71-76
20075143-3	2010	We assessed the hypothesis that increasing the plasma concentration of GLP-1 by DPP-4 inhibition would protect the heart from ischemic left ventricular (LV) dysfunction during dobutamine stress echocardiography in patients with coronary artery disease.	Dobutamine	176-186	dipeptidyl peptidase 4	Homo sapiens	80-85
20729741-8	2010	Dobutamine induced a marked improvement in myocardial performance associated to a decrease in BNP levels.	Dobutamine	0-10	natriuretic peptide B	Homo sapiens	94-97
20889987-8	2010	Dobutamine stress, however, led to an increase in Eed in the entire ToF cohort indicating an abnormal diastolic response to catecholamines in these patients.	Dobutamine	0-10	embryonic ectoderm development	Homo sapiens	50-53
20849043-7	2010	TGF-beta3 immunostaining was mildly increased in groups sham, control and dobutamine, whereas it was found moderate in group levosimendan.	Dobutamine	74-84	transforming growth factor, beta 3	Rattus norvegicus	0-9
20446911-5	2010	Specifically, SULT1 ST1, SULT1 ST2, and SULT1 ST3 showed the highest specific activities, at 26.9, 29.3, and 31.5 nmol/min/mg, toward aesculetin, 4-methylembelliferone, and dobutamine, respectively.	Dobutamine	173-183	sulfotransferase family 1, cytosolic sulfotransferase 1	Danio rerio	14-23
20446911-5	2010	Specifically, SULT1 ST1, SULT1 ST2, and SULT1 ST3 showed the highest specific activities, at 26.9, 29.3, and 31.5 nmol/min/mg, toward aesculetin, 4-methylembelliferone, and dobutamine, respectively.	Dobutamine	173-183	sulfotransferase family 1, cytosolic sulfotransferase 2	Danio rerio	25-34
20446911-5	2010	Specifically, SULT1 ST1, SULT1 ST2, and SULT1 ST3 showed the highest specific activities, at 26.9, 29.3, and 31.5 nmol/min/mg, toward aesculetin, 4-methylembelliferone, and dobutamine, respectively.	Dobutamine	173-183	sulfotransferase family 1, cytosolic sulfotransferase 3	Danio rerio	40-49